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ABSTRACT 
IL-10-treated tolerogenic dendritic cells (DC10) have been used as a powerful 
tool for the treatment of experimental asthmatic responses. We explored the important 
role of CD4+CD25+Foxp3+ regulatory T cells (Treg) in the induction of tolerance by 
DC10 in three levels. We first used the siRNA approach to silence IL-10 gene expression 
in murine DC10 and we generated DC10 from CD80/86 or H-2Iab gene-KO mice. When 
used to treat asthmatic mice, the IL-10-silenced and MHCII-deficient DC10 had lost their 
abilities to induce tolerance, as determined by airway hyperresponsiveness (AHR), 
eosinophilia and Th2 responses, while the CD80-/-/86-/- DC10 had reduced tolerogenic 
activities. Further studies showed that the OVA-presenting DC10 up-regulated expression 
of the Treg-associated markers ICOS, PD-1, GITR, LAG-3 and CTLA-4 on pulmonary 
Treg cells in treated asthmatic mice while DC10 (CD80-/-CD86-/-), DC10 (Iab-/-) and 
DC10 (IL-10-/-) treatments lead to reduced Treg activation. This demonstrated that the 
activities of tolerogenic DCs are differentially affected by their expression of IL-10, 
MHC II and costimulatory molecules.  
DC10 induce allergen tolerance in asthmatic mice, during which the animals-lung 
Th2 T effector cells (Teff) are displaced by activated Treg cells. Intestinal DCs have been 
shown to promote oral tolerance by inducing antigen-naïve T cells to differentiate into 
Treg, but whether DCs can induce Teff to differentiate into Treg remains uncertain. We 
addressed this question in OVA-asthmatic mice that were treated with DC10.  DC10 
delivery maximally activated lung Treg in these animals at 3 wk post-treatment, as 
determined by in vitro and in vivo Treg-inhibitory assays. In parallel cultures OVA-, but 
not house dust mite (HDM)-, presenting DC10 induced ≈43% of CFSE-labeled CD25-
/loFoxp3- Teff cells from asthmatic OVA-TCR transgenic mice to redifferentiate into 
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Treg. We recapitulated this in vivo using OVA-asthmatic mice that were co-injected with 
OVA- or HDM-presenting DC10 (i.p.) and CFSE-labeled CD4+CD25-/loFoxp3- Teff cells 
(i.v.) from the lungs of asthmatic DO11.10 mice. From ≈7 to 21% of the activated (i.e., 
dividing) DO11.10 Teff that were recovered from the lungs, lung-draining lymph nodes 
or spleens of the OVA-DC10 recipients had redifferentiated into Treg. These data 
indicate that DC10 treatments induce tolerance at least in part by inducing Teff to 
redifferentiate into Treg. 
Finally, we assessed the relative efficiency with which natural Treg cells (nTreg) 
and induced Treg cells (iTreg) tolerize Teff cells from asthmatic mice. The iTreg were 
induced either by culture of Teff cells with OVA-presenting DC10 or by injecting these 
Teff cells into DC10-treated asthmatic mice. We purified nTreg from allergen-naïve mice 
and also cultured them with DC10 before use, or co-injected them into DC10-treated 
recipients. The iTreg were 26-41% more effective than analogous nTreg in reducing Teff 
cell proliferation and IL-4/IL-5 secretion in vitro. Neutralization of IL-10, but not TGF, 
eliminated the suppressive activities of iTreg, which also expressed higher levels of PD-1, 
LAG3 & CTLA-4. Transfer of 5×105 nTreg had no impact on AHR or IgE levels in 
asthmatic recipients, but reduced the airway eosinophil and IL-4/IL-5 responses by 5-
19%, while the iTreg normalized AHR and reduced all airway responses to allergen 
challenge by 82-96%. Taken together, our data show that DC10 provide three signals to 
induce Treg differentiation directly from allergen-experienced Teff, and that  iTreg and 
nTreg of the same antigen specificity employ distinct mechanisms to effect tolerance.  
They also indicate that iTreg are distinctly superior to nTreg in induction of tolerance.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1. IMMUNOPATHOLOGY OF ASTHMA 
1.1.1. Definition and overall asthmatic response 
Asthma is a chronic inflammatory disorder of the airways that causes episodic 
wheezing and difficulty breathing. Despite significant pharmacological advances in 
asthma therapy, asthma rates for Canadian children have jumped four-fold over the past 
20 years to a level where more than one in ten people have been diagnosed with this 
respiratory ailment. The estimated prevalence of asthma is 300 million persons across the 
world. It affects 16.2 million adults and 6.7 million children in the United States 
according to 2007 investigation (Locksley 2010). In North America asthma has become 
the most common chronic childhood disease; it now costs Canadians and Americans-
Health Care Systems around $600 million and $20 billion per year respectively (Busse 
and Lemanske 2001; Cohn, Elias et al. 2004 Locksley 2010). 
Type 2 T-helper cell (Th2) immune responses play a key role in the initiation, 
progression and persistence of asthma. Allergens (e.g., animal dander, cockroach 
particles, house dust mites, grass, tree pollen, cat dander) enter the airways and cross the 
epithelial surface of the endobronchial tree via uptake by dendritic cells (DCs), which are 
antigen presenting cells (APCs). These APCs process their ingested allergens and present 
them to naïve Th cells in the lung-draining lymph nodes (LNs). Allergen-specific 
activation of naïve Th cells induces their differentiation into Th2 cells. Finally, the Th2 
responses culminate in the tightened airways and airway hyperresponsiveness (AHR) that 
typify asthma, the symptoms of which include shortness of breath, chest tightness, 
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 wheezing and coughing (Cohn and Ray 2000; Busse and Lemanske 2001; Lambrecht and 
Hammad 2003; Hawrylowicz and O'Garra 2005). 
 
1.1.2. Immunobiology of asthma 
The immunology of asthma is complex and involves various immune and non-
immune cells and molecular components. Inhaled allergens recognize the surface-bound 
immunoglobulin-E (IgE) to activate sensitized mast cells, resulting in the release of 
several bronchoconstrictor mediators, including leukotrienes and prostaglandin. 
Allergens are taken up and processed by DCs, while the epithelium secrete the pro-Th2 
cytokines interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TLSP), which 
act on both T cells and non-T cells to promote Th2 responses. Th2 cells play a dominant 
role in inflammatory responses in asthma via secretion of cytokines IL-4, IL-5, IL-6, IL-9 
and IL-13. IL-4 and IL-13 stimulate B cells to produce IgE, IL-5 is required for 
eosinophilic inflammation and IL-9 induces mast-cell proliferation. The deficiency of 
regulatory T cell (Treg) may favour further Th2-cell proliferation (Barnes 2008). 
 
1.1.2.1. Mast cells 
Mast cells are widely present in many tissues, including the skin, mucosa of the 
respiratory, genitourinary and gastrointestinal tracts, and the lymphoid organs. Fibroblast-
derived stem cell factor (SCF), which engage its c-kit receptor expressed on Mast cells, 
promotes the development of mast cells, while IL-3 secreted by T cells increases the 
development of mucosal mast cells but not connective tissue mast cells. Mast cells 
 2  
 express an array mediators and co stimulatory molecules. They are "tuneable", and will 
respond variably based on their physiologic or pathologic environment. Mast cells are 
best known as effector cells in IgE-mediated allergic responses, although the 
multifunction ability of mast cells in innate and adaptive immunity have been extensively 
reported recently. They can function as effector cells that elicit inflammation or as 
regulatory cells that suppress responses (Sayed, Christy et al. 2008). 
 
1.1.2.1.1. Mast cell activation 
Mast cells highly express FcRI, the high-affinity receptor for IgE. Antigen-
specific IgE produced by B cells binds with FcRI on mast cells to prime them. When 
primed mast cells encountered their cognate antigen, the antigen-specific IgE on the mast 
cells interacts with the antigen which results in the activation of mast cells. The activated 
mast cells secrete three classes of mediators: (1) preformed mediators that are stored in 
the cells and immediately released through degranulation; (2) newly-synthesized 
proinflammatory lipid mediators such as prostaglandins and leukotrienes; (3) and 
cytokines and chemokines such as IL-1, -2, -3, -4, -5, -6, -7, -8, -10, -12, -13, -15, -18, -
21, -23, IFN-α,-β,-γ, and TSLP and TNF (Kalesnikoff and Galli 2008). Activated mast 
cells also increase expression of costimulatory molecules. Upon secretion by mast cells 
these mediators subsequently activate others cells, such as T cells, B cells, eosinophils, 
and smooth muscle cells, which induce continuation of the cycle and further release of 
the mediators. Therefore, IgE plays a key role in the acute reaction to antigens and in the 
induction of airway inflammation. Allergic asthma patients have high level of FcRI- 
bound IgE on mast cells (Andersson, Tufvesson et al. 2011). 
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 Mast cells can also be activated to perform important functions by IgE-
independent pathways (Sayed, Christy et al. 2008). Human mast cells express high-
affinity IgG receptors FcγRI and low-affinity IgG receptors FcγRII and FcγRIII. Cross-
linking of IgG receptors on mast cells through antigen-IgG complexes results in 
degranulation, which is associated with Type II and III hypersensitivity reactions. Mast 
cells also can be activated by a variety of stimuli through receptor-mediated pathways 
such as TLRs or complement receptors and thereby exert extremely versatile functions.  
 
1.1.2.1.2. Mast cell influence on immune responses 
Mast cells and DCs are closely co-located in all tissues. Both DCs and mast cells 
can be activated by the same microbial signals through (e.g.TLRs). Activated mast cells 
promote DC maturation or suppression and control T cell differentiation pathways 
through cytokine release and costimulatory molecules expression. For example, 
histamine, the best-known mast cell mediator, has potent influences on DCs and Th cells, 
both of which express histamine receptors. Histamine suppresses the production of IL-12 
and increases the secretion of IL-10 from DCs, thereby inhibiting production of Th1 (e.g. 
IFN-γ) and promoting the production of Th2 (e.g. IL-4) cytokine, by T cells (Mazzoni, 
Siraganian et al. 2006). It was reported that the co-culture of human DCs and activated 
mast cells in vitro lead to significantly increases of MHC I and II, CD80, CD86, CCR7 
expression on DCs, which promote Th2 responses in allergy (Kitawaki, Kadowaki et al. 
2006). 
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 1.1.2.1.3. Mast cell and immunosuppression 
In addition to being promoters of inflammation, mast cells can have 
immunosuppressive effects on immune cells. An early study demonstrated that the 
systemic immunosuppression of contact hypersensitivity responses induced by ultraviolet 
B irradiation of skin was mast cell-dependent (Hart, Grimbaldeston et al. 1998). The 
chemokine receptor CXCR4 on mast cells mediated ultraviolet irradiation-induced 
migration of mast cells from the skin to the draining LNs, which is a crucial step for the 
immunosuppressive induction (Byrne, Limon-Flores et al. 2008). A study conducted by 
Lu et al showed that the maintenance of the immunosuppression in a murine skin 
transplant model was mast cell-dependent and Treg-mediated. Mast cell-deficient mice 
were unable to maintain skin allografts. Graft tolerance relied on interaction between 
mast cells and T cells. On the one hand, Treg secrete IL-9, a mast cell growth factor that 
enhances mast cell recruitment and activation in the allograft but, on the other hand, mast 
cells produce IL-10 to mediate negative immunomodulatory suppression (Lu, Lind et al. 
2006). In addition, proteases (e.g. β-tryptase) released by mast cells can cleave IgE 
(Rauter, Krauth et al. 2008), which may limit IgE-dependant allergic hypersensitivity 
reactions such as allergic asthma and food allergies. 
 
1.1.2.2. Basophils 
Basophils represent less than 0.5% of blood cells in the blood circulation in the 
steady state. Being the least common leukocyte, it has received the little recognition other 
than as the source of intracellular mediators such as histamine and leukotrienes released 
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 in IgE-mediated allergic reaction. Recently it has been reported that basophils are the 
primary source of IL-4 for initiation of Th2 responses and professional APC to prime 
naive T cell in allergic inflammation (Min, Brown et al. 2012). Although DCs are 
sufficient and necessary to mediate asthmatic response to many allergens, in some 
situations basophils present antigen for induction of Th2 immune response to some 
allergens (Karasuyama, Mukai et al. 2011). 
 
1.1.2.2.1. Basophils and their features 
Basophils are derived from bone marrow precursors, but they are released into the 
peripheral blood as fully mature cells. The cytokines IL-3 is involved in basophil 
differentiation. The frequency of basophils significantly increases in Th2-related 
responses, including allergic inflammation and parasitic infection, suggesting that they 
may contribute to the induction of Th2 type responses (Gauvreau, Lee et al. 2000; 
Macfarlane, Kon et al. 2000). Three reports have demonstrated that basophils function as 
potent antigen presenting cells in draining LNs to prime specific Th2 and IgE responses 
against allergic proteins and protease released from parasitic helminths. Basophils secrete 
IL-4 upon encounter with allergens thereby contribute to the initiation of Th2 immune 
responses (Perrigoue, Saenz et al. 2009; Sokol, Chu et al. 2009; Yoshimoto, Yasuda et al. 
2009). 
There are some evidences that basophils possess classical features of antigen 
presenting cells for Th2 immunity. (1) express MHC II molecules and costimulatory 
molecules such as CD80, CD86, CD40 and CD54; (2) express FcεRI to capture IgE-
antigen complexes; (3) endocytose antigens and present peptide-MHC II complexes to 
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 CD4 T cells; and (4) express CD62L to migrate to lymphoid tissues. Uniquely and 
importantly, basophils secrete cytokines IL-4, IL-13 and TSLP to polarize Th2 response. 
TSLP inhibits IL-12 production by DCs and promote Th2 cell differentiation (Perrigoue, 
Saenz et al. 2009; Sokol, Chu et al. 2009; Yoshimoto, Yasuda et al. 2009). 
 
1.1.2.2.2. The role of DCs and basophils in airway infection 
DCs have a broader, more potent capacity to induce anti-pathogen immune 
responses in term of quantity and quality when compared with basophils. First at all, DCs 
can take up particulate antigens while basophils do not (Sokol, Chu et al. 2009). Airway 
infections with viruses, bacteria or fungi cause full maturation of DCs, at least partially 
through toll like receptors (TLRs). Mature DCs highly express MHC class II, 
costimulatory molecules and homing receptors (e.g. CCR7), while even activated 
basophils have lower level expression of MHC class II and costimulatory molecules than 
mature DCs. Thus, as professional antigen presenting cells, DCs possess much greater 
capacity to present antigen to naïve T cells, and they migrate into the lung-draining LN to 
stimulate naïve T cells. Mature DCs can secrete the type 1 cytokines IL-12 and IFN-γ to 
stimulate the expression of transcription factor T-cell-specific T-box transcription factor 
21 (T-bet) and thereby induce Th1 cells for resistance to viruses and intracellular bacteria 
(Huang, Hao et al. 2007). DC can also directly induce cytotoxic T lymphocytes (CTLs) to 
kill cells infected with these pathogens. DCs prompt the expression of retinoic-acid-
related orphan receptor (RORγt) to induce Th17 cells with IL-6, IL-23 and TGF-β for 
resistance to extracellular bacteria. On the other hand, DCs can stimulate the expression 
of Foxp3 to induce CD4+CD25+Foxp3+ Treg with IL-10 and TGF-β to counter-regulate 
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 adaptive immunity (Reiner 2007; Yamazaki, Bonito et al. 2007; Dumitriu, Dunbar et al. 
2009; Reiner 2009). The role of basophils as APCs in airway infection has not been clear. 
It is reported that during respiratory syncytial virus (RSV) infection, basophils are the 
primary source of IL-4 which contributes to the Th2 immunopathology induced by the 
infection (Moore, Newcomb et al. 2009). 
 
1.1.2.2.3. Basophils rather than dendritic cells play a dominant role as APCs in the 
allergen-induced Th2 responses. 
Th2 immunoinflammatory responses play a key role in the initiation, progression 
and persistence of allergic reactions. Allergens (e.g., house dust mites, grass and tree 
pollens and cat dander) enter the mucosal system and cross the epithelial surface via 
active APCs uptake. These APCs process their ingested allergens and present allergen 
related peptides to naïve Th cells. Allergen-specific activation of naïve Th cells induces 
their differentiation into the Th2, but not Th1 pathway, characterized by T cell 
proliferation, Th2 cytokine (IL-4, -5, -9, -10, -13) production, inflammation, eosinophilia 
and IgE production. These effects cumulatively culminate in the allergic reaction (Cohn 
and Ray 2000; Busse and Lemanske 2001; Lambrecht and Hammad 2003; Hawrylowicz 
and O'Garra 2005). 
DCs are known as the most efficient APCs for initiation of adaptive immune 
responses. In allergic reactions, the availability of an early source of IL-4 is critical to 
driving the Th2-type immune response. However, since DCs do not produce IL-4 (Galli, 
Tsai et al. 2008), the mechanisms of Th2 responses primed by APCs have not been 
understood clearly. An accepted old model is that Th2 initiation is driven by DCs that 
present antigens to Th2 cells together with extrinsic initial provision of IL-4 by other 
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 cells such as mast cells, basophils, eosinophils and NKT cells. Recently it was reported 
that DCs are not required for the development of Th2 responses to (papain) (Sokol, Chu 
et al. 2009), antigen-IgE complexes (Yoshimoto, Yasuda et al. 2009) or helminth-derived 
secreted proteins (Perrigoue, Saenz et al. 2009). Each study identified basophils as the 
referent professional APCs and IL-4 producers. Basophils can take up soluble antigens, 
migrate to LNs rapidly and present antigen to Th2 cells (Siracusa, Comeau et al. 2011). 
However, unlike DCs, they can not process particulate antigens (Sokol, Chu et al. 2009). 
Basophils express the high affinity IgE Fc receptor (i.e. FcεRI). After allergens 
enter body of an allergic patient, the binding of allergen-IgE complexes to FcεRI on the 
surface of basophils leads to rapid cellular degranulation with secretion of IL-4 and other 
Th2 mediators. Moreover basophil stimulation with IL-3 plus LPS or peptidoglycan 
induces the production of IL-4 and IL-13, implying that basophils may also be involved 
in bacterial infections (Yoshimoto and Nakanishi 2006). 
In summary, DCs and basophils possess the following common features that 
allow them to function as antigen presenting cells: (1) expression of pattern recognition 
receptors (PRR) (e.g. TLRs) to recognize various conserved molecules from microbes; 
(2) ability to take up and process engulfed antigens into peptides; (3) up-regulation of 
MHC class II and costimulatory molecules following cellular activation; (4) ability to 
migrate to lymphoid tissues to present peptide-MHC II complexes to CD4 T cells; and (5) 
release of relevant cytokines for Th cell differentiation. However, as APCs, DCs and 
basophils also have their own distinct features: (1) basophils use different pattern 
recognition receptors to sense various pathogen-associated signals, but also express 
FcεRI to capture IgE-antigen complexes; (2) DCs are able to take up both particulate and 
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 soluble antigens, but basophils can only handle soluble ones; (3) basophils can be 
activated immediately upon encounter of Th2 antigens and thereby release stored 
mediators; (4) DCs produce cytokines such as IL-12, IL-6 and IL-23, but not IL-4, to 
favor Th1 and/or Th17 responses. In contrast, basophils secrete IL-4, the key driver of 
Th2 responses, and other Th2 polarized cytokines including IL-13 and TSLP; and (5) 
DCs also present peptides to CD8 T cells by the MHC class I pathway and thereby induce 
CD8 activation (Perrigoue, Saenz et al. 2009; Sokol, Chu et al. 2009; Yoshimoto, Yasuda 
et al. 2009; Siracusa, Comeau et al. 2011; Min, Brown et al. 2012).  
Recent reports present evidence that basophils initiate Th2 responses to allergens 
and helminthes by acting as professional APCs and IL-4 producers. However, Th2 
responses are vastly heterogeneous, such that a large number of studies demonstrated 
DC-mediated Th2 responses (Hammad, Plantinga et al. 2010; Lambrecht and Hammad 
2012), while other studies reported that M2-polarized macrophages, eosinophils and mast 
cells can also act as APCs to induce Th2 differentiation. Thus it is likely that basophils 
are not the only APCs to induce Th2 responses to antigens. There would also be potential 
co-operation between basophils and DCs or other APCs in the initiation and maintenance 
of Th2 response, alternatively, the different types of APCs may play dominate roles 
under different situations.  
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 1.1.2.3. T lymphocytes 
1.1.2.3.1. T cells subsets 
T lymphocytes or T cells consist of functionally and phenotypically distinct 
populations, such as CD4+ T cells, CD8+ T cells, NKT cells and γδ T cells. There are at 
least four subsets of CD4+ T cells, including Th1, Th2, Th17 and Treg cells (Zhu, 
Yamane et al. 2010). Th1, Th2 and Th17 cells exert critical functions to mediate adaptive 
immunity to various pathogens. Th1 and Th17 cells also play important roles in bacterial 
and viral infection and autoimmunity (Dardalhon, Korn et al. 2008), whereas Th2 cells 
are associated with allergic responses (Kim, DeKruyff et al. 2010). Treg cells are 
essential for the maintenance of self-tolerance and the modulation of immune responses 
to infections (Lloyd and Hawrylowicz 2009).  
 Naïve CD4 cells are activated by their cognate antigen presented by antigen 
presenting (APC) such as DCs to further differentiate into a variety of lineages, as 
determined by the cytokines in the T cell's microenvironment (Zhu, Yamane et al. 2010). 
IL-12 and IFN- are essential for Th1 cell differentiation, IL-4 is a key cytokine for Th2 
cell differentiation, TGF-β and IL-6 together stimulate Th17 cell differentiation. TGF-β, 
retinoic acid (RA) and IL-2 can induce Treg differentiation. Moreover, master 
transcription factors distinct for each Th subset control their differentiation programs, 
including T-bet for Th1 cells, GATA3 for Th2 cells, RORγt for Th17 cells and Foxp3 for 
Treg cells (Zhu, Yamane et al. 2010). 
 Th1 cells produce IFN-γ as signature cytokine and exclusively make lymphotoxin, 
Th2 cells make IL-4, IL-5, IL-13 as their signature cytokines, Th17 cells are 
characterized by their IL-17 and IL-22 signature cytokines, while Treg cells produce IL-
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 10 and play critical roles in the maintenance of immune homeostasis by regulating Th1, 
Th2 and Th17 responses and therefore in prevention of immunological damage. 
 There exists a crossregulation between Th1 cells and Th2 cells. Th1 cell cytokines 
suppress Th2 differentiation, while Th2 cytokines suppress IL-12 signalling and thus 
prevent Th1 cell differentiation. In addition, it has been reported that both Th1 and Th2 
signals potently inhibit Th17 cell differentiation. 
 The Th17 cells and Treg subsets may switch to other Th cell subsets under the 
incorrect cytokine environment (Zhou, Chong et al. 2009). Th17 cells can convert into 
Th1 or Th2 cells under IL-12 and IL-4 stimulation, respectively. Treg cells can become 
Th17 cell under the influence of IL-6 and IL-21. 
 
 1.1.2.3.2 T cells in asthma 
There are many T cell subsets involved in the immunopathology of asthma. Th2 
cells are the most important cells to mediate asthma inflammation. Numerous studies 
demonstrated that asthma was characterized by Th2 type inflammation (Robinson 2010). 
Allergens activated airway epithelium through toll-like receptors (TLRs) (Barrett and 
Austen 2009; Robinson 2010; Holgate 2011). The activated epithelium can secrete the 
pro-Th2 cytokines IL-25, IL-33 and TLSP, which can directly act on both T cells and 
non-T cells to promote Th2 cytokine production, including IL-4, IL-5, IL-6, IL-9 and IL-
13. Eosinophils also produce some of these cytokines and can be activated by these 
cytokines, such that eosinophils can play an important role in asthma exacerbations. Mast 
cells and basophils, and IL-4 and IL-13 induce B cells to isotype switch to IgE production. 
Mast cells can also interact with airway smooth muscle cells to induce AHR, while the 
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 Th2 cytokine IL-4 can act on epithelium which enhance mucus production. 
 Asthma induced by the Th2 response is characterized by predominant eosinophil 
and basophil infiltration of the airway (eosinophilic asthma). Eosinophilic asthma can be 
efficiently treated with corticosteroids. By contrast, it was reported that Th1 and Th17 
cells induce predominantly neutrophilic inflammation (neutrophilic asthma) (Cho, 
Stanciu et al. 2005; Alcorn, Crowe et al. 2010), which is generally more severe due to the 
involvement of TNF-α, IFN-γ, and IL-17, and is largely steroid-resistant. 
 Treg cells can suppress allergen-driven inflammation and maintain airway 
tolerance (Braga, Quecchia et al. 2011) through release of IL-10 and TGF-β, which 
controls several aspects of the asthma reaction. Treg cells inhibit allergen-associated T 
cell activation, and also inhibit eosinophils, basophils and mast cells to restrict allergic 
inflammation. Their IL-10 efficiently suppresses allergen-specific IgE production, and 
induces non-inflammatory phenotype IgG4 synthesis. 
 Th9 and Th22 were recently identified Th cell subsets which produce IL-9 and 
IL-22, respectively, which can induce tissue inflammation in autoimmune diseases or 
atopic dermatitis (Jutel and Akdis 2011). However the roles of Th9 and Th22 in allergic 
asthma remain unclear. CD8 T cells, NKT cells and γδT cells can produce Th2 cytokines 
but also inhibit Th2 responses under some conditions, such that their roles in asthma need 
to be clarified (Robinson 2010). 
 
1.1.2.4. Eosinophils 
Eosinophils have been considered as protective effector cells for helminth 
infections (Shin, Lee et al. 2009), but also as an important feature in allergic 
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 inflammation and asthma. The type 2 cytokine IL-5 mediates eosinophil differentiation, 
survival and expansion, while the chemokines CCL11, CCL24, CCL26 (i.e. eotaxins) 
attract eosinophils into allergic tissue. Eosinophils produce an array of cytotoxic agents 
and chemokines. Cytotoxic granule contents include major basic protein (MBP), 
eosinophil cationic protein (ECP), eosinophil peroxidase (EPO) and eosinophil-derived 
neurotoxin (EDN), each of which damage tissue and compromise their functions 
(Rothenberg and Hogan 2006). High number of eosinophils can be observed in the 
bronchoalveolar lavage (BAL) of asthmatic people and mice. 
Eosinophils develop in the bone marrow under the influence of IL-3, IL-5 and 
GM-CSF, which play dominant roles in their differentiation and expansion. IL-5 also 
regulates the migration of eosinophils from the bone marrow into the peripheral blood. A 
number of chemokines are eosinophil chemoattractants, including CCL3, CCL5 and 
eotaxin. Eotaxin, which interacts with CC chemokine receptor-3 (CCR3), primarily 
expressed on eosinophils, is the only chemokine characterized as a specific eosinophil 
chemoattractant. It functions synergistically with IL-5 to recruit eosinophils into the 
allergic lung (Pope, Brandt et al. 2001). 
Eosinophil adhesion molecules promote the transit of eosinophils across epithelial 
and endothelial barriers. The interaction of the integrin very late antigen-4 (VLA-4) and 
its ligands vascular cell adhesion molecule-1 (VCAM-1), P-selectin glycoprotein ligand-1 
(PSGL-1) and P-selectin promotes eosinophil recruitment into the lung compartment, 
while the interactions of integrin α4β7 and its ligand, mucosal addressin cell adhesion 
molecule (MAdCAM)-1, promotes eosinophil recruitment into the intestinal 
compartment. Eosinophils express Fc receptors for IgE, IgA and IgG, and cross-linking 
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 of these receptors by allergen co-activate eosinophils. Activated eosinophils secrete 
cytokines (IL-2, 3, 4, 5), chemokines (eotaxin-1 and RANTES) and lipid mediators 
(leukotrienes), which promote recruitment of cells, mucus secretion and smooth muscle 
constriction (Rothenberg and Hogan 2006; Rosenberg, Phipps et al. 2007; Wegmann 
2011).  
 
1.1.2.5. Dendritic cells (DC) 
1.1.2.5.1. Introduction to the dendritic cells 
DCs are the most efficient professional antigen presenting cells (APCs) and have 
an important role in the control of the adaptive immune responses (Steinman 2012). After 
antigen is engulfed by APCs, it is digested into its constituent peptides, which bind in the 
grooves of major histocompatibility complex (MHC) class I and/or MHC class II 
molecules. The MHC I or II-peptide complex is then transported to the surface of the 
APC to provide an antigen specific signal to CD8 or CD4 T cells, respectively. APCs 
also provide costimulatory signals (e.g., CD40, CD80 and 86, CD54) and cytokine 
signals to activate T cells (Chen, Linsley et al. 1993) although if the T cell expresses the 
Fas (CD95) molecule on its surface and receives signals from APCs that express Fas 
ligand, the T cells then undergo apoptosis. Other types of inhibitory T cell:APC 
interaction also can occur, such as the binding of CD80 expressed on DCs to cytotoxic T-
lymphocyte antigen-4 (CTLA-4, or CD152) on T cells (Steinman, Hawiger et al. 2003). 
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 1.1.2.5.2. Subsets of dendritic cells 
DCs arise from both of lymphoid and myeloid progenitors and are usually divided 
into two major subsets, conventional (previously known as myeloid) DCs (cDCs) and 
plasmacytoid DCs (pDCs). The many CD11chi DC populations can be classified as cDCs, 
which can potently stimulate T cell proliferation. CD11clow DC precursors with the 
appearance of plasma cells have been identified in human blood and are identical to the 
natural interferon (IFN) α/β–producing cells which secrete high levels of IFN-α/β in 
response to virus challenge. These plasmacytoid cells can give rise to DCs in vitro in the 
presence of IL-3 or during viral infections (Kadowaki, Antonenko et al. 2000). The 
corresponding murine type of IFNα/β-producing cell, consists of a population of 
Ly6C/Gr-1+, B220+, CD11b- and CD11clow DC (Asselin-Paturel, Boonstra et al. 2001; 
Nakano, Yanagita et al. 2001), which show a homogeneous plasmacytoid structure (i.e., a 
round shape, a smooth surface, and an eccentric nucleus). These plasmacytoid DCs 
(pDCs) can have immunostimulatory (Shaw, Wang et al.) and also immunoinhibitory 
properties (Wang, Peters et al. 2006), depending on the stimulus. In addition, CD103+ 
DCs, found in the gut, are found to be immunoinhibitory cells that can promote Foxp3+ 
Treg differentiation via retinoic acid (RA) to maintain oral tolerance (Coombes, Siddiqui 
et al. 2007; Sun, Hall et al. 2007). 
 
1.1.2.5.3. Dendritic cells and the polarization of the immune response 
Immature DCs express low levels of costimulatory and MHC Class II molecules, 
but possess high levels of phagocytosis function. On encounter of PRL-expressing 
pathogens these DC then become mature. Mature DCs up-regulate expression of LN-
 16  
 homing receptor CCR7; binding its ligands, CCL19 and CCL21, secreted by LN stromal 
cells, recruits those maturing DCs into the draining LNs (Sozzani, Allavena et al. 1998; 
Alvarez, Vollmann et al. 2008). In the draining LNs, the mature DCs express high levels 
of costimulatory and antigen-peptide loaded MHC Class II molecules and secrete IL-1, 
IL-6, IL-12, TNF-α and IFN-γ, and thereby activate cognate naïve T cells with which 
they interact. 
Both CD4+ T-helper cell (Th) and Treg are the central to the orchestration of 
asthmatic responses. After interaction of DCs and cognate naïve T cells in the draining 
LNs, the different cytokine predicts to induce different subsets of Th. IL-2, IL-12 and 
IFN-γ stimulate the expression of transcription factor T-bet (T-cell-specific T-box 
transcription factor 21) to induce Th1 cells for resistance to viruses, intracellular bacteria 
and tumors (Huang, Hao et al. 2007); IL-4 and IL-9 stimulate the expression of Gata-3 to 
induce Th2 cells for resistance to ectoparasites, but they are also associated with asthma; 
IL-6, IL-23 and TGF-β stimulate the expression of RORγt (retinoic-acid-related orphan 
receptor) to induce Th17 cells for resistance to extracellular bacteria; and IL-10 and TGF-
β stimulate the expression of Foxp3 to induce CD4+CD25+Foxp3+ Tregs for counter-
regulation of adaptive immunity (Figure 1-1) (Reiner 2007; Yamazaki, Bonito et al. 
2007; Dumitriu, Dunbar et al. 2009; Reiner 2009). 
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Figure 1-1. The Plasticity of CD4 T cells. 
After interaction between antigen-presenting DC and cognate naïve T cells, 
different cytokines differentially induce CD4 T cell differentiation. For example, IL-4 
and 9 induce Th2 cells which protect against parasites were associated with allergic 
disorders, including asthma. In another hand, TGF-β and IL-2 induce Treg cell which 
down-regulate adaptive immunity. 
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 1.1.2.5.4. Role of dendritic cells in infection 
During viral, bacterial, and parasitic infections, the induction of specific immunity 
related to these pathogens have been attributed to the relevant subsets of cDCs, including 
pulmonary interstitial DC, gut CD11c+ DC (Qualls, Tuna et al. 2009), migratory 
epidermal Langerhans cells (LCs), dermal DCs, as well as resident CD8+ and CD8- DCs 
found in the peripheral LNs and the spleen (Villadangos and Schnorrer 2007). Dramatic 
increases in the number of cDCs have been widely reported in both the infection sites, 
such as the skin, and the associated draining LNs or the spleen (Martin, Ruiz et al. 2002). 
In skin infections, dermal DCs can efficiently activate CD4+ T cells within the draining 
LNs, whereas CD8+ DCs are highly efficient in activating CD8+ T cells and resident 
CD8- DCs preferentially activate CD4+ T cells (Dudziak, Kamphorst et al. 2007). Other 
studies have suggested that CD8+ and CD8- DCs induce Th1- and Th2-polarized 
responses, respectively (Maldonado-Lopez, Maliszewski et al. 2001). Th1 cells can also 
promote CD8+ cytotoxic T lymphocytes (CTL) development for cytolysis of tumors and 
viruses, and cells infected with intracellular bacteria (Wong and Pamer 2003). Th2 cells 
are for resistance to parasitic worms (Reiner 2007; Yamazaki, Bonito et al. 2007; 
Dumitriu, Dunbar et al. 2009; Reiner 2009). 
 
1.2. ASTHMA THERAPEUTICS 
There are many effective inhaled and oral drugs for the treatment of asthma. 
Generally these are classified into two categories: quick-relief medications and long-term 
control medications. Quick-relief medications are used to treat acute symptoms. They 
include short-acting beta2-adrenoceptor agonists and anticholinergic medications. Long-
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 term control medications are often used daily to control asthma inflammations and 
symptoms thereby prevent acute episodes. They include glucocorticoids (GCs), long- 
acting beta2-adrenoceptor agonists (bronchodilators), leukotriene antagonists and 
theophylline. Asthma medications in different categories can be used alone or in 
combination to maintain control of symptoms and prevent further exacerbation. Anti-IgE 
therapy is a supplementary treatment and can be considered in patients who have poorly 
controlled and persistent asthma. Anti-cytokine therapy for asthma is being explored in 
clinical trails and has succeeded in some studies. In addition, cyclooxygenase is a key 
mediator of inflammation and cyclooxygenase (COX) antagonists may have the potential 
to become an attractive medicine for asthma therapeutics. 
 
1.2.1. Steroids vs bronchodilators 
Currently, the main drugs used to treat asthma include anti-inflammatory drugs 
(steroids) that suppress inflammation in the airway and bronchodilators that act by 
relaxing airway smooth muscle (Bateman, Hurd et al. 2008). 
Glucocorticoids are the most effective treatment to control asthma. Inhaled 
corticosteroids (ICS) have become a major therapy for all asthma patients with long-term 
symptoms. There are several cellular and molecular mechanisms involved in the anti-
inflammatory effects of glucocorticoids (Barnes 2011). Lipid-soluble glucocorticoids are 
able to easily pass through the cell membrane and bind to glucocorticoid receptors (GRs) 
in the cytoplasm. Once bound, GRs are activated and quickly translocate to the nucleus 
where they perform their molecular functions. GRs homodimerize and bind to 
glucocorticoid response elements within the promoters for target genes such as SLPI 
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 (secretory leukoprotease inhibitor), MKP-1 (MAPK phosphatase-1) and GILZ 
(glucocorticoid-induced leucine zipper). The DNA-bound GRs also suppress 
transcription of multiple inflammatory genes by interacting with transcriptional activators 
such as CBP (cAMP-responsive element-binding protein-binding protein). The 
inflammatory genes switched off by glucocorticoids include cytokines, chemokines, 
adhesion molecules and inflammatory enzymes. In addition, glucocorticoids have post-
transcriptional effects through destabilizing mRNAs of inflammatory proteins such as 
TNF-, IL-6 and GM-CSF and thus reduce expression of these cytokines. For example, 
glucocorticoids are able to increase the expression of a zinc finger protein, tristetraprolin, 
which binds to the AU-rich untranslated region of mRNAs of inflammatory proteins, 
resulting in mRNA destabilization (Barnes 2011).  
2-adrenoceptor agonists are the most effective bronchodilators for asthma. They 
function as antagonists by reversing smooth muscle contraction in the airway. 2-
adrenoceptor agonists bind to 2-adrenergic receptors and increase the formation of 
intracellular cAMP via coupling of 2-adrenergic receptors to a stimulatory G protein 
(Gs protein). cAMP activates PKA, which phosphorylates myosin light chain kinase, 
resulting in the relaxation of airway smooth muscle. Increased cAMP also inhibits the 
proliferation of airway smooth muscle cells. In addition, interactions between 2-
adrenergic receptors and their agonists directly open large conductance Ca2+ channels, 
decreasing intracellular Ca2+ level, thereby inhibiting the activation of myosin light chain 
kinase and eventually relaxing airway smooth muscle cells (Barnes 2011). 
There are important interactions between glucocorticoids and 2-adrenoceptor 
agonists (Newton, Leigh et al. 2010). They are often used in fixed-combination inhalers. 
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 Glucocorticoids increase cell surface expression of the 2-adrenergic receptors, which 
compensate for the down-regulation of the 2-adrenergic receptors after long-term use of 
2-adrenoceptor agonists. Glucocorticoids also enhance the activity of 2-adrenoceptor 
agonists by promoting the coupling of 2-adrenergic receptors to Gs protein. On the other 
hand, 2-adrenoceptor agonists increase the anti-inflammatory effects of glucocorticoids 
by affecting glucocorticoid receptor function. Long-acting 2-adrenoceptor agonists 
enhance the translocation of glucocorticoid receptor from the cytoplasm to nucleus 
following activation by glucocorticoids. Therefore, steroids and bronchodilators enhance 
each other’s advantageous effects in asthma therapy. 
 
1.2.2. Anti-IgE therapy 
IgE is a crucial mediator in allergic asthma. IgE can be synthesized locally in 
airway mucosa. Antigen-specific IgE binds to high-affinity receptors (FcRI) on mast 
cells, basophils and neutrophils. FcRI-bound IgE enhances antigen presentation and 
promotes Th2 responses. When IgE encounters the same antigen again, it cross-links and 
activates mast cells and basophils, which triggers the degranulation and release of various 
inflammatory mediators. It has been shown that IgE levels correlate with the occurrence 
of asthma symptoms, AHR and severe exacerbations. 
Because of the pivotal role of IgE in allergic asthma, targeting IgE and blocking 
its functions may bring significant clinical benefits for asthmatic patients (Kuhl and 
Hanania 2012). Xolair (Omalizumab) is the only available anti-IgE medicine approved by 
the FDA. It is a recombinant humanized IgG1 monoclonal antibody given by injection 
one to two times a month. Xolair attaches to circulating free IgE and prevents it from 
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 binding with FcRI on mast cells and basophils to block the downstream cascade of 
asthma responses. 
Xolair is an add-on therapy to inhaled corticosteroids (ICS) and long acting 2-
adrenoceptor agonists. It is used for patients over 12 years of age with poorly controlled 
moderate to severe persistent allergic asthma. Xolair's beneficial effects include reduction 
of free IgE levels in serum, downregulation of FcRI expression on basophils, mast cells 
and DCs, and reduction of cell number in eosinophils, T cells and B cells in the airway of 
patients with allergic asthma (Holgate, Buhl et al. 2009; Holgate, Smith et al. 2009). 
Xolair has been demonstrated to decrease asthma episodes and has long-term beneficial 
efficacy in some patients. In addition, clinical data shows the long-term safety of Xolair 
adminstration. There are several rare, yet severe side-effects reported, including 
anaphylaxis and malignancy. Future research will need to evaluate the long-term effects 
of Xolair, particularly in children and elderly people.  
 
1.2.3. Anti-cytokine therapy 
The inflammatory processes in asthma are orchestrated by a cytokine network. 
Asthma is now recognized as a heterogeneous disorder. Th2 responses dominate in mild 
to moderate allergic asthma, whereas a mixed Th2/Th1 responses with a Th17 constituent 
involve in severe steroid-resistant asthma (Hansbro, Kaiko et al. 2011). Cytokine profiles 
produced by innate immune cells and structural cells in the airway are responsible for 
driving the differentiation of various Th cell subsets and sequentially presenting different 
pathogenetic features of asthma. IL-1, IL-6 and TGF- drive Th17 cell development. IL-
12 and IFN- promote Th1 responses. IL-4, TSLP, IL-25 and IL-33 induce Th2 responses, 
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 which elicit predominately eosinophil, basophil and mast cell inflammation in the airway 
(allergic or eosinophilic asthma). Patients with eosinophilic asthma are generally 
sensitive to steroid treatment and have stable mild-to-moderate symptoms. Th1 and Th17 
responses in the lung facilitate neutrophilic or neutrophilic with low level eosinophilic 
inflammation (neutrophilic asthma). Patients with neutrophilic asthma are mainly steroid-
resistant and have severe asthma symptoms that involve TNF-, IFN- and IL-17. 
Patients with both subtypes of asthma can have acute exacerbations triggered by various 
allergens and infections (Hansbro, Kaiko et al. 2011).  
Glucocorticoids, either alone or in combination with long-acting 2-adrenoceptor 
agonists are the mainstay for asthma therapy, excluding that of steroid-resistant patients. 
Anti-cytokine therapy may become an alternative tool to treat refractory asthma. To date, 
there have been many clinical trials employing inhibitors of cytokines. These cytokines 
include IL-4, IL-5, TNF-, IL-13, IL-9, GM-CSF, IFN-, IFN-, IL-10 and IL-12 (Desai 
and Brightling 2009; Hansbro, Kaiko et al. 2011). Other potential cytokines such as IL-25, 
IL-33, TSLP, IL-17 and IL-27 that involve in severe asthma are being developed as new 
anti-inflammatory targets for asthma therapy (Hansbro, Kaiko et al. 2011).  
Recently Corren et al conducted a clinical trial with a monoclonal antibody to IL-
4R (AMG317) in patients with moderate-to-serve asthma (Corren, Busse et al. 2010). 
IL-4 and IL-13 are two key cytokines made by Th2 cells and thereby are essential for 
allergic inflammation. IL-4R is a common component of IL-4 and IL-13 receptors. 
Therefore AMG317 would block both IL-4 and IL-13 pathways. The results 
demonstrated that AM317 had beneficial effects on asthma symptoms and lung function 
in patients with uncontrolled and severe asthma, but not in all groups of patients. 
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 Anti-IL-5 monoclonal antibody (mepolizumab) was evaluated in several clinical 
trials (Flood-Page, Swenson et al. 2007). The results showed that anti-IL-5 treatment was 
beneficial to patients with elevated numbers of eosinophils and severe exacerbations that 
are resistant to steroid treatment. 
Anti-TNF- monoclonal antibody (Infliximab) was tested in humans and shown 
to improve some lung functions and to decrease exacerbations in moderate asthma (Erin, 
Leaker et al. 2006; Morjaria, Chauhan et al. 2008). A soluble TNFα receptor-IgG1Fc 
fusion protein (etanercept) that neutralize TNF- was evaluated in a clinical trial with 
some promising results, including decreased airway histamine levels and AHR and 
improved lung function in refractory asthma (Berry, Hargadon et al. 2006). 
Although various anti-cytokine clinical trials are being explored for asthma 
therapy, only a few of them have had success. This may reflect various treatment regimes 
and the patients selected in the different studies, but since many cytokines are involved in 
asthma, combination therapies that inhibit multiple cytokines may prove to be most 
effective. 
 
1.2.4. Cyclooxygenase (COX) antagonists 
The cyclooxygenase is the enzyme that promotes the conversion of arachidonic 
acid (AA) into prostaglandins (PGs), the key mediators of inflammation. PGs released by 
inflammatory cells amplify smooth muscle contraction and airway inflammation. 
Because of its crucial role in PG production, COX has the potential to be a target for 
asthma therapy (Malhotra, Deshmukh et al. 2012). 
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 The COX enzyme exists as two isoforms, COX-1 and COX-2. COX-1 is 
constitutively expressed in most normal tissues and has a role in regulating basal 
physiological processes. For example, PG regulated by COX-1 in the stomach lining 
prevents the stomach mucosa from being corroded by its own acid. COX-2 is normally 
expressed at low levels and is highly induced by pro-inflammatory cytokines such as IL-1 
and TNF-, which indicates that COX-2 may play a role in the pathophysiology of 
inflammatory conditions such as asthma. The discovery of COX-2 raised the idea that 
selective inhibition of COX-2 would result in only anti-inflammatory effects without 
interfering with the protective physiological processes of PGs.  
To date, COX inhibitors, such as the non-steroidal anti-inflammatory drugs 
(NSAID) for pain and arthritis, have been extensively studied and widely used in the 
clinic, but data on COX inhibitors for respiratory disease is limited and conflicting. 
Aspirin and other NSAIDS inhibit both COX-1 and COX-2. It is generally 
accepted that the beneficial anti-inflammatory effects of NSAIDS are due to inhibition of 
COX-2 and the harmful effects of NSAIDS are due to inhibition of COX-1. Aspirin can 
cause asthma to worsen in 3-5% of asthmatic people. Research has shown that when 
aspirin blocks PG formation in these asthma-sensitive people, the arachidonic acid 
cascade shifts entirely to leukotrienes, overproduction of which leads to the severe 
allergy-like effects. A recent study conducted by Ishiura et al demonstratrd that a potent, 
specific COX-2 inhibitor (etodolac) attenuated airway cough reflex sensitivity in asthma 
patients (Ishiura, Fujimura et al. 2009).  
Studies using knockout (KO) mice showed that COX-1- and COX-2-KO mice 
had normal basal lung function and lung histology (Gavett, Madison et al. 1999). 
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 Following allergen challenge, both COX-1- and COX-2-KO mice had more 
inflammatory cells and mediators in the lung than wild-type mice. Both COX-1- and 
COX-2-KO mice had increased brochoconstriction compared with wide-type mice 
(Zeldin, Wohlford-Lenane et al. 2001). There are several studies demonstrating that COX 
products reduce inflammation and AHR and that these effects are regulated through 
inhibition of Th2 responses. Therefore, although the current concepts favor COX 
inhibitors as potential drugs for airway diseases, these studies suggest that COX enzyme 
itself may serve as a drug for asthma. More research is required to clarify the mechanisms 
of action of COX metabolites. 
 
1.3. TOLERANCE IN ALLERGIC DISEASE  
There is a fine balance between immunity and tolerance in the stable state. In 
general, stimulatory DCs (e.g. mature CD11chicDC) and Teff cells (e.g. Th1, Th2, Th17) 
mediate antigen-specific immunity, whereas, tolerogenic DCs (e.g. pDC, intestinal 
CD103+DC, IL-10-secreting DC) and regulatory lymphocytes (e.g. Treg cells, CD8+ T 
regulatory cells, Breg cells) mediate antigen specific tolerance. The imbalance between 
immunity and tolerance results in allergic decease, autoimmunity or cancer (Maldonado, 
von Andrian et al. 2010). 
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 1.3.1. Regulatory lymphocytes 
1.3.1.1. CD4+CD25+ T regulatory cells 
CD4+CD25+ Tregs are characterized as having a powerful inhibitory capacity, 
consistent with their role in maintaining immunological self-tolerance in the periphery. 
Tregs not only control the development of autoimmune diseases, but also regulate or 
suppress allergy, transplant rejection, tumor immunity and responses to microbes. 
 
1.3.1.1.1. The biology of CD4+CD25+ T regulatory cells 
The IL-2 receptor α-chain (CD25) has been considered an activated T cell marker 
by immunologists for decades. In 1995, Sakaguchi published the seminal discovery that 
one subset of CD4+ T cells very strongly expressed CD25 in naïve mice and these 
CD4+CD25+ T cells potently down-regulated immune responses to self and non-self 
antigens (Sakaguchi, Sakaguchi et al. 1995). Subsequently, numerous laboratories 
confirmed that CD4+CD25+ Treg cell expressed the forkhead box protein 3 (Foxp3). So 
far, Foxp3 has been found as the most important marker for Tregs (Randolph and 
Fathman 2006; Yamazaki, Bonito et al. 2007). 
There are at least two main types of Foxp3+CD25+CD4+Treg: natural Treg 
(nTreg), naturally occurring from thymus, and induced Treg (iTreg), derived from Foxp3-
CD25-CD4+ T cells in the periphery by stimulation with transforming growth factor 
(TGF)-β (Bilate and Lafaille 2012). The iTreg are further comprised of IL-10-producing 
regulatory type 1 T cells (Tr1), TGF-β producing T helper cells (Th3), and inducible 
Foxp3+ T cells. At present, there are no markers to distinguish nTreg and iTreg. Both 
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 types are Foxp3+ and CD4+ and the majority are CD25+. Treg represent about 5% of 
peripheral blood CD4+ T cells in normal rodents and humans. Treg cells can directly 
suppress responder Foxp3- T cells via the following mechanisms: (1) Treg cells may 
secrete suppressor cytokines (IL-10, TGF-β) to directly inhibit the function of responder 
T cells and myeloid cells; (2) Treg cells highly express CD25 to compete with effector T 
cells for IL-2. The effector cells undergo apoptosis without sufficient stimulation of IL-2 
(Pandiyan, Zheng et al. 2007); and (3) some Treg cells can express granzyme A, B and 
perforin to kill target effector cells (Grossman, Verbsky et al. 2004; Gondek, Lu et al. 
2005). Treg cells can also indirectly suppress responder Foxp3- T cells through 
suppression of antigen-presenting cell (APC) (Randolph and Fathman 2006).  
Other markers which are thought to be associated with regulatory functions 
include inducible costimulatory molecule (ICOS), programmed cell death-1 (PD-1), 
glucocorticoid-induced TNF-receptor-related protein (GITR), lymphocyte activation gene 
3 (LAG3) and CTLA-4 (Ohkura and Sakaguchi 2011). Treg cells substantially express 
CTLA-4 on their surface (Marta, Xuguang et al. 2008), which downregulates the 
costimulatory molecules (CD80 and CD86) on the APC (Wing, Onishi et al. 2008). LAG-
3 on Treg cells interacts with the MHC class II molecule on DCs, resulting in an 
inhibitory signal that suppresses DC maturation (Liang, Workman et al. 2008). In 
general, immature DCs expressing low amounts of costimulatory molecules are 
immunoinhibitory (Perrot, Blanchard et al. 2007). It will be essential to understand how 
to control antigen-specific Treg so that these can specifically suppress a given clinical 
problem like autoimmunity, allergy and transplant rejection by Treg-based immune 
therapy, without blocking critical immune responses to tumor and microbes.  
 29  
  
1.3.1.1.2. Therapeutic applications for CD4+CD25+ T regulatory cells 
1.3.1.1.2.1. Preclinical evidence to support Treg cell adoptive therapy in asthma and 
allergy 
Numerous laboratories have noted the importance of Treg cells in asthma, and 
suggested that asthma is due to an imbalance between allergen-specific Treg cells and 
Th2 cells (Stock, DeKruyff et al. 2006). A number of recent studies indicate that Treg 
cells play an important role in controlling allergic diseases and asthma that are caused by 
exaggerated Th2 -biased immune responses (Wing and Sakaguchi 2006). Strickland et al 
demonstrated that prevention of the aeroallergen-induced airway mucosal T cell 
activation and resultant airways hyperresponsiveness (AHR) in sensitized rats was 
mediated by CD4+CD25+Foxp3+LAG3+ CTLA-4+CD45RC+ T cells which appeared in 
the airway mucosa and regional LNs, and inhibited subsequent Th2-mediated 
upregulation of airway mucosal DCs function (Strickland, Stumbles et al. 2006). 
Lewkowich et al reported that depletion of Treg cells enhanced HDM-specific IgE 
synthesis and Th2 cytokine (IL-4, IL-5, IL-10 and IL-13) production (Lewkowich, 
Herman et al. 2005). Evidence from preclinical models demonstrates a central role for 
Tregs in controlling allergic disease. Adoptive transfer of Treg cells represents a potential 
therapeutic approach. 
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 1.3.1.1.2.2. Clinical trials of adoptively transferred Treg cells and Treg cell large-
scale manufacturing 
When purifying Treg cells, it is difficult to avoid contamination with activated 
CD4+ T cells, because, as an intracellular molecule, Foxp3 can not be used as a marker to 
purify Treg cells and CD25 is also expressed on activated T cells. Additionally, like 
conventional T cells (Tconv), Treg cells need T cell receptor (TCR) triggering and 
costimulation to become fully activated. 
Large-scale ex vivo generation of Treg cells has been reported. Briefly, Treg cells 
are purified from adult peripheral blood apheresis preparations or umbilical cord blood. 
For peripheral blood apheresis, CD4+ T cells are negatively selected by depletion of CD8, 
CD14, and CD19 with either magnetic beads or flow cytometry techniques (Godfrey, Ge 
et al. 2004). For umbilical cord blood, the negative selection of CD4+ T cells is not 
required (Godfrey, Spoden et al. 2005), while CD4+CD25hi cells are positively selected 
using sub-saturating concentration of CD25 antibody, after which the purified Treg cells 
are expanded by activating the cells with CD3 and CD28 mAb-coated microbeads. 
Exogenous IL-2, rapamycin and an irradiated feeder cell layer are also added to the 
cultures (Godfrey, Ge et al. 2004; Battaglia, Stabilini et al. 2005; Godfrey, Spoden et al. 
2005; Hippen, Merkel et al. 2011). Recently, Wang J et al found that all-trans-retinoic 
acid (ATRA) and TGF-β consistently induces de novo generation of CD4+Foxp3+ Treg 
cells with potent and constant suppressive ability from CD4+CD25–CD45RA+ naive T 
cells in adult human peripheral blood (Wang, Huizinga et al. 2009). Such de novo 
generation of Treg cells from non-Treg cells represents a promising strategy to obtain 
sufficient Treg cells for adoptive immunotherapy. 
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 Although adoptive Treg cell therapy is a promising approach for autoimmune and 
allergic diseases, we still have a long way to go to cure these diseases. The real 
challenges are to identify Treg cell-specific surface markers to distinguish Treg cells 
from active T effector cells and to expand antigen-specific, highly-purified active Treg 
cells.  
 
1.3.1.2. CD8+ T regulatory cells 
CD4+ Foxp3+ Treg cells have been extensively studied over the past ten years and 
shown to play critical roles in preventing inflammatory damage in various disease models. 
Although CD8+ Tregs were shown in early studies to suppress CD4+ T cells (Noble, Zhao 
et al. 1998), their exact function and mechanisms of action were mostly unknown. Recent 
evidence has revealed that CD8+ Treg can play an important role in maintaining self-
tolerance (Kim and Cantor 2011). The regulation of self-tolerance was mediated by Qa-1-
restricted CD8+ T regulatory cells. Qa-1 is a non-classical MHC class I molecule that is 
expressed mainly on activated T cells, B cells and DCs. Qa-1 interacts with two distinct 
receptors that have opposing functions. Qa-1 engages with the TCR of CD8+ Treg, which 
results in the activation and proliferation of CD8+ Treg, but Qa-1 engages with 
CD94/NKG2A receptors, which results in the inhibition of CD8+ Treg. Kim et al 
generated Qa-1-mutant mice (Qa-1 D227K) in which the binding of Qa-1 to TCR on 
CD8+ Treg was interrupted but the interaction between Qa-1 and the Inhibitory NKG2A 
receptor on CD8+ Treg was intact (Kim, Verbinnen et al. 2010). Therefore these Qa-1-
mutant mice lack CD8+ Treg activity. At about six months of age, the Qa-1-mutant mice 
develop a severe lupus-like autoimmune disorder characterized by generation of 
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 autoantibodies to multiple tissues (Kim, Verbinnen et al. 2010). Follicular T helper cells 
(TFH) are a subset of Th cells (~5% CD4 cells) that control antigen-specific B cell 
immunity (Crotty 2011). TFH highly express Qa-1 in the normal state and are the 
preferential target of Qa-1-restricted CD8+ Treg cells. Since Qa-1-restricted CD8+ Treg 
cells from Qa-1 mutant mice are unable to be activated through Qa-1-and TCR receptor 
interaction, the lack of suppressive effects of Qa-1-restricted CD8+ Treg cell on TFH leads 
to production of autoantibodies. 
Qa-1-restricted CD8+ Treg cells can be identified by a triad of surface markers: 
CD44, CD122 and Ly49 (Kim, Wang et al. 2011). Ly49 is a MHC class I inhibitory 
receptor. Ly49+CD8 cells effectively inhibit CD4+ T cells from wild-type, but not from 
Qa-1 mutant, mice indicating that Ly49+ CD8+ T cells possess Qa-1-dependent inhibitory 
activity. However Ly49- CD8+ T cells do not inhibit CD4 responses (Kim, Wang et al. 
2011). CD44+CD122+Ly49+ CD8+ T cells comprise 3-5% of all CD8+ T cells.  
The suppressive activity exerted by Qa-1-restricted CD8+ Treg cells is mediated 
by perforin, which results in elimination of target TFH cells (Kim, Verbinnen et al. 2010). 
Such elimination of target TFH cells, which may include self-reactive CD4+ T cell clones, 
may represent a very efficient suppressive mechanism compared with induction of anergy. 
In addition, Qa-1-restricted CD8+ T reg cells are dependant on IL-15 for development 
and activity (Kim, Verbinnen et al. 2010).  
Further studies demonstrated that TFH cells from Qa-1 mutant mice but not from 
wild-type mice promote potent antibody responses in syngeneic mice with a complete 
supplement of CD4+ Treg cells, indicating that this immune response was controlled via 
host Qa-1-restricted CD8+ Treg cell-dependant suppression on donor TFH cells (Kim, 
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 Verbinnen et al. 2010). Therefore, Qa-1-restricted CD8+ Treg cells are essential to 
maintaining self-tolerance and preventing autoimmune. 
 
1.3.1.3. Regulatory B cells 
B cells have been mainly considered to positively regulate immune responses 
through their production of antibodies and by acting as APCs to promote T cell activation. 
However, recent findings revealed that B cells also include a regulatory subset 
(regulatory B cell, Breg) that can suppress immune responses in both mice and humans 
(Mauri and Bosma 2012). The key trait of Breg is production of IL-10, which suppresses 
proinflammatory cytokine generation and facilitates Treg differentiation. Emerging data 
have demonstrated that IL-10-producing Bregs inhibit excessive inflammatory responses 
that are present in autoimmune diseases or that can arise during unresolved infections. It 
is reported that mice lacking endogenous IL-10-producing Bregs develop exacerbated 
disease and present with an increased frequency of Th1/Th17 cells and reduced numbers 
of Tregs (Carter, Vasconcellos et al. 2011). 
Since Bregs have much diversity in phenotype and no identified master regulator 
transcription factor, there has been no unique marker or set of markers to identify this 
population. It is generally accepted that Bregs may have a common progenitor: 
transitional 2-marginal zone precursor B cells (T2-MZP B cells) that are CD19+Cd21hi 
CD23 hi CD24 hi IgD hi IgM hi CD1d hi. T2-MZP B cells are immature B cells and able to 
differentiate into various phenotypes of Bregs after exposure to different environmental 
triggers. 
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 A number of molecules are involved in Breg cell function and differentiation. 
Toll-like receptors (TLRs) are a family of pattern recognition receptor (PRR) that 
recognize structurally-conserved molecules derived from pathogens. TLR engagement on 
DCs drives proinflammatory responses, but TLR engagement on B cells initiates a 
negative-regulatory effect that restrains excessive inflammatory responses. It is reported 
that the stimulation of marginal zone (MZ) B cells with TLR2 and TLR4 agonists induces 
IL-10 and IL-6 production (Lampropoulou, Hoehlig et al. 2008). 
Interaction between CD40 on B cells and CD40L (CD154) on activated T cells 
generally induces B cell maturation and antibody production, but prolonged strong 
stimulation via CD40 has a suppressive effect on antibody production (Miyashita, 
McIlraith et al. 1997). Several studies have showed that CD40-CD40L interactions are an 
essential signal for Breg activation. In addition, the IL-10 induced by TLR engagement 
on marginal zone (MZ) B cells is further increased after CD40 engagement. These results 
suggest that the optimal production of IL-10 takes place when B cells receive signals via 
both TLR and CD40. 
In addition to TLR and CD40 stimulation, several studies have shown that the 
activation of Bregs also requires B cell receptor (BCR) signalling or antigen recognition 
by Bregs (Yanaba, Bouaziz et al. 2008), such that a two-step pathway for Breg 
development has been proposed. In step 1, common progenitor T2-MZP Bregs are 
initially activated by TLR stimulation and release the first wave of IL-10. In step 2, as the 
inflammatory response ensues and intensifies, Bregs are further activated via CD40 and 
BCR pathways and release an optimal amount of IL-10. The release of IL-10 is the main 
suppressive mechanism for Bregs (Mauri and Bosma 2012). IL-10 production by Bregs 
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 results in the suppression of Th1, Th17, and cytotoxic CD8+ T cells and the 
differentiation of Tregs. Several studies have demonstrated that IL-10 produced by Bregs 
is pivotal for the differentiation and maintenance of the pool of Foxp3+ Tregs (Sun, Flach 
et al. 2008; Sun, Czerkinsky et al. 2012) and Tr1 cells (Blair, Chavez-Rueda et al. 2009). 
It was also reported that Bregs induced the proliferation of Tregs in an IL-10-independent 
manner (Ray, Basu et al. 2012). In addition, activated Bregs can express Fas ligand (FasL) 
to mediate apoptosis of the target T cells and secrete TGF-β to induce immune 
suppression (Mauri and Bosma 2012). 
 
1.3.2. Regulatory DC 
Besides being inducers of immune reactivity, DCs are also critical regulators in 
the induction and maintenance of immune tolerance. Regulatory DCs comprise a 
heterogenous population that shows phenotypical and functional plasticity. Regulatory 
DCs induce immune tolerance by a variety of mechanisms, including the generation of 
anergy, deletion of effector T cells, stimulation of Treg cells and production of inhibitory 
molecules such as IL-10 or IDO. 
 
1.3.2.1. CD103+ DC 
Numerous research groups found that a functionally specialized population of 
intestinal CD103+ DC induces Foxp3+ Tregs via a TGF-β- and retinoic acid (RA)-
dependent mechanism. CD103+ DCs used not only endogenous TGF-β to induce Foxp3+ 
Treg, but also RA, which acts as a co-factor with TGF-β to induce Foxp3+ Treg 
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 (Coombes, Siddiqui et al. 2007; Sun, Hall et al. 2007; McDole, Wheeler et al. 2012). RA 
alone cannot induce Foxp3+ Treg from Foxp3- cells, but the Treg induced by TGF-β plus 
RA are more stable and more efficient than the Treg induced by TGF-β alone (Sun, Hall 
et al. 2007). It is well recognized that intestinal CD103+ DCs present intestinal antigens 
to induce Foxp3+ Treg maintains oral tolerance (Scott, Aumeunier et al. 2011). 
The function of pulmonary CD103+ DCs are still controversial. Furuhashi K et al 
reported that CD103+ DCs predominantly induce Th1, Th17 immune responses, while 
CD11bhigh DCs provoke Th2 responses under steady state conditions in the lung, whereas 
Nakano H et al reported that pulmonary CD103+ DCs prime Th2 responses to inhaled 
allergens (Furuhashi, Suda et al. 2012; Nakano, Free et al. 2012). More work is required 
to determine the exact function of CD103+ DC in the lung, but current evidence suggests 
that, unlike their intestinal counterparts, they can promote Teff cell responses. 
 
1.3.2.2. CD8+ DEC-205+ DC 
Conventional DCs can be divided into two major subsets in the mouse spleen. 
One is CD8+ DEC-205+ and the other is CD8- DCIR-2+ (dendritic cell inhibitory receptor-
2) (Dudziak, Kamphorst et al. 2007). CD8+ DEC-205+ DCs can induce Foxp3+ Treg from 
Foxp3- DO11.10 RAG-2 deficient CD4+ T cells with antigen but without any exogenous 
source of TGF-β (Yamazaki, Dudziak et al. 2008). The induction of Foxp3+ Treg by 
CD8+ DEC-205+ DCs was blocked by neutralizing anti-TGF-β mAb, indicating an 
endogenous source of TGF-β. In contrast, CD8- DCIR-2+ DCs from the spleen require 
TGF-β as well as antigen in the culture to induce Foxp3+ Treg in vitro. The induced 
Foxp3+ Treg in these experiments showed suppressive activity in vitro. It is reported that 
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 CD8+ splenic DCs preferentially express Programmed death 1 ligand (PDL-1) and that 
this is essential to induce Foxp3+ Treg in the presence of exogenous TGF-β (Wang, Pino-
Lagos et al. 2008). CD8+ DEC-205+ DCs might contribute to systemic tolerance in the 
periphery by inducing tissue-antigen specific Foxp3+ Treg. In order to investigate the 
importance of these two DC subsets in inducing Foxp3+ Treg in vivo, OVA was 
engineered into anti-DEC-205 mAb (DEC-OVA) or anti-DCIR-2 33D1 mAb (33D1-
OVA). In vivo injection of these chimera Abs delivers antigen to each DC subset 
selectively. The results showed that antigen targeting via DEC-205 led to the induction of 
Foxp3+ Treg from Foxp3- precursors, whereas antigen targeting via 33D1 mAb expanded 
natural Foxp3+ Treg in vivo(Yamazaki, Dudziak et al. 2008). These data suggest that 
CD8+ DEC-205+ DCs and CD8- DCIR-2+ DCs may have different roles in inducing 
Foxp3+ Treg from Foxp3- precursors and maintaining natural Foxp3+ Treg in the 
periphery.  
The functions of CD8α+ and CD8α- DCs were also explored in our previous study 
(Gordon, Li et al. 2005). We reported that CD8α+, but not CD8α- DCs from the spleens of 
normal mice used multiple mechanisms to inhibit the Th2 responses of cells from OVA 
induced asthmatic mice. This inhibition could largely be reversed by anti-IL-10 or anti-
TGF-β Ab treatment. In addition, loss of direct DC-T cell contact also reduced inhibition, 
although to a lesser extent. Adoptive transfer of OVA-pulsed CD8α+, but not CD8α- DCs 
was able to reverse AHR, Th2, and eosinophil responses in mice with well-established 
asthma.  
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 1.3.2.3. Plasmacytoid DC 
The conventional DCs (cDC) cells enter LNs through the afferent lymphatics 
under the influence of CCR7 binding to its ligands, CCL19 and CCL21, which are 
secreted by LN stromal cells. In contrast, pDC enter LNs through high endothelial 
venules (HEVs) via utilization of L-selectin (CD62L) and E-selectin (CD62E), CXCR3 
play a critical role in the pDC migration (Randolph, Ochando et al. 2008). 
The pDCs produce large amounts of type I interferons (IFNs) following Toll-like 
receptor (TLR) recognition of nucleic acids. Numerous experiments have demonstrated 
that pDCs play an important role in the induction of tolerance within the airway mucosal 
system (Castellaneta, Abe et al. 2004; Goubier, Dubois et al. 2008). In contrast to cDCs, 
pDCs present the antigen in an immunosuppressive manner to CD4+ T cells (de Heer, 
Hammad et al. 2004). That pDCs stimulate the induction of Treg cells has been found in 
both in vitro and in vivo studies, possibly in an ICOSL-dependent manner (Ito, Yang et 
al. 2007). The induced Treg cells also can give feedback to pDC to inhibit Th2 response 
by inducing the production of the tryptophan catabolizing enzyme indoleamine 2, 3-
dioxygenase (IDO) by the pDCs. Passive transfer of PD-L1-deficient (CD274-/-) pDCs 
failed to transfer this regulatory effect in allergic airway inflammation, indicating that 
pDC PD-L1 has a prominent role in dampening lung immune responses (Kool, van 
Nimwegen et al. 2009). 
Many laboratories have reported that pDCs mediate the induction of tolerance and 
the differentiation of Tregs in the lung. The deletion of pDCs turns inhalation of harmless 
antigen from a tolerance to a full immune response (de Heer, Hammad et al. 2004; 
Lambrecht and Hammad 2012). 
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1.3.2.4. The function of IL-10-treated DC 
IL-10 has been identified as a key immunomodulatory cytokine that is capable of 
mediating immunosuppressive effects in the immune systems. It has long been implicated 
in the induction and maintenance of T cell tolerance (Moore, de Waal Malefyt et al. 
2001; Ye, Huang et al. 2007). It reduces expression of MHC class II, ICAM-1, CD80 and 
CD86 on DCs, and this in effect prevents DCs from activating naïve T cells into Teff. IL-
10 also acts directly on CD4+ T cells to decrease their cytokine production and 
proliferation. As suggested above, antigen presentation by such ‘immature’ DC results in 
the induction of T cell anergy (Taga, Mostowski et al. 1993) or upregulation of Treg cell 
functions, leading to suppression of antigen-specific T cell responses (Steinbrink, 
Graulich et al. 2002). Many studies have demonstrated that IL-10-treated tolerogenic 
DCs (DC10) have powerful tolerogenic function in both mouse models and humans (ex 
vivo) (Steinbrink, Wolfl et al. 1997; Rutella, Danese et al. 2006; Koya, Matsuda et al. 
2007). Administration of allergen-presenting DC10 to ‘asthmatic’ mice restores their 
AHR, eosinophilia and Th2 responses to near normal levels (Shigeharu, Naomi et al. 
2008; Nayyar, Dawicki et al. 2012). 
In vitro, culture of bone marrow cells in the presence of IL-10 induces the 
differentiation of a distinct subset of DCs that express CD45RB (DC10). These DC10 
display an immature-like phenotype and secrete elevated levels of IL-10 after activation. 
The observation that DC10 secrete IL-10 may be linked to the stability of their immature-
like phenotype. As noted, IL-10 inhibits MHC class II and costimulatory molecules on 
APC, and this is thought to account for their reduced ability to productively present 
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 protein antigens to T cells. Immature DCs induce T cell anergy or Tregs, whereas mature 
DCs are potent inducers of effector T cells (Steinman, Hawiger et al. 2003).  
Both mouse and human IL-10-treated tolerogenic DCs have been used as 
powerful tools to abrogate asthmatic responses (Steinbrink, Wolfl et al. 1997; 
Bellinghausen, Brand et al. 2001; Muller, Muller et al. 2002; Wakkach, Fournier et al. 
2003; Bellinghausen, Konig et al. 2006; Koya, Matsuda et al. 2007; Perona-Wright, 
Anderton et al. 2007; Lau, Biester et al. 2008). Numerous laboratories, including ours (Li, 
Yang et al. 2010; Lu, Dawicki et al. 2011; Nayyar, Dawicki et al. 2012), have reported 
that administration of allergen-presenting bone marrow-derived DC10 to ‘asthmatic’ 
mice powerfully dampens their AHR, eosinophilia and Th2 responses. However, the 
mechanisms regulating this asthma tolerization by DC10 remain largely unknown. We 
previously reported that DC10 up-regulated the activity of CD4+CD25+ Treg (Li, Yang et 
al. 2010; Lu, Dawicki et al. 2011) and reversed the asthmatic Th2 phenotype via IDO 
(Nayyar, Dawicki et al. 2012). In this study, we further explored the differentiation of 
Treg cells in induction of tolerance by DC10.  
 
1.3.3. The interaction between DC and CD4+CD25+ T regulatory cells 
A large number of studies have reported the various mechanisms by which Treg 
can be induced. Overall, APCs, particularly DCs, are central to orchestration of the 
induction of Treg cells. Here, the role of DCs in inducing antigen-specific Foxp3+ Treg in 
the experimental settings is discussed. 
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 1.3.3.1. DCs can expand antigen-specific natural Treg  
Antigen-presenting DCs can stimulate the natural Treg cell proliferation. This 
nTreg expansion is partly dependent on CD80/CD86 on the DCs and IL-2. IL-2 is an 
imperative factor for the survival and homeostasis of Treg in vivo. Furthermore, the 
expanded Treg suppress graft versus host disease (GVHD) in an alloantigen-specific 
manner. Therefore, DCs are important APCs to expand antigen-specific natural Treg 
(Sayuri, Kayo et al. 2006). 
 
1.3.3.2. DCs can induce Foxp3+ Treg from Foxp3- precursors in the presence of 
TGF-β and IL-10. 
Numerous in vitro and in vivo studies have shown that co-delivery of TCR 
signaling, suboptimal costimulatory signals and immunosuppressive cytokines (IL-10 and 
TGF-β) facilitates the differentiation of Foxp3+Treg cells from Foxp3- precursor cells 
(Josefowicz, Lu et al. 2012). 
It has been reported that Foxp3+Treg cells can differentiate from CD25-CD4+ T 
cells under the influence of anti-CD3 and -CD28 antibodies and TGF-β (Chen, Jin et al. 
2003). DCs along with TGF-β can efficiently induce Foxp3+ Treg from CD25-CD4+ T 
cells, and these Treg induced have suppressive activity (Luo, Tarbell et al. 2007). One 
study by Yamazaki et al. has showed that both immature and mature populations of DCs 
induce antigen-specific Foxp3+Tregs from Foxp3- precursors with TGF-β. Using 
endogenous TGF-β, spleen DCs are 100-fold more potent than DC-depleted APCs for the 
induction of Tregs and require 10-fold lower doses of peptide antigen. IL-2 is essential, 
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 and can be provided endogenously by T cells stimulated by DCs, but not by other APCs. 
The induced Foxp3+Tregs exert suppression in vitro and block tumor immunity in vivo. 
These results indicate that DCs are more efficient in inducing Foxp3+ Treg from Foxp3- 
precursors than other APCs. Moreover, the induced Foxp3+ Tregs suppress immune 
responses in an antigen-specific manner (Yamazaki, Bonito et al. 2007). 
 
1.3.3.3. TGF-β- or IL-10-treated bone marrow-derived DCs induce Foxp3+ Treg 
from Foxp3- precursors. 
TGF-β treated tolerogenic DCs also have been reported to reverse or prevent 
asthmatic responses (Kosiewicz and Alard 2004; Zhang-Hoover, Finn et al. 2005). Many 
studies have reported that DC10 have powerful tolerogenic functions in both mouse 
models and humans (Steinbrink, Wolfl et al. 1997; Bellinghausen, Brand et al. 2001; 
Muller, Muller et al. 2002; Wakkach, Fournier et al. 2003; Bellinghausen, Konig et al. 
2006; Koya, Matsuda et al. 2007; Perona-Wright, Anderton et al. 2007; Lau, Biester et al. 
2008). Increasing evidence shows that DC10 can up-regulate the function and frequency 
of Treg cells (Bellinghausen, Konig et al. 2006; Li, Yang et al. 2010; Lu, Dawicki et al. 
2011). DC10 express low levels of costimulatory molecules (CD40, CD80, CD86) and 
MHC II, but secrete inhibitory cytokines (IL-10) and express inhibitory receptors or 
molecules [Ig-like transcript-2 (ILT2)]. Thus DC10 have a potential capacity to induce 
Treg cell. Our lab have reported that activated CD4+CD25+Foxp3+ Treg cells are induced 
by co-culture of specific allergen-presenting DC10 from atopic patients with autologous 
peripheral blood Th2 phenotype cells (Li, Yang et al. 2010). 
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CHAPTER 2: HYPOTHESIS AND OBJECTIVES 
 
Hypothesis: 
Tolerogenic DCs require at least three T cell-DC signals to induce 
CD4+CD25+Foxp3+ T regulatory cells in a mouse model of asthma. The induced Tregs 
are distinctly superior to natural regulatory T cells of the same specificity of allergen in 
their abilities to induce tolerance.  
 
Objectives: 
1. To demonstrate activities of tolerogenic DC10 that are affected by the 
expression of MHC II and costimulatory molecules as well as cytokine. 
2. To assess the role of three signals in Treg-associated marker expression of 
CD4+ Foxp3+ Treg cells by DC10. 
3. To demonstrate that tolerogenic DCs abrogate asthmatic response via induction 
of CD4+CD25+Foxp3+ T regulatory cells. 
4. To clarify whether iTreg or nTreg express higher Treg-associated markers  in 
the induction of tolerance by DC10. 
5. To clarify whether iTreg or nTreg from DC10-treated mice have greater 
inhibitory function for Th2 cells.  
6. To compare the in vivo regulatory activities of iTreg and nTreg in a mouse 
model of asthma.  
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Chapter 3: REGULATORY DENDRITIC CELL EXPRESSION OF MHCII AND 
IL-10 ARE JOINTLY REQUISITE FOR INDUCTION OF TOLERANCE IN A 
MURINE MODEL OF ASTHMA1  
 
Running title: Dendritic cell IL-10 and MHCII in tolerance 
Key Words: asthma; CD80/CD86; IL-10; MHCII; tolerogenic dendritic cells 
 
1This Chapter was has been invited for revision by Allergy for publication. 
 
 
Huang, H., W. Dawicki, M. Lu, X. Zhang, and J. R. Gordon. 2012. Regulatory Dendritic 
Cell Expression of MHCII and IL-10 Are Jointly Requisite for Induction of Tolerance in 
a Murine Model of Asthma. Submitted. 
 
Contribution: J.R.G. and H.H. designed the research; M.L. did preliminary experiments 
for Figure 3-1; X.Zh. set up the asthma mouse model, harvested BAL and did cytospin; 
H.H performed  all other experiments; J.R.G. and H.H. analyzed the results; J.R.G., H.H. 
and W.D. contributed to the writing of the manuscript; H.H wrote the first draft. 
 45  
 3.1. Abstract 
 
Allergen-presenting dendritic cells differentiated with IL-10 (DC10) reverse the 
asthma phenotype in mice by converting their Th2 cells to regulatory T cells (Treg). 
DC10 express elevated levels of IL-10 but substantially reduced levels of MHCII and co-
stimulatory molecules, so the relationships of these factors with each other and 
tolerogenicity have not been clearly elucidated. We assessed the roles of these inputs in 
DC10-driven reversal of asthma by treating affected mice with DC10 generated from 
wild-type or IL-10-sufficient MHC-II-/- or CD80/CD86-/- mice, or with MHCII-intact IL-
10-silenced DC10. IL-10 silencing did not discernibly affect the cells’ immunobiology 
(e.g., costimulatory molecules, chemokines), but it eliminated IL-10 secretion and the 
cell’s abilities to induce tolerance, as determined by assessments of airway 
hyperresponsiveness, eosinophilia and Th2 responses to recall allergen challenge. MHC-
II-/- DC10 expressed normal levels of IL-10, but nevertheless were unable to induce 
allergen tolerance in asthmatic mice, while tolerance induced by CD80/CD86-/- DC10 
was attenuated but not eliminated. We also assessed the induction of multiple Treg 
markers (e.g., ICOS, PD-1, GITR) on pulmonary CD25+Foxp3+ cells in the treated mice. 
Wild-type DC10 treatments up-regulated expression of each marker, while neither IL-10-
silenced or MHC-II-/- DC10 did so, and the CD80/86-/- DC10 induced an intermediate 
Treg activation phenotype. Both IL-10 and MCHII expression by DC10 are requisite, but 
not sufficient for tolerance induction, suggesting that DC10 and Th2 effector T cells must 
be brought together in a cognate fashion in order for their IL-10 to induce tolerance.  
 46  
 3.2. Introduction 
 
As professional antigen presenting cells (APCs), dendritic cells have an important 
role in the control of the adaptive immune responses. Activation of T cells by APCs 
requires three signaling events, one elicited by T cell receptor (TCR) recognition of the 
major histocompatibility complex (MHC)/peptide complex presented by the APC, 
another by the APCs’ co-stimulatory molecules (e.g., CD80, CD54) and a third T cell-
polarizing signal that emanates from the stimulated APC (e.g., IL-12 or IL-10). 
Depending on the nature of these three signals the dendritic cells can induce either T 
effector cell (Teff cell) or regulatory T cell (Treg cell) responses (Enk, Jonuleit et al. 1997; 
Steinbrink, Wolfl et al. 1997). It is thought that dendritic cells that express reduced levels 
of MHCII and costimulatory molecules thereby present antigen in an inherently 
inefficient manner, leading to T cell unresponsiveness or anergy (Taga, Mostowski et al. 
1993), but tolerogenic dendritic cells can also upregulate the activity of 
CD4+CD25+Foxp3+ Treg cells (Sakaguchi, Yamaguchi et al. 2008). IL-10 has been 
implicated in the induction and maintenance of T cell tolerance (Moore, de Waal Malefyt 
et al. 2001; Ye, Huang et al. 2007). It can reduce expression of MHC class II and co-
stimulatory molecules on dendritic cells and thereby induce anergy (Taga, Mostowski et 
al. 1993), but IL-10-exposed dendritic cells can express IL-10 themselves and thereby 
augment Treg cell responses (Steinbrink, Graulich et al. 2002). 
 There have been numerous reports of IL-10-treated or -exposed dendritic cells 
influencing tolerance in mouse models and in people (Enk, Jonuleit et al. 1997; 
Steinbrink, Wolfl et al. 1997; Rutella, Danese et al. 2006).  Instillation of allergen-
presenting DC10 into the airways of systemically-sensitized mice reduces the 
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 establishment of the asthma phenotype following airway allergen challenge and that is at 
least in part dependent on the dendritic cell’s IL-10 expression (Koya, Matsuda et al. 
2007). However, this leaves open the question of whether the IL-10 that is secreted by 
dendritic cells operates in the context of cognate dendritic cell-Th2 Teff cell interactions 
or whether it may exert its tolerogenic influence through by-stander effects. For example, 
infusion of IL-10 into the airway (van Scott, Justice et al. 2000) or airway epithelial 
transfection with an IL-10-expressing adenovirus (Fu, Chuang et al. 2006) both 
reportedly can dampen asthmatic Th2 responses. There are multiple reports showing that 
treatment of asthmatic mice with DC10 (Huang, Dawicki et al. 2010; Li, Yang et al. 2010; 
Lu, Dawicki et al. 2011) or with IL-10 lentivirus-transfected dendritic cells (Henry, 
Desmet et al. 2008) can fully reverse even well-entrenched asthma. Similarly, DC10 
generated from asthmatic individuals can induce autologous Th2 cell tolerance ex vivo, 
and they also do so by fostering the outgrowth of CD25+Foxp3+ Treg from within the 
donor’s Th2 Teff cell populations. These Treg express the activation markers lymphocyte 
activation gene 3 (LAG3) and cytotoxic T-lymphocyte antigen-4 (CTLA4) (Li, Yang et 
al. 2010). In mouse models DC10 induce Th2 Teff cells to trans-differentiate into Treg, 
and these activated Treg also express an array of activation markers, including LAG3, 
CTLA4, inducible costimulatory molecule (ICOS), programmed cell death-1 (PD-1), and 
glucocorticoid-induced TNF-receptor-related protein (GITR) (Huang, Dawicki et al. 
2010). Despite our knowledge regarding the capacity of DC10 to induce such tolerance, 
the contributions to tolerance outcomes of each of the three antigen-presentation signals 
offered by these cells, and their relationship(s) to one another have not been rigorously 
investigated. Herein we critically assessed the roles that the MHC-Ag-TCR complex, 
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 CD80/CD86 (i.e., costimulatory molecules) and IL-10 have in DC10-induced asthma 
tolerance. We generated DC10 from the bone marrow of H-2Iab-/- (i.e., MHC-II-/-) or 
CD80/86-/- mice and silenced IL-10 expression in wild-type DC10 using IL-10 small 
interfering RNA (siRNA), used these cells to treat asthmatic mice, and then characterized 
their impact on the asthma phenotype and on pulmonary Treg activation. 
 
3.3. Materials and methods 
 
3.3.1. Antibodies, cytokines and animals 
FITC-conjugated antimouse CD11c, CD40, CD54, CD80, CD86 and MHC class 
II (Iad) antibodies (Abs) as well as their isotype controls were purchased from BD 
Pharmingen Inc. (Mississauga, Ontario, Canada). PE-conjugated anti-mouse ICOS-1, 
PD-1, GITR, LAG-3 and CTLA-4 Abs as well as mouse regulatory T cell staining kit 
were purchased from eBioscience, Inc. (San Diego, CA). The recombinant mouse 
granulocyte macrophage colony stimulating factor (GM-CSF) and IL-10 were obtained 
from R & D Systems (Minneapolis, MN). Wild-type CD45.2+ and congenic CD45.1+ 
female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, 
MA), while CD80/86 and H-2Iab gene KO mice on C57BL/6 background were obtained 
from the Jackson Laboratory (Bar Harbor, Maine). All mice were maintained in the 
animal facility at Animal Care Unit and treated according to Animal Care Committee 
guidelines of University of Saskatchewan. 
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 3.3.2. Establishment of asthma mouse model and DC10 treatments 
The generation of DC10 and establishment of ASTHMA mouse were described 
previously (Gordon, Li et al. 2005; Huang, Dawicki et al. 2010). Briefly, DC10 were 
differentiated from bone marrow of wild type or CD80/86 and H-2Iab gene KO mice. To 
establish ASTHMA mice, C57BL/6 mice are given 2μg of ovalbumin (OVA)/alum by 
i.p. injection on day 0, 14, and on day 28, 30, 32, they were exposed to 1% OVA aerosols 
for 20 min/day. This protocol reliably induces a severe asthma-like phenotype, 
characterized by high-level pulmonary Th2 cytokine (IL-4, -5, -9, and -13) and antibody 
(IgE and IgG1) responses to OVA, ≈40-60% airway eosinophilia and AHR to 
methacholine challenge. After a period of two wks, during which the pulmonary 
inflammatory responses (but not AHR or Th2 reactivity) subside, the mice are injected 
i.p. with 1×106/mouse DC10 (Schneider, Li et al. 2001). 
 
3.3.3. Tracking of DC10 in vivo 
Allergen-loaded CD45.1+ congenic B6 mouse DC10 were injected i.p. into 
asthmatic CD45.2+ congenic B6 mice (5×106 cells/mouse). After 2, 7, 14, 21 d, we 
collected the lungs, spleens, mesenteric and mediastinal (i.e., lung-draining) LN from 
each animal and generated single cell suspensions either by mechanical (spleens, LNs) or 
enzymatic (lungs) dispersal of the tissues (Schneider, Li et al. 2001). In addition, we 
performed bronchoalveolar (BAL) and peritoneal lavages on the recipients to recover the 
cells from these compartments. Each cell population was analysed by flow cytometry 
(Beckman Coulter Epics XL, analysis by Flowjo v.8 software). 
  
 50  
 3.3.4. Silencing of IL-10 expression by DC10 
The IL-10 siRNA sequences were designed using online software (Qiagen, 
Valencia, CA); BLAST searches were carried out to ensure that the sequences would not 
target other transcripts. The target sequence of the IL-10siRNA was 5'-
CAGGGATCTTAGCTAACGGAA-3’. The sense and antisense alignment for the siRNA 
were 5'-GGGAUCUUAGCUAACGGAAtt-3' and 3'-gtCCCUAGAAUCGAUUGCCUU-
5', respectively. The siRNA’s were transfected into DC10 using a commercial kit (RNAi 
human/mouse starter kit, Qiagen), according to the supplier’s protocol. A non-silencing 
random nucleotide control siRNA of no known specificity was transfected into wild-type 
DC10 as an irrelevant siRNA control. All ribonucleotides were synthesized and annealed 
by the supplier (Qiagen). 
 
3.3.5. ELISA 
Our type 2 cytokine ELISA protocols have been reported in detail 
previously(Schneider, Li et al. 2001; Gordon, Li et al. 2005). The culture supernatants of 
the DCs or BAL fluids were collected and analysed with respect to IL-4, 5, 9, 13 
production with a sandwich ELISA using corresponding specific capture and detection 
antibodies. Cytokine levels were calculated using standard curves constructed by 
recombinant murine cytokines (R&D). 
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 3.3.6. Quantitative RT-PCR 
Total RNA was obtained from DC cells by RNeasy Mini Kit (Qiagen, Valencia, 
CA). 1 µg total RNA was used for RT-PCR by RT-PCR ThermoScript One-Step System 
(Invitrogen) according to the manufacturer's instructions. The specific PCR IL-10 primers 
are the sense (5’-AAGCCTTATCGGAAATGATCCA-3’) and antisense (5’-
GCTCCACTGCCTTGCTCTTATT-3’) In addition, another one set of primers was also 
used for control home keeping gene β-actin, including the sense (5’-
AGAGGGAAATCGTGCGTGAC-3’) and antisense (5’-
CAATAGTGATGACCTGGCCGT-3’). About RT-PCR conditions, cDNA synthesis is at 
50℃ (30 min), PCR is 1 cycle at 95℃ (5 min) and 35 cycles at 95℃ (15 sec), 60 ℃ (1 
min). All PCR reaction products were resolved on 1% agarose gels with ethidium 
bromide staining.  
 
3.3.7. Chemotaxis assay 
The chemotactic responses of DC to MIP-1 and MIP-3 were examined using 
modified Boyden microchemotaxis chambers (Neuroprobe, Gaithersburg, MD) and 
polyvinyl pyrrolidone-free 5 µm pore size polycarbonate membranes, essentially as 
described previously(Gordon, Li et al. 2005). Recombinant MIP-1 and MIP-3, diluted in 
DMEM-0.1% BSA to 100 ng/ml, was added to triplicate lower chambers of the wells, 
and 105 DC in DMEM-BSA were added to the upper chambers. After incubation for 2 h 
at 37°C, adherent cells were stained using Diff-Quik staining kit (EM Science, Inc. Cat. 
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 No. 65044/93). Mount the membrane shiny side down on microscope slides with 
Permount and Xylene. Count 5 fields per well at 40X power. 
 
3.3.8. Measurement of AHR  
Measurement of AHR was detailed in our previous paper (Gordon, Li et al. 2005). 
Briefly, AHR was assessed by head-out, whole-body plethysmography in conscious 
animals. Each mouse was sequentially exposed to aerosols of methacholine (0.5-20 
mg/ml saline). AHR was monitored by sensor linked to a computer data collector system. 
 
3.3.9. Activation markers  of Treg cells 
DC10 were generated from wild type, CD80/86 KO and Iab KO mice. DC10, 
DC10(CD80-/-86-/-), DC10(Iab-/-) and DC10/siRNAIL-10 [DC10(IL-10-/-)] as well as saline 
were injected to asthmatic mice respectively. Then at 3 wk post-treatment we purified T 
cells from the lungs and draining LNs and stained them with FITC-CD4, PE-cy5-Foxp3 
and PE-labeled antibodies against the Treg cell markers CD25, ICOS, PD-1, GITR, 
LAG3 and CTLA-4. The CD4+ cells were gated then Foxp3+PE+ cells were assessed by 
cytometry. 
 
3.3.10. Statistical analysis 
All data were analyzed with the aid of a software program (GraphPad Prism 5.0). 
Multigroup comparisons were assessed by one-way ANOVA with Tukey post test. 
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 whereas AHR to methacholine was assessed by linear regression analyses. Values of p < 
0.05 were considered significant. All results are expressed as the mean ± SEM. 
 
3.4. Results 
 
3.4.1. DC10 delivered i.p. migrate to the lungs and lung draining LNs 
We have reported previously that the onset of tolerance in DC10-treated asthmatic 
mice is progressive, such that AHR is moderately diminished in mice at 2 wk after 
treatment and disappears entirely within 3 wk of treatment, while the airway Th2 
responses to recall allergen challenge (i.e., eosinophilia, Th2 cytokines) lags behind 
somewhat (Lu, Dawicki et al. 2011; Nayyar, Dawicki et al. 2012). We questioned 
whether there were temporal relationships between the onset of this tolerance and 
trafficking of the DC10 within the recipients. Others have reported that leukocytes within 
the peritoneum traffic via the diaphragmatic lymphatics to the thoracic duct and thereby 
into the peripheral circulation, although materials in the pleural cavity can be tracked to 
the mediastinal LN (Yoffey and Courtice 1970). To track our treatment DC10 we injected 
asthmatic CD45.2+ B6 mice i.p. with DC10 generated from the bone marrow of CD45.1+ 
congenic B6 mice and used FACS to detect the CD45.1+ cells in an array of organs 
across 3 weeks (Figure 3-1 and Table 3-1). At 2 d post-transplant a substantial proportion 
of the cells recovered from the airways (BAL) and lung parenchyma (Lung par.) were 
CD45.1+ (i.e., the injected DC10), with modest numbers also appearing in the lung-
draining mediastinal LNs (Med. LN), while few DC10 were detectable in the spleens or 
cervical LNs (Cer. LN). At 1 wk the numbers of DC10 peaked in the lungs and 
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 mediastinal LNs, and some DC10 were evident at this time in the spleens, but not 
cervical LNs. The numbers of DC10 were markedly reduced within each site at 2 wk 
post-treatment, and by 3 wk DC10 were no longer discernible in either the peripheral 
organs or LNs. We found negligible numbers of marker-positive cells in the blood, bone 
marrow or liver at any time (data not shown). These data indicate that DC10 that are 
delivered intraperitoneally increasingly accumulate in the asthma target-organs, the lungs 
and lung-draining LNs, across one week after implantation, and that they continue to 
have a presence at two weeks after treatment. We have reported previously that DC10 
treatment is associated with activation of pulmonary Tregs beginning at 1 wk after 
treatment (Huang, Dawicki et al. 2010), although significant effects of DC10 on AHR are 
first discernible in asthmatic mice at 2 wk (Nayyar, Dawicki et al. 2012). This suggests 
that the treatment DC10 may well engage their target Th2 effector T cells in situ in the 
lungs or lung-draining LNs. 
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Figure 3-1. IL-10-differentiated dendritic cells that are delivered intraperitoneally 
in asthmatic mice migrate to the lungs and draining LNs. 
IL-10-differentiated dendritic cells (DC10) were generated from the bone marrow 
of CD45.1+ B6 mice and injected into asthmatic congenic CD45.2+ B6 recipient mice. 
After 2, 7, 14 or 21 d the mice were sacrificed and the proportions of CD45.1+ cells 
among total cells recovered from their airways (BAL), lung parenchyma (Par.), 
mediastinal (Med LN) and mesenteric (Mes. LN) LNs, and spleens, were assessed by 
flow cytometry, as noted in the materials and methods section. 
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Figure 3-1. DC10 delivered i.p. migrate to the lungs and draining lymph nodes.
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Table 3-1. Anatomical distribution of DC10 over three wks following intraperitoneal 
delivery to asthmatic mice. 
 
  Time 
(d) 
Peri. BAL Lung par. Med. LN Spleen Mes. LN Cer. LN 
2 2.63 4.66 2.83 0.93 0.39 0.80 0.17 
7 0.72 6.05 7.64 1.46 0.89 2.23 0.31 
14 0.61 2.37 1.54 0.23 0.42 0.00 0.14 
21 0.00 0.06 0.00 0.00 0.10 0.06 0.18 
 
In vitro-differentiated DC10 cells from CD45.1 congenic mice were injected i.p. 
into asthmatic B6 mice. After 2, 7, 14 and 21 d, BAL, lung parenchyma (Par.), 
mediastinal (Med) and mesenteric (Mes.) LN, spleen, and peritoneal (Peri.) wash cells 
from recipients were recovered and stained using a PE-anti-CD45.1 antibody. CD45.1-
positive cells were assessed by flow cytometry. Values are %. 
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3.4.2. IL-10 secretion is essential to DC10-induced tolerance in established asthma 
As noted, DC10 can prevent localization of allergic disease to the lungs in mice, 
and IL-10 plays a role in that process (Koya, Matsuda et al. 2007), but we wished to 
confirm whether IL-10 produced by DC10 also plays a role in the reversal of the asthma 
phenotype in our model. To test this we first generated DC10 in which IL-10 expression 
had been silenced using siRNA approaches, and then used these cells to treat asthmatic 
mice. We assessed the efficiency of our DC10 transfection protocols using a fluorescent 
control siRNA construct, and found that at 48 h after transfection essentially all DC10 in 
our cultures were siRNA-positive (Figure 3-2A). We then optimized the dose of IL-10-
specific siRNA required to negate IL-10 secretion. Transfection of DC10 with 40 nmol 
siRNA essentially eliminated IL-10 secretion by our DC10, even after they had been 
stimulated overnight with LPS (1 μg/ml; Figure 3-2B), and brought DC10 IL-10 mRNA 
levels to background (Figure 3-2C), while transfection with 40 nmol scrambled nonsense 
siRNA had no discernible impact on IL-10 expression (Figure 3-2B). We also evaluated 
the potential toxicity of the siRNA and transfection reagents for our DC10 by measuring 
their viability at 24 h after transfection, as determined using annexin V and propidium 
iodine (PI) staining to assess apoptosis and necrosis, respectively (Figure 3-2D). The 
results confirmed that neither reagent affected DC10 viability. We also assessed the 
abilities of the control siRNA and IL-10 siRNA transfected cells to phagocytose FITC-
dextran, as a surrogate antigen, and to respond to CCL3 and CCL19, as ligands for the 
tissue inflammatory chemokine receptor CCR5 and the lymph node-homing chemokine 
receptor CCR7, respectively. IL-10-silencing had no impact on the DC10’s phagocytic 
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Figure 3-2. Silencing of IL-10 expression in the tolerogenic DC by transfection with 
siRNAIL-10.  
 
(A) IL-10 siRNA efficiently transfected DC10. DC10 cells were transfected with 
Alexa Fluor 488-labeled IL-10 siRNA and the efficiency of transfection was evaluated by 
flow cytometry and fluorescent microcope 48 hours later. (B) IL-10 secretion was 
assessed in tolerogenic DC transfected with different concentrations of siRNAIL-10 using 
ELISA after 48 hour transfection. 40nmol siRNAIL-10 was observed to be optimal for 
silencing IL-10 secretion by using RNAi Human/Mouse Starter Kit. (C) IL-10 mRNA 
expression level of DC10/siRNAIL-10 was measured by RT-PCR. (D) Apoptosis and 
necrosis of DC10/siRNAIL-10 was assessed using annexin V and propidium iodine (PI) 
staining.  
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Figure 3-3. Characterization of IL-10-silenced DC10 (DC10/SiRNAIL-10) in terms of 
surface markers, phagocytosis and migratory abilities. 
 
 
 (A) DC10/SiRNAIL-10 or DC10 cells were incubated for 30 min with FITC-
dextran (100μg/ml; 40 kD MW), and then analyzed by FACS. (B) The impact of the IL-
10 silencing on chemokine receptor (CCR5 and CCR 7) expression was determined by 
modified Boyden chamber micro chemotaxis assays. (C) Surface markers [Iad, CD11c 
(HL3), CD40 (3/23), CD54 (3E2), CD80 (16-10A) and CD86] of DC10/SiRNAIL-10 or 
DC10 cells were detected by flow cytometry.  
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Figure 3-3. Characterization of the IL-10-silenced DC10 (DC10/SiRNAIL-10) in terms 
of surface markers, phagocytosis and migratory abilities.
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 activities or chemotactic responses to dendritic cell-relevant chemokines (Figure 3-3A, 
B), and had no discernible impact on the cell’s expression of MHCII, CD11c, CD40, 
CD54, CD80 or CD86, as determined by flow cytometry (Figure 3-3C). This data 
confirmed that silencing IL-10 expression by DC10 did not significantly alter their 
expression of these antigen presentation-associated markers or parameters. We next 
evaluated the impact of IL-10 silencing on the therapeutic effectiveness of DC10 in a 
mouse model of asthma. We treated asthmatic B6 mice with saline or 1×106 wild-type, 
IL-10-silenced, or scrambled nonsense siRNA-transfected DC10 and 25 days later 
assessed the treated animal’s AHR to methacholine, as well as that of normal healthy 
control mice (Figure 3-4A). The airways of the saline-treated asthmatic animals were 
fully hyperresponsive to methacholine, while those of wild-type DC10- and negative 
control siRNA-transfected DC10-treated animals were normoresponsive. On the other 
hand, the IL-10-silenced DC10 were completely ineffective in reducing AHR in these 
animals. One day after assessing their AHR, we challenged the animals with aerosolized 
allergen (1 mg/ml OVA, 20 min) and two days later we sacrificed the animals and 
examined their airways for evidence of Th2 recall responses to the allergen challenge, 
looking at BAL fluid eosinophils and Th2 cytokines (IL-4, -5, -9 and -13). The wild-type 
and scrambled nonsense siRNA-transfected DC10 treatments brought each of these 
parameters to near baseline, while IL-10 silencing again negated the tolerogenic activities 
of the DC10 (Figure 3-4B, C). Taken together, this data indicates that IL-10 expression 
by DC10 is essential to their tolerogenic activities in our model. 
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 3.4.3. DC10-induced asthma tolerance is also critically dependent on MHCII-TCR 
interactions 
As suggested above, in principle the IL-10 that is secreted by DC10 could affect 
tolerance through by-stander effects. Infusion of recombinant IL-10 into the airway is 
known to reduce Th2 immunoinflammatory responses in experimental asthma(van Scott, 
Justice et al. 2000). Thus, we next assessed whether DC10 that do not express a MHCII 
molecule (i.e., cannot engage T cells through their TCR) or CD80 and CD86 are 
compromised in their abilities to induce tolerance. For this and the next experiment we 
generated DC10 from the bone marrow of MHCII-/- and CD80/CD86-double knockout 
mice, incubated them with specific allergen in vitro, and then used them to treat OVA-
asthmatic mice, as above. We assessed whether these DC10 secreted IL-10 at levels 
observed in wildtype cells, and found no differences in IL-10 expression between the 
three populations of cells. The wild-type DC10 released 347+/-138 pg/ml over 48 hr, 
while the MHCII-/- DC10 secreted 241+/-44 pg/ml IL-10 and the CD80/CD86-/- DC10 
secreted 249+/-55 pg/ml of IL-10 (for both knockout DC10 populations, p≥0.05 versus 
wild-type DC10). 
When we assessed the AHR of the mice at ≈4 wk post-treatment, we found that 
the recipients of the MHCII-/- DC10 still presented with a fully developed AHR (p≥0.05 
versus saline-treated asthmatic mice), while the animals that had been treated with wild-
type DC10 were normoresponsive (Figure 3-5A). This loss of the ability to affect AHR 
applied also to the airway eosinophil and IL-4, -5, -9, and -13 responses to recall allergen 
challenge (Figure 3-5B and 5C). In each case there were no statistically significant  
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Figure 3-4. IL-10-silenced DC10 lose their therapeutic effectiveness in a mouse 
model of asthma.  
Asthma mice were given 1×106 DC10 or DC10/siRNAIL-10 or 
DC10/siRNAcontrol via ip. (A) 25 d later, their AHR to aerosolized methacholine was 
assessed (p<0.05, DC10/siRNAIL-10 -treated group vs. the DC10 -treated group). The 
following day, we challenged the animals for 20 min with nebulized aerosols of 1% OVA, 
and 48 h later, assessed their pulmonary immunoinflammatory responses. Eosinophil (B) 
and Th2 (C) cytokine (IL-4, IL-5, IL-9 and IL-13) responses to the recall allergen 
challenge were assessed. One representative experiment of three is shown.  *, ***, 
p<0.05 or 0.001 versus the DC10-treated group animals (n=5 mice/group). 
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Figure 3-4. IL-10-silenced DC10 lose their therapeutic effectiveness in a mouse 
model of asthma. 
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 differences in the responses of the saline- and MHCII-/- DC10-treated asthmatic mice (p
≥0.05), while asthmatic mice that had been treated with wild-type OVA-presenting 
DC10 displayed a tolerant phenotype. 
Interestingly, the AHR of the mice treated with the CD80/86-/- DC10 was partially 
reversed (Figure 3-5A), while their recall airway eosinophil and Th2 cytokine responses 
to OVA aerosol challenge were unaffected by the CD80/86-/- DC10 treatment (Figure 3-
5B, 5C). Indeed, these costimulation-attenuated DC10 were no different than MHCII-/- 
DC10 in terms of their abilities to affect the airway Th2 cytokine response (Figure 3-5C). 
This data suggests that IL-10 expression alone is insufficient to render DC10 tolerogenic, 
and that they must engage their target Th2 Teff cells in a cognate (i.e., MHCII-dependent) 
fashion in order for their IL-10 to induce a Th2 to Treg phenotype switch. Moreover, 
optimal phenotype switching also required participation of CD80 and/or CD86, likely 
because of their contributions to high avidity immunological synapse formation. 
 
3.4.4. IL-10 and MHCII expression by DC10 are essential for activation of Treg in 
DC10-treated asthmatic mice 
We recently have reported that DC10 treatments lead to conversion of Th2 Teff 
cells into CD4+CD25+Foxp3+ Treg in the lungs of treated mice (Huang, Dawicki et al. 
2010), and that these Treg display augmented levels of the activation markers ICOS, PD-
1, GITR, LAG-3 and CTLA-4 (Huang, Dawicki et al. 2010). We thus sought to 
determine whether the altered antigen presentation skills of our various compromised 
DC10 also translated into a reduced ability to activate pulmonary Treg in our treated mice. 
We treated the asthmatic animals with saline, or with wild-type, IL-10-silenced, MHCII-/-  
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Figure 3-5. CD80/86- or MHC II- knockout DC10 had lost their therapeutic 
effectiveness in a mouse model of asthma.  
 
 
ASTHMA mice were given 1×106 DC10 or DC10(CD80-/-) or DC10(MHCII-/-) 
via ip. (A) 25 d later, their AHR to aerosolized methacholine was assessed [p<0.05, 
DC10(CD80-/-) or DC10(MHCII-/-) -treated group vs the DC10 -treated group]. The 
following day, we challenged the animals for 20 min with nebulized aerosols of 1% OVA, 
and 48 h later, assessed their pulmonary immunoinflammatory responses. Eosinophil (B) 
and Th2 (C) cytokine (IL-4, IL-5, IL-9 and IL-13) responses to the recall allergen 
challenge were assessed [p<0.001, DC10(CD80-/-) or DC10(MHCII-/-) -treated group vs 
the DC10 -treated group]. One representative experiment of three is shown.  *, ***, 
p<0.05 or 0.001 versus the DC10-treated group animals (n=5 mice/group). 
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Figure 3-5. CD80/86- or MHC II- knockout DC10 had lost their therapeutic 
effectiveness in a mouse model of asthma. 
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 or CD80/CD86-/- DC10, and 3 wk later we purified T cells from the lungs of these mice 
using nylon wool columns and assessed their expression of each of these markers by 
FACS. It was readily apparent that the OVA-presenting DC10 up-regulated expression of 
each marker as we had observed previously, while the pulmonary CD4+ T cells of the IL-
10-silenced or MHCII-/- DC10-treated mice did not up-regulate these markers above the 
levels seen in asthmatic mice (Figure 3-6). Interestingly, the CD80/CD86-/- DC10 
induced an intermediate level of Treg activation relative to that seen with wild-type, IL-
10-silenced or MHCII-/- DC10 (Figure 3-6). In keeping with our previous observations of 
no differences in the numbers of CD4+CD25+ cells in normal, asthmatic or tolerant mice 
(Huang, Dawicki et al. ; Li, Yang et al. 2010; Lu, Dawicki et al. 2011), we did not  
observe marked differences in the proportions of CD25+Foxp3+ T cells in the lungs of our 
mice. This experiment confirmed that both IL-10 expression and an ability to engage 
target Th2 cells in a cognate fashion are both critical to DC10-induced asthma tolerance, 
but also that the costimulatory molecules CD80 and/or CD86 are also involved in this 
process.  
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Figure 3-6. Roles of by IL-10, MHC II and CD80/86 costimulatory molecule 
expression by DC10 in Treg-associated marker expression on CD4+Foxp3+ Treg 
cells.  
 
 
DC10 were generated from wild type, CD80/86 knock-out and Iab knock-out mice. 
DC10, DC10(CD80-/-86-/-), DC10(Iab-/-) and DC10/siRNAIL-10 [DC10(IL-10-/-)] as well as 
saline were injected to asthmatic mice. Then at 3 wk post-treatment we purified T cells 
from the lungs and draining LNs and stained them with FITC-CD4, PE-cy5-Foxp3 and 
PE-labeled antibodies against the Treg cell markers CD25, ICOS, PD-1, GITR, LAG3 
and CTLA-4. The CD4+ cells were gated then Foxp3+PE+ cells were assessed by 
cytometry. One representative experiment of two is shown. 
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Figure 3-6. Roles of by IL-10, MHC II and CD80/86 costimulatory molecule 
expression by DC10 in Treg-associated marker expression on CD4+Foxp3+ Treg 
cells.  
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 3.5. DISCUSSION 
In this study we assessed the importance of IL-10 and MHCII expression by 
cognate allergen-presenting DC10 on their induction of immunologic tolerance in 
asthmatic mice, but also the role(s) of costimulatory molecule expression by these cells. 
Specifically, we used DC10 that were deficient in MHCII or CD80 and CD86, or IL-10-
silenced DC10, and found in each case that the deficiency reduced the tolerogenic 
activity of these cells as determined by assessments of AHR and Th2 
immunoinflammatory responses to recall allergen challenge. IL-10 silencing did not 
discernibly affect the viability of the DC10, their expression of MHCII or co-stimulatory 
molecules, or their phagocytic or chemotactic activities, indicating that it was indeed their 
IL-10 that was the critical effector molecule for these DC10. On the other hand, MHCII-/- 
DC10, which expressed wild-type DC10 levels of IL-10, were also incapable of inducing 
tolerance, while IL-10-sufficient CD80/CD86-/- DC10 were decidedly suboptimal in their 
abilities to induce tolerance. 
IL-10 is a key immunomodulatory cytokine, with both immunosuppressive and 
immunostimulatory effects on T cells having been reported (Mocellin, Panelli et al. 2003; 
Mocellin, Marincola et al. 2004). It can directly inhibit T cell growth (Taga, Mostowski 
et al. 1993) and induce long-lasting antigen-specific T cell anergy (Groux, Bigler et al. 
1996). IL-10 knock-out mice do not develop AHR after allergen sensitization and 
challenge despite a significant pulmonary inflammatory response that includes increased 
airway eosinophilia (Makela, Kanehiro et al. 2002), while IL-10 infusion into the airways 
of asthmatic mice dampens their responses to recall allergen challenge (van Scott, Justice 
et al. 2000). It had been reported that, unlike wild-type DC10, DC10 that are generated 
from the bone marrow of IL-10-knockout mice are unable to prevent the development of 
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 asthma in a mouse model (Koya, Matsuda et al. 2007), Whether the IL-10 released by 
these DC is critical for reversal of the asthma phenotype in animals with well-established 
disease (Huang, Dawicki et al. 2010; Lu, Dawicki et al. 2011; Nayyar, Dawicki et al. 
2012) had not been assessed, nor had it been determined whether cognate T cell 
engagement by the IL-10-expressing DC10 is critical to that tolerance. Our data indicates 
that the dendritic cell indeed must engage target Th2 Teff cells in a cognate manner in 
order for the IL-10 they secrete to productively affect the latter cells. It has been reported 
that expression of IL-10 by the host’s cells, presumptively their Treg cells, is also critical 
to the induction of tolerance in asthmatic mice, even when the treatment dendritic cells 
have been engineered to express exceptional levels of IL-10 (Henry, Desmet et al. 2008). 
We have shown previously that DC10 induce the host’s effector Th2 cells to 
transdifferentiate to a CD25+Foxp3+ Treg cell phenotype and that IL-10 expression by 
these Treg drives their suppression of Th2 responses, at least in vitro (Huang, Dawicki et 
al. 2010). IL-27 can promote the development of IL-10-secreting T cells (Awasthi, 
Carrier et al. 2007) and IL-27 produced by galectin-1-differentiated tolerogenic dendritic 
cells has been shown to induce IL-10 production by T cells with which these cells 
interact (Ilarregui, Croci et al. 2009). IL-10-silenced DC10 did not induce tolerance 
despite the fact that the recipient’s Treg would be fully capable of secreting IL-10, 
suggesting that the lack of tolerance was attributable to a failure to induce or activate 
Treg by the IL-10-compromised DC10. In keeping with this, our data confirms that while 
wild-type DC10 treatments led to robust activation of the host’s Treg, as determined by 
expression of ICOS-1, PD-1, GITR, LAG-3 and CTLA4, IL-10-silenced DC10 induced 
no such Treg activation. We had documented previously that DC10-induced Treg up-
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 regulate each of these activation markers (Huang, Dawicki et al. 2010; Li, Yang et al. 
2010; Lu, Dawicki et al. 2011; Nayyar, Dawicki et al. 2012).   Thus, our data confirms in 
another way the importance of IL-10 expression by DC10 in the development of Treg 
cells. 
As suggested above, the fact that IL-10-intact, but MHCII-/- DC10 were also 
unable to induce tolerance clearly indicates that DC10 must be engaged in cognate 
interactions with T cells in order for their IL-10 to have a significant impact. This is of 
substantial significance in the therapeutic setting, because it indicates that tolerance 
induced by DC10 will be exquisitely antigen-specific and therefore not lead to broad 
immunosuppression. Our previous observations that DC10 must present cognate allergen 
in order to intimately engage Th2 cells (as determined by fluorescence resonance energy 
transfer [FRET] assays) from asthmatic people or mice and induce tolerance therein(Li, 
Yang et al. 2010; Lu, Dawicki et al. 2011; Nayyar, Dawicki et al. 2012) fit well with our 
present data. Our data also has implications for therapeutic use of these cells in the 
context of poly-allergic individuals. In principle, each allergen to which an individual is 
sensitive would need to be individually targeted by DC10, although it is open to 
speculation as to whether one could treat sensitivity to two independent allergens by 
loading dendritic cells with both. Others have reported that human CD14+ monocyte-
derived dendritic cells can present multiple antigens (Garritsen, Macke et al. 2010). 
The dendritic cell’s costimulatory molecules provide important signals that can 
independently influence the outcomes of antigen presentation, such that these cells can 
have either immunosuppressive or immunostimulatory effects on T cells (Hawiger, Inaba 
et al. 2001; Steinman 2003; Steinman, Hawiger et al. 2003).  It is well recognized that 
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 dendritic cells require both MHC-peptide-TCR complex and co-stimulatory molecule 
engagement in order to optimally activate T cells(Golovina, Mikheeva et al. 2008; 
Weaver, Charafeddine et al. 2008), but there is increasing evidence that co-stimulatory 
molecules are integral to the induction of tolerance by regulatory dendritic cells. Thus, 
CD40L/CD154 blockade can engender long-lived, antigen-specific tolerance (Quezada, 
Jarvinen et al. 2004), while the CD80/CD86 ligand CTLA-4 attenuates T-cell activation 
and fosters peripheral tolerance (Scalapino and Daikh 2008).  The late-acting co-
stimulatory molecules CD80 and CD86 are important to full induction of Teff cell 
activation (Hochweller and Anderton 2005), and our data from the present study suggests 
that these molecules are also required for successful activation of Treg cells. Dendritic 
cells have the capacity to acquire, and present, antigens from dying cells (Steinman, 
Turley et al. 2000) such that it might be argued that in our model DC10 or parts thereof 
(e.g., exosomes) are taken up by the recipient’s APC, and that it is those endogenous 
APC that induce tolerance. The observed requirement for MHC II, CD80/86 and IL-10 
expression by the treatment DC10 indicates that the these cells must directly interact with 
T cells to promote tolerance and that their therapeutic effects are not realized by transfer 
of their ingested allergens to the recipient’s dendritic cells or other APC. An unanswered 
question in these studies is the impact on the tolerance outcomes of varying the intensity 
of the antigen presentation signaling between the DC10 and the Teff cells. For example, 
would the levels of IL-10 that are expressed by wild-type DC10 still induce tolerance if 
the DC10 expressed high levels of MHCII and co-stimulatory molecules (e.g., equivalent 
to that of endotoxin-activated dendritic cells) and thereby provided otherwise strong 
activation signals to the Teff cells? Or, would increasing the expression levels of IL-10 
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 by DC10 induce a distinct form of tolerance? It has been reported that dendritic cells that 
IL-10-lentivirus-transfected dendritic cells, which express IL-10 at levels that are orders 
of magnitude greater than our DC10, induce a very robust tolerance (Henry, Desmet et al. 
2008). The answers to these types of questions may allow us in the future to optimize 
such cell-based immunotherapies. 
Taken together our observations confirm that DC10 engage intimately with 
pulmonary Teff cells to promote their conversion to Treg and show that MHCII and 
CD80/86 engagement, combined with the DC10’s secretion of IL-10, are each integral to 
operationalization of DC10-induced asthma tolerance. Thus, DC10-induced tolerance 
would not arise because of a lack of Teff cell stimulation, but rather because these cells 
are engaged and activated by the tolerogenic APC in precisely the manner that induces 
Treg differentiation. 
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 4.1. Abstract 
IL-10-differentiated dendritic cells (DC10) induce allergen tolerance in asthmatic 
mice, during which their lung Th2 T effector cells (Teff) are displaced by activated 
CD4+CD25hiFoxp3+ T cells (Treg). Intestinal DCs promote oral tolerance by inducing 
antigen-naïve T cells to differentiate into CD4+CD25+Foxp3+ T cells (Treg), but whether 
DCs can induce Teff to differentiate into Treg remains uncertain. Herein we addressed 
this question in OVA-asthmatic mice that were treated with DC10. OVA-presenting 
DC10 treatment maximally activated lung Treg in these animals at 3 wk post-treatment, 
as determined by upregulation of Treg-associated markers  (ICOS, PD-1, GITR, LAG3 
and CTLA-4) and in functional assays. This in vitro regulatory activity was ≥90% 
reduced by treatment with anti-IL-10 but not anti-TGF-β antibodies. In parallel cultures 
OVA-, but not house dust mite (HDM)-, presenting DC10 induced ≈43% of CFSE-
labeled CD25-/loFoxp3- Teff cells from asthmatic OVA-TCR transgenic mice to 
differentiate into tolerogenic CD25hiFoxp3+ Treg. We recapitulated this in vivo using 
OVA-asthmatic mice that were co-injected with OVA- or HDM-presenting DC10 (i.p.) 
and CFSE-labeled CD4+CD25-/loFoxp3- Teff cells (i.v.) from the lungs of asthmatic 
DO11.10 mice. From ≈7 to 21% of the activated (i.e., dividing) DO11.10 Teff that were 
recovered from the lungs, lung-draining LNs or spleens of the OVA-DC10 recipients had 
differentiated into CD4+CD25hiFoxp3+ Treg, while no CFSE-positive Treg were 
recovered from the HDM-DC10-treated animals. These data indicate that DC10 
treatments induce tolerance at least in part by inducing Teff to differentiate into 
CD4+CD25hiFoxp3+ Treg. 
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 4.2. Introduction 
Multiple laboratories have reported on the tolerogenic activities of IL-10-
differentiated DCs (DC10) in mouse models or ex vivo with human T cells (Steinbrink, 
Wolfl et al. 1997; Bellinghausen, Brand et al. 2001; Muller, Muller et al. 2002; Wakkach, 
Fournier et al. 2003; Koya, Matsuda et al. 2007; Perona-Wright, Anderton et al. 2007; 
Lau, Biester et al. 2008; Li, Yang et al. 2010). Thus, DC10 can protect against the 
development of OVA-induced asthma (Koya, Matsuda et al. 2007) or reverse the 
asthmatic phenotype in OVA (Nayyar, Zhang et al. 2004) or house dust mite allergen- 
(HDM) (Lu, Dawicki et al. 2011) sensitized mice, reducing AHR to methacholine, 
eosinophilia and Th2 responses to allergen challenge, and circulating levels of allergen-
specific IgE and IgG1. DC10-mediated asthma tolerance is allergen-specific (Koya, 
Matsuda et al. 2007; Li, Yang et al. 2010) and IL-10-dependent (Koya, Matsuda et al. 
2007). In our hands, tolerance is first discernible at 2 wk following i.p. delivery of 
allergen-presenting DC10 and by 3 wk the asthmatic animal’s AHR disappears entirely. 
The Th2 reactivity of pulmonary T cells wanes progressively from 2 wk forward, such 
that by 8 months their responsiveness to recall allergen challenge in vivo is near 
background (Nayyar 2009). Four DC10 treatments at two week intervals bring the asthma 
phenotype to near background within 8 weeks (Nayyar 2009). Studies employing DCs 
that have been transfected with an IL-10-expressing lentivirus, and which thus express 
exceptionally high levels of IL-10, indicated that endogenous IL-10 expression (e.g., by T 
cells) is also critical to asthma tolerance in that model (Henry, Desmet et al. 2008). In 
inducing a robust asthma tolerance, treatments with these virally-transfected DC increase 
the numbers of CD4+CD25+Foxp3+ cells present in the lung-draining (mediastinal) LNs 
(Henry, Desmet et al. 2008). This occurs also in the lungs and mediastinal LNs of DC10-
 81  
 treated HDM-asthmatic mice, and adoptive transfer of pulmonary CD4+ T cells from 
these mice into asthmatic recipients induces full HDM tolerance in the recipients (Lu, 
Dawicki et al. 2011).  
Intestinal DCs that present innocuous environmental (e.g., commensal bacterial) 
antigens to naïve T cells in the mesenteric LNs induce their differentiation to 
CD4+CD25+Foxp3+ Treg, and evidence indicates that expression of TGF-β is central to 
this process (Mowat 2003). Naïve T cells can be readily converted to a Treg phenotype 
by culture with either CTLA-4-Ig (Razmara, Hilliard et al. 2008) or TGF-β (Chen, Jin et 
al. 2003; Pyzik and Piccirillo 2007; Siewert, Lauer et al. 2008), but there has been no 
hard data to date regarding the conversion of antigen-experienced (i.e., effector) T cells 
(Teff). It has been reported that tuberculin purified protein derivative (PPD)-specific 
IFNγ-producing CD4+ cell lines from PPD-sensitive donors become anergized after 
stimulation with immobilized anti-CD3 and begin to express high levels of Foxp3 mRNA 
(Vukmanovic-Stejic, Agius et al. 2008), but Foxp3 expression by itself does not confer 
activated regulatory cell status on CD4+CD25+ T cells (Strickland, Stumbles et al. 2006; 
Lu, Dawicki et al. 2011). Co-culture of specific allergen-presenting DC10 from atopic 
asthmatic donors with autologous peripheral blood Th2 phenotype cells also induces 
allergen-tolerance associated with the outgrowth of activated CD4+CD25+Foxp3+ Treg 
(Li, Yang et al. 2010). Nevertheless, while DC10 induce asthma tolerance through 
activation of Treg, it is not known whether activated Teff cells differentiate into Treg in 
treated subjects. Herein we examined the mechanisms by which DC10 induce Tregs in 
asthmatic mice. Our data indicate that DC10 do activate Treg in the lungs of asthmatic 
mice and that these cells do differentiate from CD4+CD25-Foxp3- Teff. 
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4.3. Methods 
 
4.3.1. Reagents and mice 
Phycoerythrin-conjugated anti-mouse CD25, ICOS, PD-1, GITR, LAG3 and 
CTLA-4 Ab and a mouse regulatory T cell staining kit were purchased from eBioscience 
Inc (San Diego, CA). Mouse rGM-CSF and IL-10, and matched capture and detection Ab 
pairs and protein standards for our ELISAs were obtained from R & D Systems 
(Minneapolis, MN). Anti-mouse CD4 MACS beads and mouse CD4+CD25+ regulatory T 
cell isolation kits were purchased from Miltenyi Biotec (Auburn, CA). The lipid dye DiI 
was purchased from Molecular Probes (Carlsbad, CA). The sources of all other reagents 
have been reported previously (Gordon, Li et al. 2005; Li, Yang et al. 2010). Female 
BALB/c and C57BL/6 mice (6~8 week old) were purchased from Charles River 
Laboratories (Charles River, Maine). DO11.10 OVA-specific TCR-transgenic mice were 
obtained from the Jackson Laboratory (Bar Harbor, Maine). C57BL/6 mice that 
expressed GFP under the control of the Foxp3 promoter were kindly provided through 
Dr. S. Rudensky (University of Washington) and bred in our institutional animal care 
unit. All mice were treated in accord with the guidelines of the Canadian Council for 
Animal Care. 
 
4.3.2. Generation of tolerogenic dendritic cells 
Bone marrow DCs were generated largely as reported previously (Inaba, Inaba et 
al. 1992; Manfred B. Lutz 2000), and differentiated to tolerogenic or immunostimulatory 
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 phenotypes by further culture with 50 ng/ml of rmIL-10 (DC10) or 1 µg/ml E. coli 
serotype 0127:B8 LPS (DC-LPS), respectively. The cells were pulsed with 50 μg/ml 
OVA or irrelevant control house dust mite allergen (HDM) for 2 hr, then washed 
extensively before use. In our hands DC10 express low levels of costimulatory molecules 
(e.g., CD40, CD80) and MHC II compared to mature DCs, and secrete significantly 
higher levels of IL-10, but little TGF-β, relative to immature DCs (Nayyar 2009; Li, 
Yang et al. 2010). 
 
4.3.3. Establishment of the asthma mouse model and DC10 treatments 
OVA-specific asthma was induced in BALB/c, C57BL/6 or OVA-TCR-
transgenic DO11.10 or GFP-Foxp3 transgenic mice by sensitization with OVA-alum and 
airway exposure to nebulized aerosols of 1% OVA, as noted in detail previously 
(Schneider, Li et al. 2001; Gordon, Li et al. 2005). The asthmatic mice were treated i.p. 
with 106 allergen-presenting DC10 two weeks after their last airway exposure to allergen, 
also as noted previously (Nayyar 2009). 
 
4.3.4. Assessments of T cell regulatory activities 
We used in vitro and in vivo approaches to assess the regulatory activities of 
CD4+CD25+ T cells recovered from the enzymatically-dispersed lung tissues (Schneider, 
Li et al. 2001) of asthmatic mice that had been treated with OVA-presenting DC10 1, 2, 
3, or 4 week earlier. The putative Tregs were purified by positive-selection magnetic 
sorting from these or untreated normal mice and assessed in functional assays for 
regulatory activities. 
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 Flow cytometry for expression of activation markers. We purified T cells from the 
lungs of asthmatic GFP-Foxp3 transgenic mice that had been treated 3 week earlier with 
1×106 OVA- or HDM-presenting DC10 (i.p.). The cells were stained with PE-cy5-CD4 
and PE-labeled specific Ab against CD25, ICOS, PD-1, GITR, LAG3 or CTLA-4, then 
the CD4+ cells were gated and GFP+ (i.e., Foxp3+) cells were analyzed by FACS. 
In vitro assessments. CD4+ Th2 Teff for the assays were magnetically sorted from 
the lungs of untreated asthmatic donor mice. In preliminary experiments done in 96-well 
plates we titrated the numbers of Th2 cells and irradiated (3000 rads) OVA-pulsed DC-
LPS required to optimally stimulated Th2 cell proliferation and Th2 cytokine secretion, 
and the impact of similarly irradiated putative Tregs on this response. Thus, for the 
experiments reported herein, we co-cultured Th2 cells (105 cells/well) with half-maximal 
numbers of OVA-presenting DC-LPS (3.7×103 cells/well) and putative Tregs (105 
cells/well). In some assays, we added neutralizing anti-IL-10 (IL-10) or anti-TGF-β Ab 
(each, 10 µg/ml) to the cultures. After 2 day the CD4+ Th2 cells’ proliferative and 
cytokine (IL-4, -5, -9, and -13, and IFN-γ) responses were assessed using standard 3H-
thymidine uptake and ELISA assays, respectively. 
In vivo assessments. We injected 106, 5×105, 2.5×105 or 1.25×105 Treg i.v. into 
untreated asthmatic recipient mice and four weeks later assessed the AHR of the mice. 
The following day we challenged them for 20 minute with aerosols of 1% nebulized 
OVA and 2 day later we euthanized them to assess their pulmonary immunoinflammatory 
responses as noted in detail (Schneider, Li et al. 2001). We did differential cell counts on 
their BAL leukocytes and assessed the BAL fluid levels of IL-4, -5, -9 and -13.  
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 4.3.5. Measurement of AHR 
AHR was assessed in conscious animals by head-out, whole body 
plethysmography, as noted in detail (Schneider, Li et al. 2001; Gordon, Li et al. 2005). 
Briefly, air was supplied to the body compartment of a plethysmograph via a small 
animal ventilator and changes in the airflow through the body compartment were 
monitored. Doubling doses of nebulized methacholine (0.75–25 mg/ml) were delivered to 
the head compartment and bronchoconstriction data were gathered as running 1-s means 
of the air-flow at the 50% point in the expiratory cycle (Flow@50%TVe1). This 
parameter accurately reflects bronchiolar constriction, as opposed to alveolar constriction 
or airway occlusion (Vijayaraghavan, Schaper et al. 1993; Vijayaraghavan, Schaper et al. 
1994). 
 
4.3.6. ELISA for airway Th2 cytokines 
Our capture cytokine ELISA protocols have been reported in detail previously 
(Schneider, Li et al. 2001; Gordon, Li et al. 2005). BAL fluids were not diluted for the 
assays. Cytokine levels are presented as pg/ml based on recombinant protein standard 
curves; all assays were sensitive to 5-10 pg/ml. 
 
4.3.7. Assays for conversion of CD4+CD25-Foxp3- T effector cells to CD4+CD25+ T 
cells 
We assessed whether Treg could differentiate from CD4+CD25-Foxp3- Teff both 
in vitro and in vivo, using CD25-Foxp3- cells purified by negative selection from the 
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 pulmonary CD4+ cells of asthmatic OVA-specific TCR-transgenic DO11.10 mice. These 
cells were stained with CSFE (2 µM; 20 minute at 37˚C). 
In vitro assay. We co-cultured Teff (105/well) with OVA- or HDM (i.e., 
nonspecific allergen)-presenting DC10 or OVA-presenting immunostimulatory DC-LPS 
(3×104/well) in culture medium that was supplemented with IL-2 (10 U/ml) as a growth 
factor. After 5 days, cells were fixed and permeabilized, then stained with PE-Cy5-
labeled anti-Foxp3 antibody. For the FACS analysis we gated on the CFSE-positive cells 
and assessed both proliferation and Foxp3 expression. We also assessed the in vitro 
regulatory activities of the cells arising in these cultures as noted above. 
In vivo assay. We injected 5×106 CFSE-stained Teff from asthmatic DO11.10 
donors i.v. into asthmatic BALB/c recipient mice and at the same time treated the 
recipients with 1×106 OVA- or HDM-presenting DC10 i.p.. Two weeks later, single cell 
suspensions generated from the lungs, mediastinal LNs (MLNs) and spleens of the 
recipients were stained with PE-Cy5 Foxp3 and PE-CD25 mAbs and analyzed by FACS, 
wherein we gated on the activated (i.e., dividing) CSFE+ cells. 
 
4.3.8. Statistics 
All data are expressed as the mean ± SEM. Multi-group comparisons were 
assessed by ANOVA with post-hoc Fisher’s LSD testing, while AHR to methacholine 
was assessed by linear regression analyses. Significance was established at p≤0.05. 
 
4.4. RESULTS  
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 4.4.1. Pulmonary CD4+CD25+Foxp3+ cells become activated following tolerogenic 
dendritic cell treatment of asthmatic mice. 
Treatment of asthmatic mice with DC10 broadly ameliorates airway Th2 and 
eosinophil responses to allergen challenge within 4 week of treatment (Nayyar 2009). In 
both OVA and HDM models tolerogenic DC treatments augment the regulatory activities 
of CD4+ T cells at this time (Henry, Desmet et al. 2008; Lu, Dawicki et al. 2011). 
However, when we assessed the numbers of CD4+CD25+Foxp3+ cells in the lungs of 
saline or DC10-treated OVA-asthmatic mice 4 week following DC10 delivery, we found 
no differences in the proportions of these cells in the two groups (Figure 4-1A). Thus, 
CD4+CD25+Foxp3+ cells comprised a mean of 7.07+/-0.88% of the pulmonary CD4+ T 
cells in the saline-treated animals, and 8.24+/-1.41% in the DC10-treated animals. This 
agrees with findings reported in other models of tolerance (Lu, Dawicki et al. 2011). We 
further analyzed the CD25+Foxp3+ Treg cells in the MLNs (lung draining LN) from 
saline or DC10-treated OVA-asthmatic mice 4 week following DC10 delivery, and found 
no differences in the proportions of these cells between the two groups (data not shown). 
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 Figure 4-1. DC10 treatment of asthmatic mice increases the regulatory activity of 
their pulmonary CD4+CD25+ cells.  
Asthmatic BALB/c mice were treated with 1×106 specific allergen-presenting 
DC10 and, at varying times thereafter, we MACS-sorted CD4+CD25+ from their lungs. 
We assessed the abilities of these cells (105 cells/well) to regulate proliferation and 
cytokine expression by allergen-presenting immunostimulatory DC (DC-LPS)-activated 
Th2 effector (Teff) cells (3.7×104 and 105 cells/well, respectively) from asthmatic donor 
mice. (A) The lung mononuclear cells were analyzed by FACS for expression of CD25 
and Foxp3, after gating on CD4+ T cells, from DC10 treatment and saline control group. 
(B) FACS analysis of the freshly purified CD4+CD25+ and CD4+CD25- cells after co-
staining for Foxp3. (C) CD4+ Th2 cells from untreated asthmatic mice and irradiated DC-
LPS and were cultured alone (medium) or with irradiated pulmonary CD4+CD25+ and 
CD4+CD25- cells from asthmatic mice that had been treated with DC10 four weeks 
earlier. After 48 hour we assessed the Teff cell proliferative responses by 3H-thymidine 
uptake assays as well as (D) the levels of IL-4, -5, -9, and -13 in the culture supernatants 
by ELISA (*p<0.05, n=3, comparing with Teff group). (E) We also added 10 µg/ml of 
neutralizing anti-IL-10 or -TGF- antibodies to some wells in order to assess the 
contributions of these mediators to the putative CD4+CD25+ T cell regulatory functions 
(*p<0.05, n=3, comparing with Treg group). (F) To determine whether the kinetics of 
Treg activation in the lungs of the DC10-treated mice matched the in vivo observation of 
greater tolerance at 4 week (versus 2 or 3 week) post-treatment, we harvested 
CD4+CD25+ cells from mice at 1, 2, 3 or 4 weeks after DC10 treatment and assessed their 
regulatory activities. The putative regulatory cells we isolated from DC10-treated 
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 asthmatic mice were near 70% CD25+Foxp3+, while the CD4+CD25- cells were <5% 
positive for these markers. These cells displayed significant regulatory activity, inasmuch 
as they, but not CD4+CD25- cells, reduced expression of each Th2 cytokine in the 
cultures. Anti-IL-10 antibodies eliminated the regulatory activity of the CD25+Foxp3+ 
cells, while the anti-TGF- antibodies had no impact. Peak activation of these regulatory 
cells in DC10-treated mice occurred at 3 week post-treatment. One representative 
experiment of two is shown. 
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Figure 4-1. DC10 treatment of asthmatic mice increases the regulatory activity of 
their pulmonary CD4+CD25+ cells. 
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 We MACS-sorted CD4+CD25+Foxp3+ and CD4+CD25- T cells from the lungs of 
asthmatic mice that had been treated with OVA-presenting DC10 4 wk earlier (Figure 4-
1B) and assessed their abilities to suppress the activation of pulmonary Teff from 
asthmatic donors by OVA-presenting immunostimulatory DCs (DC-LPS). The 
CD4+CD25+ T cells from the lungs of the DC10-treated mice reduced proliferation of 
these Teff by 53.8+/-11.8% (Figure 4-1C) and reduced their expression of Th2 cytokines 
by 35-40% (Figure 4-1D). In order to determine whether the regulatory activity of these 
cells was dependent on their expression of IL-10 or TGF-β, we also tested the impact on 
this Th2 proliferative response of neutralizing antibodies. Anti-TGF-β antibody had no 
effect on T cell proliferation, but the anti-IL-10 antibodies eliminated the tolerogenic 
activities of the CD4+CD25+Foxp3+ cells from the DC10-treated asthmatic mice (Figure 
4-1E).  
We next examined the kinetics of pulmonary Treg induction after DC10 
treatment, purifying CD4+CD25+Foxp3+ cells from the lungs of normal mice or asthmatic 
mice that had been treated with DC10 1-4 week earlier. We had previously found that 
DiI-stained DC10 traffic from the peritoneal cavities of recipient mice to the airways and 
lung-draining (mediastinal) LNs (Lu, Dawicki et al. 2011). Maximal accumulation of 
these cells in the mediastinal nodes occurs at 3 wk post-implantation, when up to 15% of 
the cells recovered from the nodes were signal-positive (Huang and Gordon, unpublished 
observation). In the present study we found that CD4+CD25+ T cells from the lungs of 
normal mice had modest regulatory activity in our in vitro assay, while pulmonary 
CD4+CD25+ T cells from the DC10-treated asthma phenotype mice were significantly 
more active (Figure 4-1F). At 1 week after DC10 delivery there was an ≈2-fold increase 
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 in regulatory activity relative to the CD4+CD25+ T cells from normal mice and this 
activity continued to increase to a maximum (≈72% inhibition) at 3 week. Interestingly, 
despite the fact that tolerance in asthmatic mice is progressive well beyond 4 weeks 
(Nayyar and Gordon, unpublished), the activity of the purified 4-week Treg was 
diminished relative to that of 3-week Treg (Figure 4-1F).  
To further assess the activation of Treg in our model, we used asthmatic mice that 
expressed green fluorescent protein (GFP) under the control of the Foxp3 promoter as a 
means of easily tracking Treg. Three weeks after treating these mice with OVA- or 
irrelevant allergen (i.e., HDM)-presenting DC10 and DC-OVA we examined the 
expression of a panel of regulatory cell surface markers (i.e., ICOS, PD-1, GITR, LAG3 
and CTLA-4) on Treg recovered from their lungs and found that the OVA-pulsed DC10 
treatments led to increased expression of a number of these (Figure 4-2). Thus, the 
proportions of Foxp3+ cells expressing ICOS, PD-1, GITR and LAG3 were increased 
about 2 to 10 folds relative to the analogous cells from HDM-presenting DC10-treated 
and DC-OVA treated (i.e., non-tolerant) asthmatic mice. In keeping with our observation 
of no differences in the numbers of CD4+CD25+ cells in normal, asthmatic or tolerant 
mice (Figure 4-2), we did not observe any differences in CD25 expression in these mice. 
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Figure 4-2. CD4+CD25hi cells from the lungs of DC10-treated asthmatic animals 
express augmented levels of regulatory T cell activation markers. 
OVA-asthma was induced in GFP-Foxp3 transgenic mice as noted above for 
BALB/c mice. These mice were then treated with either OVA- or irrelevant allergen 
(house dust mite; HDM)-presenting DC10 (DC10-OVA and DC10-HDM, respectively) 
and non-tolerance DC-OVA in order to induce tolerance, then at 3 week post-treatment 
we purified T cells from the lungs of each mouse and stained them with PE-cy5-CD4 and 
PE-labeled antibodies against the Treg activation markers ICOS, PD-1, GITR, LAG3 or 
CTLA-4. It is readily apparent that the OVA-presenting DC10 upregulated expression of 
ICOS, PD1, GITR, and LAG3 on pulmonary CD4+CD25+ cells relative to their 
expression on CD4+CD25+ cells from the lungs of HDM-presenting DC10-treated and 
DC-OVA-treated mice. One representative experiment of three is shown. 
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Figure 4-2. CD4+CD25hi cells from the lungs of DC10-treated asthmatic animals 
express augmented levels of regulatory T cell activation markers. 
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4.4.2. Passive transfer of tolerance with DC10-induced pulmonary 
CD4+CD25+Foxp3+ cells. 
We next sought confirmation that the CD4+CD25+Foxp3+ cells from the lungs of 
DC10-treated mice could operate as regulatory cells in vivo. We titrated the numbers of 
Treg required to transfer tolerance, giving asthmatic mice either saline or 1.25 - 10×105 
CD4+CD25+ cells (i.v.) from mice treated 3 week earlier with DC10. We assessed AHR 
in the recipients weekly thereafter, then administered a recall allergen challenge (20 min 
of nebulized 1% OVA aerosol) on day 28 and sacrificed the animals two days later. We 
assessed airway eosinophilic inflammation and Th2 cytokine responses, as determined by 
BAL fluid IL-4, -5, -9, and -13 levels. The AHR of the animals given 106 DC10-induced 
Treg was fully normalized by 21 days post-transfer (Figure 4-6) and remained so at 4 
week (Figure 4-3A). When we transferred 5×105 3-week Treg, AHR was not discernibly 
affected at 2 or 3 week (Figure 4-6) but by 4 week it was significantly reduced (p<0.05 
versus saline-treated asthmatic mice). Lower numbers of Treg were without effect on 
AHR, at least as of 4 week post-transplant (Figure 4-3A). Passive transfer of Treg also 
reduced airway eosinophilia and Th2 cytokine levels in a dose-dependent manner. 
Specifically, either 5×105 or 106 cells reduced the eosinophil responses to background, 
while 2.5×105 or fewer cells were without effect (Figure 4-3B; p>0.05 versus saline-
treated asthmatic mice). In accord with this, Th2 responses were also amenable to Treg 
tolerance, such that delivery of 106 cells reduced the Th2 response to near background 
and 5×105 Treg reduced them very markedly (p<0.05, versus saline-treated asthmatic 
animals), whereas transfer of fewer cells was without discernible effect (Figure 4-3C). 
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 For a more finely tuned in vivo confirmation of the kinetics for DC10-driven 
pulmonary Treg induction, we transferred a limiting number (5×105) of pulmonary Treg 
from mice treated 1-4 week earlier with DC10 and again assessed their impact on AHR 
and on Th2 cytokine and eosinophilic inflammatory responses to airway recall allergen 
challenge (Figure 4-7). When used at these limiting numbers, only the cells from animals 
treated 3 week earlier with DC10 were sufficiently activated to alter AHR or eosinophilia 
(for both, p<0.05 versus saline-treated asthmatic recipients) in the asthmatic recipients. 
The airway Th2 responses were slightly more amenable to regulation, such that 5×105 
Treg from mice treated with DC10 either 3- or 4-week earlier significantly affected 
airway cytokine levels (p<0.05 for each cytokine versus saline-treated asthmatic 
recipients). The 1- and 2-week cells were ineffective in reducing airway Th2 cytokine 
expression (p>0.05 for each cytokine). 
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Figure 4-3. Passive transfer of CD4+CD25hi Treg from DC10-treated animals 
reverses the asthma phenotype in asthmatic recipient mice.  
CD4+CD25hi cells were purified from the lungs of asthmatic mice treated 3 week 
earlier with DC10, as in Figure 4-1. We passively transferred 106, 5×105, 2.5×105 or 
1.2×105 of these Treg into asthmatic recipients (i.v.), and 25 day later (A) assessed their 
AHR to aerosolized methacholine. The following day we challenged the animals for 20 
min with nebulized aerosols of 1% OVA and 48 h later assessed their airway. The 10×105 
Treg treatments nearly normalized AHR (relative to the normal saline controls) at 4 wk 
post-treatment. The AHR in the 5×105 Treg-treated mice was significantly different 
relative to the asthma phenotype mice (*P<0.05, n=5). (B) eosinophil and (C) Th2 
cytokine responses to the recall allergen challenge. We observed reductions in each 
asthma parameter assessed, based on the numbers of Treg passively transferred. We 
found that Treg inhibited Th2 cytokine secretion in a dose-dependent manner and 5×105 
Treg still significantly inhibited Th2 cytokine secretion in terms of IL-4, -5, -9 and -13 
compared with the saline control group (*p<0.05, n=5). But transfer of ≤2.5×105 Treg 
had no discernible impact on the asthma phenotype of the recipients. One representative 
experiment of two is shown. 
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Figure 4-3. Passive transfer of CD4+CD25hi Treg from DC10-treated animals 
reverses the asthma phenotype in asthmatic recipient mice. 
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4.4.3. DC10 induce the differentiation of CD4+CD25-Foxp3- Teff cells into CD4+ 
Foxp3+ Treg. 
It has been reported that naïve T cells are readily converted to a regulatory 
phenotype when co-stimulated with CTLA-4-Ig (Razmara, Hilliard et al. 2008) or TGF-β 
(Chen, Jin et al. 2003; Pyzik and Piccirillo 2007; Siewert, Lauer et al. 2008). Our DC10 
do not express significant levels of TGF-β relative to either immature or TNF-treated in 
vitro-differentiated DCs (Nayyar 2009), but our data indicates that they are clearly 
tolerogenic in asthmatic animals, wherein they appear to fully reverse Th2 Teff cell 
responses. Thus, we questioned whether they induce CD25-Foxp3- Teff cells to 
differentiate into Treg. It has been shown that Teff cell lines generated from tuberculin 
PPD-challenge skin sites can be anergized ex vivo and that Foxp3 expression is 
upregulated in concert with this induction of anergy (Vukmanovic-Stejic, Agius et al. 
2008) but, as far as we are aware, there have been no reports demonstrating that Treg can 
differentiate from antigen-experienced Teff cells. To test this directly, we set up an in 
vitro culture system in which CD4+CD25-Foxp3- Teff cells purified from the lungs of 
asthmatic OVA-TCR transgenic DO11.10 mice were stained with CSFE and co-cultured 
with specific (OVA) or irrelevant allergen (HDM)-presenting DC10 or OVA-presenting 
immunostimulatory cells (DC-LPS). After 5 day we analyzed the CFSE+ cells from these 
cultures to assess their proliferation (CFSE dilution) and expression of Foxp3 (Figure 4-
4A), but we also used magnetic sorting to purify the CD25+ cells that were induced in 
these cultures and titrated their regulatory activities (Figure 4-4B). In the cultures 
containing irrelevant allergen-presenting DC10 we observed little if any proliferation of 
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 the Teff cells and no expression of Foxp3 by the CFSE-labeled cells, and this makes 
sense based on the known allergen-specificity of DC10-induced tolerance (Koya, 
Matsuda et al. 2007; Li, Yang et al. 2010). The DC-LPS strongly induced Teff cell 
proliferation but not Foxp3 expression, but the bulk of the CD4+CD25-Foxp3- cells in the 
OVA-presenting DC10 co-cultures had proliferated and ≈45% of them expressed Foxp3 
at high levels (Figure 4-4A). When we MACS-purified the induced CD25+ cells back out 
of these cultures and titrated their activity in vitro we found them to be highly effective in 
dampening DC-LPS-induced Teff cell proliferation (Figure 4-4B; p≤0.05 versus CD25+ 
T cells MACS purified from DC-LPS/ Teff cell cultures). These data confirmed that 
DC10 are fully capable of efficiently inducing CD4+CD25-Foxp3- Teff cells from 
asthmatic mice to differentiate into functional regulatory cells in vitro and that this 
response is fully dependent on cognate allergen presentation. 
In order to confirm the in vivo relevance of this observation we also assessed 
whether delivery of DC10 to asthmatic mice would similarly induce Teff cells to 
differentiate into CD25+Foxp3+ Treg. We MACS-purified CD4+CD25-Foxp3- Teff cells 
from OVA-asthmatic DO11.10 mice, labeled them with CFSE, and injected them i.v. into 
asthmatic recipients. At the same time we injected the recipients i.p. with either OVA- or 
HDM-presenting wild-type DC10. Two weeks later we generated single cell suspensions 
from the lungs, mediastinal LNs and spleens of the treated mice, stained the cells with 
anti-Foxp3 and anti-CD25 antibodies and analyzed the cells by FACS, gating on the 
dividing (i.e., activated) CFSE+ cells (Figure 4-5). We found negligible numbers of 
CFSE+CD25+Foxp3+ T cells in the lungs (0.21%), lung-draining LNs (0.64%) or spleens 
(0.43%) of the animals we had treated with HDM-presenting DC10, but there were  
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Figure 4-4. Specific, but not irrelevant, allergen-presenting DC10 induce the 
differentiation of CD4+CD25-/loFoxp3- Teff cells from asthmatic donors into 
CD4+Foxp3+ Treg in vitro.  
OVA-asthma was induced in OVA TCR transgenic DO11.10 mice as noted 
above, then we purified CD4+CD25-/loFoxp3- Teff cells from the lungs of these mice. (A) 
Teff from asthmatic DO11.10 mice were stained with CSFE and co-cultured with specific 
(OVA)- or irrelevant (HDM) allergen-presenting DC10 or OVA-presenting DC-LPS (105 
Teff + 3×104 DC/well); 10 µg/ml IL-2 was added to the cultures as a growth factor. Five 
day later the cells in the cultures were analyzed by FACS for CFSE-dilution (Teff cell 
proliferation) and Foxp3 expression. (B) To confirm that the induced CD4+CD25+Foxp3+ 
were functional as regulatory cells, we used magnetic sorting to purify the CD25+ T cells 
from 5 day co-cultures of asthmatic DO11.10 mouse pulmonary Teff and OVA-DC10 or 
OVA-DC-LPS. These induced OTII CD4+CD25+ Treg (or control Teffs) were then 
irradiated (3000 rad) and added to cultures of OVA-presenting DC-LPS + Th2 Teff cells 
from asthmatic C57BL/6 mice. Th2 Teff cell proliferative responses were assessed as in 
Figure 4-1C. *p<0.05, n=4, comparison of proliferation between 10×104/well Treg and 
Teff group. One representative experiment of two is shown. 
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Figure 4-4. Specific, but not irrelevant, allergen-presenting DC10 induce the 
differentiation of CD4+CD25-/loFoxp3- Teff cells from asthmatic donors into 
CD4+Foxp3+ Treg in vitro.  
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Figure 4-5. DC10-induced differentiation of CD4+CD25hiFoxp3+ Treg from 
CD4+CD25-/loFoxp3- T effector cells in vivo. 
In order to confirm the in vivo relevance of DC10-driven conversion of 
CD4+CD25-/loFoxp3- Teff cells into regulatory cells, we injected (i.v.) 5×106 CFSE-
labeled CD4+CD25-Foxp3- T cells from OVA-asthmatic DO11.10 mice and 106 OVA- or 
HDM-presenting DC10 from wild-type BALB/c mice (i.p.) into asthmatic BALB/c 
recipients. After 2 week we prepared single cell suspensions from the lungs (upper 
panels), mediastinal LNs (middle panels) and spleens (lower panels), stained the cells for 
Foxp3 and CD25, and gated on the activated (i.e., dividing) CFSE+ cells (left panels, 
boxed in cells) to assess the expression of these markers by FACS. There was no 
conversion of CFSE-labeled CD4+CD25-Foxp3- Teff cells into CD25+Foxp3+ regulatory 
cells in the mice treated with HDM-presenting DC10, while there was substantial 
differentiation of regulatory cells from the Teff cells in the OVA-presenting DC10-
treated animals. One representative experiment of two is shown. 
 104  
  
Figure 4-5. DC10-induced differentiation of CD4+CD25hiFoxp3+ Treg from 
CD4+CD25-/loFoxp3- T effector cells in vivo. 
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Figure 4-6. Kinetics with which airway hyperresponsiveness is reduced in asthmatic 
animals given varying numbers of CD4+CD25+ Treg from DC10-treated animals. 
Varying numbers of CD4+CD25+ cells from the lungs of asthmatic mice treated 3 
week earlier with DC10 were passively transferred into asthmatic recipients as in Figure 
4-3. At 1, 2, and 3 wk post-transfer, the animals’ AHR to aerosolized methacholine was 
assessed by head-out whole-body plethysmography. Transfer of 106 Treg treatments 
nearly normalized AHR (relative to the normal saline controls) at 2 wk post-treatment, 
while transfer of ≤5×105 Treg had no significant impact on the AHR of the recipients at 
1, 2 or 3 wk. One representative experiment of two is shown. 
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Figure 4-6. Kinetics with which airway hyperresponsiveness is reduced in asthmatic 
animals given varying numbers of CD4+CD25+ Treg from DC10-treated animals. 
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Figure 4-7. In vivo confirmation of the induction kinetics for the regulatory activities 
of pulmonary Treg from DC10-treated asthmatic mice. 
In order to confirm in vivo the activation of the CD4+CD25+Foxp3+ cells induced 
by DC10 treatment of asthmatic mice, we passively transferred limiting numbers of these 
(3 week) Treg into asthmatic recipients (5×105 per mouse), then assessed their asthma 
phenotype as in Figure 4-3. (A) AHR of the recipients to methacholine as determined at 
day 25 after treatment. At 48 hour after recall allergen challenge we assessed (B) 
eosinophilic airway inflammation and (C) BAL IL-4, -5, -9 and -13 levels. When used at 
limiting numbers, it was readily apparent that the pulmonary Treg were maximally 
activated at 3-week post DC10-treatment. (*P<0.05 vs. saline group, n=5). One 
representative experiment of two is shown. 
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Figure 4-7. In vivo confirmation of the induction kinetics for the regulatory activities of 
pulmonary Treg from DC10-treated asthmatic mice. 
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 significant numbers of activated CFSE+CD25+Foxp3+ cells in the asthmatic mice that had 
been treated with specific allergen-presenting DC10. We found that 7, 16, and 21% of the 
proliferating CFSE+ cells recovered from the lungs, mediastinal LNs, and spleens, 
respectively, were now CD25+Foxp3+ (Figure 4-5). Taken together, our in vitro and in 
vivo data indicated that during DC10-mediated induction of allergen-tolerance in 
asthmatic mice, CD4+CD25-Foxp3- Teff cells do differentiate into CD4+CD25+Foxp3+ 
Treg. 
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 4.5. DISCUSSION 
Multiple labs have reported that CD4+ cells take on regulatory activities with 
tolerance induction in asthma (Strickland, Stumbles et al. 2006; Henry, Desmet et al. 
2008; Li, Yang et al. 2010; Lu, Dawicki et al. 2011), but the mechanisms by which this 
occurs had not been defined. We documented herein that in inducing tolerance in 
asthmatic mice, DC10 also induce CD4+CD25-Foxp3- Th2 effector cells (Teff) to 
differentiate into CD4+CD25+Foxp3+ Treg. The kinetics with which these cells were 
activated in the lung correlated very well with the acquisition of asthma tolerance in mice 
model (Nayyar 2009; Lu, Dawicki et al. 2011). Nevertheless, while peak Treg activation 
occurred at 3 week after the DC10 treatment, we have found that tolerance induced by a 
single DC10 treatment is progressive over many months in mice model (Nayyar 2009). 
This suggests that alternate mechanisms supplant the pulmonary Treg-dependent 
tolerance that sets in over the first few weeks following DC10 treatment, perhaps in the 
context of infectious processes that incorporate regulatory DCs and/or alternate 
regulatory T cell populations (Mahnke, Johnson et al. 2007). For example, Treg can 
induce myeloid DCs to adopt a regulatory phenotype (Misra, Bayry et al. 2004; Houot, 
Perrot et al. 2006), while DCs can reciprocally express substantial control over Treg 
populations (Darrasse-Jeze, Deroubaix et al. 2009). 
It had been shown previously that gut lamina propria or mesenteric LN, but not 
splenic, DCs can induce naïve T cells to differentiate to a regulatory phenotype without 
need for exogenous input (i.e., TGF-β) (Yamazaki, Bonito et al. 2007) and this would be 
appropriate in a compartment routinely presented with commensal (i.e., non-pathogenic) 
bacteria (Coombes and Powrie 2008). In the lungs, which are also under constant 
exposure to innocuous foreign antigens (e.g., pollens), pulmonary DCs that present such 
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 antigens to naïve T cells express a semi-mature phenotype and express IL-10 and thereby 
induce regulatory T cell responses that prevent development of pathogenic (e.g., allergic) 
responses (Akbari, DeKruyff et al. 2001). The fact that we generated Teff cell pools from 
the lungs of fully symptomatic asthmatic mice indicates that these cells would have been 
educated Teff cells, as opposed to naïve T cells. Thus, our data showing that DC10 
induced the differentiation of these Teff cells into CD4+CD25+Fopxp3+ Treg provides our 
first clear documentation that Teff cells are amenable to such a phenotypic changes. We 
have shown previously that specific allergen-presenting DC10 generated from CD14+ 
monocytes of asthmatic individuals similarly induce the outgrowth of 
CD25+Foxp3+LAG3+ CTLA-4+ Treg from autologous Th2 Teff cell populations. Those 
Treg subsequently suppressed autologous Teff responses in a contact-dependent manner 
(Li, Yang et al. 2010), as reportedly occurs with Treg in other model systems (Stephens, 
Andersson et al. 2007; Akdis and Akdis 2009). However, in the mouse model we 
employed herein our DC10-induced regulatory activity was dependent on expression of 
IL-10 by the T cells, a characteristic consistent with a Tr1-like phenotype regulatory cell. 
Others have reported that IL-10-treated DCs induce anergy among antigen-specific T 
cells in part via CTLA-4 (i.e., contact-dependent regulation)(Steinbrink, Graulich et al. 
2002). Nevertheless, IL-10 expression by both the treatment DC10 (Koya, Matsuda et al. 
2007) and endogenous host cells(Henry, Desmet et al. 2008) has been implicated in 
tolerance induction in asthmatic mice.  
Interestingly, while ectopic expression of Foxp3 alone is reportedly sufficient to 
turn Teff cells into Treg (Hawrylowicz and O'Garra 2005; Randolph and Fathman 2006; 
Stock, DeKruyff et al. 2006; Toda and Piccirillo 2006), there were equivalent numbers of 
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 CD4+CD25+Foxp3+ cells in the lungs of asthmatic mice irrespective of whether they were 
fully asthmatic or their pulmonary CD4+CD25+Foxp3+ cells were activated and expressed 
a regulatory phenotype. And, while DC10 induce Th2 Teff from atopic asthmatic 
individuals to take on an activated Treg phenotype (i.e., 
CD4+CD25+Foxp3+LAG3+CTLA4+ IL-10-secreting T cells), the cells in these cultures do 
not express increased levels of Foxp3 relative to those in cultures containing 
immunostimulatory DC-activated Teff cells (Li, Yang et al. 2010). A similar observation 
has been made with CD4+CD25+Foxp3+ cells from asthmatic rats versus those rendered 
allergen-tolerant by chronic airway exposure to allergen (Strickland, Stumbles et al. 
2006). This provides further evidence that Foxp3 expression by itself is not sufficient for 
optimal induction of a regulatory phenotype in CD4+CD25+ cells. The fact that the 
numbers of pulmonary CD4+CD25+Foxp3+ cells were equivalent in our asthmatic and 
tolerant animals despite the observation that sizable numbers of Teff had ostensibly 
converted to activated Treg in the latter group, suggests that Treg homeostatic control 
mechanisms (Almeida, Rocha et al. 2005) were operative in their lungs. It is recognized 
that DCs and Treg populations control one another in a reciprocal homeostatic fashion 
(Darrasse-Jeze, Deroubaix et al. 2009) and this raises the question of whether the 
tolerogenic DCs we introduced into asthmatic animals may exercise homeostatic control 
over lung Treg numbers. Perhaps the CD4+CD25+Foxp3+ cells that were present in the 
asthmatic lung prior to tolerance induction represent a subpopulation of cells that are 
uniquely susceptible to apoptotic (Yolcu, Ash et al. 2008) or other control mechanisms. 
Regulatory T cells play important roles in maintaining the balance between 
protective and pathogenic immune responses (Lewkowich, Herman et al. 2005; 
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 Strickland, Stumbles et al. 2006). To date, both naturally-occurring thymic CD4+CD25+ 
Treg (nTreg) and inducible regulatory T cells have been recognized, with the latter cells 
including IL-10- and TGF-β-secreting Tr1 and Th3 cells, respectively (Xystrakis, Urry et 
al. 2007). Naturally-occurring Treg constitute 1-5% of the CD4+ T cells in healthy adult 
mice and humans, but regulatory cells with similar surface markers and functions can 
also be induced in the periphery. These cells can be isolated from mice and humans based 
on their high-level expression of CD25 (the IL-2 receptor α-chain). Other markers that 
were originally thought to be specific for nTreg include CTLA-4 and GITR but, like 
CD25, they are also expressed by activated T cells. Our data indicated that DC10 
increased the expression of ICOS, PD-1, GITR, LAG3 and CTLA-4 with the acquisition 
of the regulatory phenotype, and this fits well with observations by others (Piccirillo and 
Thornton 2004).  
In summary, our data supports the novel observation that these cells induced 
CD4+CD25-Foxp3- Teff cells to differentiate into CD4+CD25+Foxp3+ Treg cells. We did 
not assess whether they also directly activated or induced proliferation of pre-existing 
CD4+CD25+Foxp3+ T cells, but these cells can indeed proliferate strongly and 
particularly so under the influence of IL-2 (Curotto de Lafaille and Lafaille 2009). We 
also did not rigorously investigate the cellular interactions between the DC10 and Teff 
cells in asthmatic animals, but we know that these populations do engage one another 
intimately and in an antigen-specific fashion (Li, Yang et al. 2010; Lu, Dawicki et al. 
2011). These will be important issues to address in the future. 
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 5.1. Abstract  
 
Recent evidence shows that natural regulatory T cells (nTreg) and induced Treg 
(iTreg) cooperate in mediating tolerance in colitis models, but they do so also in models 
of asthma.  However, there is little evidence regarding their relative contributions to such 
tolerance.  We compared the abilities of nTreg versus iTreg, both from OVA-TCR 
transgenic OTII mice, to mediate tolerance in OVA-asthmatic C57BL/6 mice. The iTreg 
were differentiated from Th2 effector T cells (Teff) by exposure to IL-10-differentiated 
dendritic cells (DC10) in vitro or in vivo, while we purified nTreg from allergen-naïve 
mice, but also exposed them to DC10 before use.  Each Treg population was subsequently 
re-purified and tested for its therapeutic efficacy in vitro and in vivo. DC10 engaged the 
nTreg in a cognate fashion in FRET assays, and these nTreg reduced in vitro OVA-
asthmatic Th2 Teff responses by 41-56%, while the comparator iTreg reduced these 
responses by 72-86%.  Neutralization of IL-10, but not TGF, eliminated the suppressive 
activities of iTreg, but not the nTreg.  Delivery of 5x105 purified nTreg reduced allergen 
challenge-induced airway IL-4 (p≤0.03) and IL-5 (p≤0.001) responses of asthmatic 
recipients by ≤23%, but did not affect airway hyperresponsiveness (AHR) or IgE levels, 
while equal numbers of iTreg of the same TCR specificity reduced all airway responses to 
allergen challenge by 82-96% (p≤0.001) and normalized AHR.  These data confirm that 
allergen-specific iTreg and nTreg have active roles in asthma tolerance, but also that iTreg 
are substantially more tolerogenic in this setting.  
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 5.2. Introduction 
The extent to which naturally-occurring regulatory T cells (nTreg) and induced 
Treg (iTreg) have non-redundant versus complementary roles in immune tolerance is not 
clear (Bilate and Lafaille 2011). For example, iTreg alone may be sufficient to induce 
tolerance in a chronic model of pulmonary inflammation (Curotto de Lafaille, 
Kutchukhidze et al. 2008), but in a mouse model of colitis both nTreg and iTreg are 
required to induce full disease tolerance (Haribhai, Williams et al. 2011). The 
observations regarding largely disparate TCR beta chain specificities within these two 
populations notwithstanding, it is clear that at least in some settings deployment of both 
nTreg and iTreg is required for the full expression of tolerance (Haribhai, Williams et al. 
2011). This contrasts with the popular notion that the raison d’etre for nTreg is to prevent 
the development of autoimmune disease (Takahashi, Tagami et al. 2000) while that of 
iTreg is to reduce the activation of T cells directed against innocuous environmental 
antigens (Bilate and Lafaille 2011). Additional observations that suggest a greater degree 
of complexity in the roles of nTreg and iTreg, at least in the context of environmental 
antigens, include the report that depletion of CD25+ T cells in naive wild-type mice leads 
to augmented asthma severity following subsequent allergen sensitization (Lewkowich, 
Herman et al. 2005; Joetham, Takeda et al. 2007). Moreover, passive transfer of 
CD25+Foxp3+ T cells from naïve mice into asthmatic recipient animals reduces their 
asthma severity if the transfers are performed within 3-4 weeks of asthma induction 
(Kearley, Robinson et al. 2008). 
The recognition that Treg are potently immunosuppressive has galvanized efforts 
to use these cells therapeutically (Horwitz, Zheng et al. 2004; Riley, June et al. 2009). 
Passive transfer of Treg that populate the periphery has been shown to suppress pathology 
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 in, for example, experimental models of autoimmune disease (Mottet, Uhlig et al. 2003; 
Wright, Ehrenstein et al. 2011). One unanswered question regarding clinical application 
of this approach is which population of Treg (i.e., nTreg versus iTreg) would be best 
employed in any specific setting (Roncarolo and Battaglia 2007; Newell, Phippard et al. 
2011). There has been speculation that, overall, iTreg would be therapeutically superior to 
nTreg in settings other than autoimmunity because iTreg would be expected to target 
antigen-specific T cells with greater efficiency, but there is a lack of compelling evidence 
to support this proposal. It was recently reported that, in mouse models of human skin 
transplantation, iTreg but not nTreg treatment led to modestly reduced expression of two 
of three inflammatory markers in one model, although no such effect was observed in the 
second model and transplant rejection was not assessed (Sagoo, Ali et al. 2011). This 
leaves open the question of just how comparable nTreg and iTreg truly are in terms of 
their abilities to ameliorate pathology.  
Herein we compared the abilities of nTreg and iTreg of the same antigen 
specificity to suppress allergic Th2 responses in vitro and to alter the asthma phenotype 
in a mouse model of firmly-entrenched OVA-asthma. In both cases the Treg were derived 
from OVA TCR transgenic OT2 mice and were exposed either in vitro or in vivo to 
OVA-presenting IL-10-differentiated DCs (DC10). We have shown previously that such 
DC10 can efficiently induce Teff cells to differentiate into CD4+CD25+Foxp3+ iTreg, but 
also that 5×105 unfractionated Treg (i.e., iTreg plus nTreg) recovered from the lungs of 
asthmatic mice rendered allergen-tolerant by treatment with DC10 can in turn reduce the 
asthma phenotype by about ≈50% in asthmatic passive transfer recipients (Huang, 
Dawicki et al. 2010). Herein we show that passive transfer of 5×105 iTreg from DC10-
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 treated asthmatic OT2 mice can suppress all aspects of the asthma phenotype, while equal 
numbers of DC10-stimulated OT2 mouse nTreg that are recovered from asthmatic 
recipient mice have only a modest impact in this model. 
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 5.3. Materials and methods 
 
5.3.1. Mice and the asthma model. 
Female 6-8 week old C57BL/6 (B6) mice were purchased from Charles River 
Laboratories (Charles River, ME). B6.CD45.1 congenic and OT2 OVA-specific TCR-
transgenic mice were obtained from the Jackson Laboratory (Bar Harbor, ME. Foxp3-
GFP knock-in mice were kindly provided through Dr. S. Rudensky (University of 
Washington). Double-positive GFP-Foxp3/B6.CD45.1 mice were generated by crossing 
GFP-Foxp3 and B6.CD45.1 mice. Triple-positive GFP-Foxp3/B6.CD45.1/OT2 mice 
were generated by crossing double-positive GFP-Foxp3/B6.CD45.1 and OT2 mice. The 
GFP-Foxp3/B6.CD45.2/OT2 mice were generated by crossing GFP-Foxp3 and OT2 mice. 
The B6.CD45.1/OT2 mice were generated by crossing B6.CD45.1 and OT2 mice. The 
phenotypes of offspring mice were confirmed by flow cytometry analyses in which 
peripheral blood leukocytes from all mice were stained with anti-mouse CD45.1 and/or 
Vβ5.1,5.2 TCR antibodies (Appendix-1). 
Asthma was induced in the mice by two i.p. injections (days 0 and 14) of 2 mg 
OVA/alum, followed by 20-min exposures (day 28, 30, and 32) to nebulized aerosols of 
1% OVA in saline (Nayyar, Dawicki et al. 2012). DC10 and Treg treatments were 
initiated two weeks later (dy 46). All mice were bred and housed in our institutional 
animal care unit and used in accord with the guidelines of the Canadian Council for 
Animal Care. 
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 5.3.2. Reagents. 
PE-conjugated anti-mouse CD25, ICOS, PD-1, GITR, CTLA-4 and LAG3 
antibodies (Abs) and mouse Treg cell staining kits were purchased from eBioscience, Inc 
(San Diego, CA). Recombinant mouse IL-4 and IL-5 and matched capture and detection 
antibody pairs and protein standards for our ELISAs and neutralizing anti-TGF-β Ab 
were obtained from R & D Systems (Minneapolis, MN). The neutralizing anti-IL-10 Ab 
was gift from Sigma-Aldrich (Mississauga, ON). Anti-mouse CD4 MACS beads and 
mouse CD4+CD25+ Treg cell isolation kits were purchased from Miltenyi Biotec (Auburn, 
CA). Bead-free mouse CD4+CD25+ regulatory T cell isolation kits were purchased from 
Invitrogen (Burlington, ON). The sources of all other reagents have been reported 
previously (McLellan, Kapp et al. ; Gordon, Li et al. 2005; Huang, Dawicki et al. 2010).  
 
5.3.3. Generation and comparison of in vitro-induced iTreg and nTreg cells. 
CD4+ CD25- Foxp3- Teff cells and CD4+ CD25+ Foxp3+ Treg were purified from 
asthmatic and naïve OT2 mice by negative- and positive-selection magnet sorting, 
respectively; these Teff cells have been previously reported as 
CD4+CD25loCD44hiCD69+CD62LloFoxp3- (Huang, Dawicki et al. 2010; Schallenberg, 
Tsai et al. 2010). The purified Teff and Treg cells (105 cells/well) were co-cultured with 
DC10 (3×104 cells/well) in U-bottom 96-well plates for five days, then the CD4+CD25+ 
iTreg and DC10-exposed CD4+CD25+ nTreg were positively selected from their 
respective cultures by magnetic sorting. Both populations of cells were stained with PE-
labelled antibodies against the Treg markers ICOS, PD-1, GITR, LAG3 and CTLA-4 to 
determine their relative expression. The 5-day-cultured iTreg and nTreg (105 cells/well) 
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 cells were also co-cultured for 48 h with LPS-activated immunostimulatory OVA-
presenting DCs (DC-LPS; 3.7×103 cells/well) and effector Th2 cells (105 cells/well) from 
asthmatic mice (Huang, Dawicki et al. 2010). The cell cultures were pulsed with 3H-
thymidine during the last 18 hr and thymidine incorporation was determined by liquid 
scintillation counting. Type 2 cytokines (IL-4, -5) were assessed in the cultural 
supernatant by ELISA. In some assays, we added neutralizing anti-IL-10 or anti-TGF-β 
Ab (each, 10 µg/ml) to the cultures.  
 
5.3.4. Generation and comparison of in vivo-induced Treg and nTreg.  
FACS Analysis. CD4+CD25-Foxp3- Teff and CD4+CD25+Foxp3+ Treg were 
purified from asthmatic GFP-Foxp3/B6.CD45.1/OT2 and naïve GFP-
Foxp3/B6.CD45.2/OT2 mice, respectively. Both Teff and Treg (5×106 cell each) were 
injected i.v. into asthmatic B6.CD45.2 recipient mice, which were also treated at the time 
of passive transfer with 1x106 B6.CD45.2+ DC10 (i.p.). CD45.1 and GFP were used as 
markers for transplanted CD45.1+ Teff that had converted to an iTreg phenotype (i.e., 
CD45.1+GFP+ cells), and as markers for the transplanted nTreg or their progeny (i.e., 
CD45.1-GFP+ cells). One wk after the injection, CD4+ T cells were purified from the 
spleens of the DC10-treated recipients and stained with PE-cy5-CD45.1 and PE-labeled 
antibodies against the indicated Treg markers and analyzed by flow cytometry. 
CD45.1+GFP+ (iTreg) and CD45.1-GFP+ (nTreg) cells were gated and evaluated for the 
expression of ICOS, PD-1, GITR and LAG3 (Figure 5-1). 
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Figure 5-1. Protocol to compare Treg-associated marker expression on iTreg and 
nTreg cells in DC10-treated asthmatic mice. 
CD4+CD25-Foxp3-Teff and CD4+CD25+Foxp3+Treg cells were purified from 
asthmatic GFP-Foxp3/B6.CD45.1/OT2 and naïve GFP-Foxp3/B6.CD45.2/OT2 mice, 
respectively. Both Teff and Treg cells were injected i.v. into asthmatic B6.CD45.2 mice 
along with DC10 (i.p.). One week after the injections, CD4+ T cells were purified from 
the recipients’spleens and stained with PE-cy5-CD45.1 and PE-labeled antibodies against 
the Treg cell markers ICOS, PD-1, GITR, LAG3 and CTLA-4. CD45.1+GFP+ (iTreg) and 
CD45.1-GFP+ (nTreg) cells were gated and the expression of ICOS, PD-1, GITR, LAG3 
and CTLA-4 was analyzed by FACS. 
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Figure 5-1. Protocol to compare Treg-associated marker expression on iTreg and 
nTreg cells in DC10-treated asthmatic mice. 
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 Assessment of T cell regulatory activities. CD4+CD25-Foxp3- Teff and 
CD4+CD25+Foxp3+ nTreg were selected from asthmatic and naïve B6.CD45.1/OT2 mice, 
respectively, using magnetic sorting, then injected i.v. into different groups of asthmatic 
B6.CD45.2 recipient mice (5×106 cell/mouse) that were simultaneously treated i.p. with 
106 OVA-presenting CD45.2+ DC10. CD45 was used as a marker for the donor-origin 
(i.e., CD45.1+) Teff and nTreg cells, versus the endogenous CD45.1- Treg of the recipients. 
One week later, CD4+CD25+ Treg cells were purified from each group of mice by 
magnetic sorting, then labelled for further sorting with PE-CD45.1 antibody and anti-PE-
magnet beads. The iTreg and nTreg cells were purified from their respective populations 
of mice and their abilities to inhibit Th2 cell activation were assayed as above. 
In vivo comparison of iTreg and nTreg cells. We injected 5×105 in vitro-induced 
iTreg and nTreg cells, generated as noted (Huang, Dawicki et al. 2010), into otherwise 
untreated asthmatic recipient mice (i.v.). 
Airway hyperresponsiveness (AHR). Four weeks later we assessed the airway 
responses of the mice to doubling doses of nebulized methacholine (0.5-20 mg/ml) using 
by head-out, whole body plethysmography (Schneider, Li et al. 2001; Lu, Dawicki et al. 
2011). This parameter, gathered as running 1-s means of the air-flow at the 50% point in 
the expiratory cycle (Flow@50%TVe1), accurately reflects bronchiolar versus alveolar 
constriction or airway occlusion (Vijayaraghavan, Schaper et al. 1993; Vijayaraghavan, 
Schaper et al. 1994) and accurately correlates with invasive measurements of AHR 
(Glaab, Daser et al. 2001; Glaab, Ziegert et al. 2005). 
Airway immunoinflammatory response. The day after AHR was assessed the mice 
were given a recall allergen challenge (1% nebulized OVA for 20 min) and 2 d later we 
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 euthanized them to assess airway eosinophil numbers and IL-4 and IL-5 levels, as well as 
their relative levels of serum OVA-specific IgE and IgG1, as noted (Schneider, Li et al. 
2001). 
 
5.3.5. Statistical analysis. 
All data are presented as means ± standard error of the mean (SEM). Multi-group 
comparisons were assessed by one-way ANOVA with Tukey post-hoc testing, whereas 
AHR to methacholine was assessed by linear regression analyses. P values of <0.05 were 
considered significant. 
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 5.4. Results 
5.4.1. Treg cells induced by co-culture with DC10 are better than DC-10-stimulated 
nTreg in inhibiting Th2 cell responses in vitro. 
We have previously shown by fluorescence resonance energy transfer (FRET) 
analysis and other approaches that, in both mouse and human systems, DC10 efficiently 
engage Teff cells in an allergen-specific fashion (Li, Yang et al. 2010; Lu, Dawicki et al. 
2011) and promote their conversion into allergen-specific iTreg cells both in vitro and in 
vivo (Huang, Dawicki et al. 2010). We took advantage of this latter observation to 
generate OVA-specific iTreg for the present study. As nTreg require cognate activation 
via their TCR for induction of their suppressive effects (Thornton and Shevach 2000), we 
previous assessed whether OVA-presenting DC10 engage freshly purified nTreg in a 
productive manner, as determined by FRET analysis. We labeled irrelevant allergen 
(house dust mite; HDM)- and OVA-presenting DC10 or LPS-activated OVA-pulsed 
(OVADC-LPS) DCs with the lipophylic FRET donor dye DiI, and stained pulmonary 
CD4+CD25+Foxp3+ nTreg cells from healthy OVA TCR-transgenic OT2 mice with the 
FRET partner dye DiO. The labeled DCs were cocultured with the stained nTreg cells, 
while negative controls included DiO-stained T cells or DiI-stained DCs alone. We found 
that the OVA-presenting DC10 and DC-LPS both intimately engaged the OT2 nTreg over 
a number of hours, albeit with somewhat different kinetics, while no FRET signals above 
background were detected in the HDM-DC10/nTreg cultures (Appendix-2). We had 
reported previously that human DC10, which express reduced levels of MHCII and 
costimulatory molecules relative to immunostimulatory DCs, induce long-lasting 
immunological synapse formation with autologous Teff cells, although less intense FRET  
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Figure 5-2. OVA TCR-transgenic Treg cells induced in vitro by DC10 treatment 
more efficiently inhibit asthmatic T effector cell activation than do nTreg of identical 
antigen specificity. 
CD4+CD25loFoxp3- T effector (Teff) cells were purified from the lungs of 
asthmatic OVA TCR-transgenic OT2 mice, while CD4+CD25+Foxp3+ nTreg were 
purified from allergen-naïve OT2 mice. OVA-presenting DC10 were cocultured for 5 dy 
with these Teff or nTreg cells, then the DC10-induced Treg (iTreg) and nTreg were 
positively selected from their respective cultures by magnetic sorting. The abilities of 
each of these Treg populations (1×105 cells/well) to inhibit (A) proliferation and (B) Th2 
cytokine (IL-4, -5) secretion by DC-LPS-activated Teff (3×104 and 1×105 cells/well, 
respectively) freshly purified from the lungs of OVA-asthmatic C57BL/6 (B6) mice were 
assessed in vitro as noted in the Materials and Methods. In order to assess the 
contributions of IL-10 and TGF- to the suppressive activities of these Treg we also 
assessed the impact of neutralizing antibodies (each, 10 µg/ml) on DC-LPS-induced (C) 
proliferation and (D) Th2 cytokine secretion. ** or ***, p<0.01 or 0.001, respectively, 
versus the indicated group(s). One representative experiment of three is shown. 
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Figure 5-2. OVA TCR-transgenic Treg cells induced in vitro by DC10 treatment 
more efficiently inhibit asthmatic T effector cell activation than do nTreg of identical 
antigen specificity.
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 signals than do immunostimulatory DCs (Li, Yang et al. 2010). This data thus indicated 
that OT2 nTreg do engage in a cognate fashion with OVA-presenting DC10. 
To directly compare the suppressive activities of iTreg and nTreg we purified 
CD4+CD25loFoxp3- Teff cells from the lungs of asthmatic OT2 mice and purified nTreg 
from allergen-naïve OT2 mice. We co-cultured each of these T cell populations with 
OVA-presenting DC10 for 5 d, isolated the iTreg and DC10-exposed nTreg from their 
respective cultures, and then assessed their relative abilities to suppress proliferation and 
Th2 cytokine expression in co-cultures of OVA-presenting DC-LPS and Th2 Teff cells 
from OVA-asthmatic mice. The Th2 Teff cells proliferated strongly and secreted IL-4 and 
IL-5 in response to the DC-LPS triggering (Figure 5-2 A, B; Med. group), and adding 
further Teff cells to these cultures did not alter that response. On the other hand, adding 
DC10-exposed nTreg to the cultures reduced each of these Th2 responses by ≈41-56%, 
while adding iTreg had a substantially greater suppressive effect (81-86%) on all three 
parameters. As IL-10 and TGF-β are two important inhibitory cytokines secreted by Treg 
cells (Josefowicz, Lu et al. 2012), we also assessed their relevance to the suppressive 
abilities of our iTreg and nTreg cells, adding specific neutralizing antibodies to the co-
cultures to determine their impact on Th2 cell proliferation and Th2 cytokine secretion 
(Figure 5-2 C, D). Neither anti-IL-10 nor anti-TGF antibodies appeared to discernibly 
affect the suppression associated with the nTreg, while neutralization of IL-10 in the iTreg 
co-cultures abrogated their suppressive effects in these cultures. The anti-TGF had no 
impact on the iTreg activities. This data indicated that DC10-induced iTreg cells had a 
substantially greater contribution to regulation of Th2 responses in vitro than do nTreg 
that are of identical antigen specificity and which have seen similar exposure to allergen-
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 presenting DC10. It also indicated that these iTreg employed IL-10 as their primary 
tolerogenic mediator, as has been reported previously for peripherally-induced 
CD4+CD25+Foxp3+ Treg (Akbari, Freeman et al. 2002; Cobbold, Nolan et al. 2003). 
 
5.4.2. DC10-induced activation of nTreg and iTreg. 
As noted, nTreg induce tolerance in a contact-dependent fashion, employing cell 
surface molecules, as opposed to secreted mediators, as primary tolerogenic effectors 
(Takahashi, Tagami et al. 2000; Thornton and Shevach 2000). To determine whether our 
DC10-induced iTreg and nTreg differentially expressed Treg-associated markers, we 
assessed their expression of ICOS, PD-1, GITR, LAG3 and CTLA-4 by FACS. We found 
that our in vitro-induced Treg expressed modestly to markedly higher levels of ICOS and 
CTLA-4 than the nTreg, but largely equivalent levels of PD-1, GITR and LAG3 (Figure 
5-3 A). As an assessment of the relevance of these in vitro findings to Treg that might 
mediate tolerance responses in vivo, we also assessed expression of these markers on 
iTreg and nTreg that were induced or stimulated in vivo. To generate the iTreg, we 
transferred CD4+CD25loFoxp3- Teff cells from asthmatic CD45.1+ GFP-Foxp3 OT2 
donor mice (Figure 5-3 B) into asthmatic B6 (CD45.2+) mice, which we simultaneously 
treated i.p. with 1×106 OVA-presenting DC10. To obtain the nTreg, we purified 
CD4+CD25+Foxp3+ nTreg from allergen-naïve CD45.2+ GFP-Foxp3 OT2 donors (Figure 
5-3 B) and co-transferred these into the DC10-treated Teff cell recipient mice. One wk 
after the DC10 treatment, the animals’ CD4+ T cells were magnetically sorted and 
submitted for FACS analysis, gating on the CD45.1+GFP+ (iTreg) and CD45.1-GFP+ 
(nTreg) CD4+ T cells (Figure 5-3 C). It was readily apparent that in vivo-induced iTreg  
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Figure 5-3. DC10-induced Treg cells express substantially higher levels of PD-1, 
LAG3 and CTLA-4 than do nTreg cells. 
In vitro (A) and in vivo (B)-induced iTreg and nTreg were assessed for expression 
of the Treg-associated markers ICOS, PD-1, GITR, LAG3 and CTLA-4, as noted in the 
Materials and Methods. (A) iTreg and nTreg were generated in vitro and sorted from their 
respective cultures as in Figure 5-2, then submitted for FACS analysis. (B) Analogous 
populations of Treg were also generated in vivo by transferring (i.v.) 5×106 
CD4+CD25loFoxp3- Teff cells that had been purified from asthmatic CD45.1+ GFP-Foxp3 
OT2 donor mice (left panel) and CD4+CD25+Foxp3+ nTreg purified from allergen-naïve 
CD45.2+ GFP-Foxp3 OT2 donors (right panel) into the same DC10-treated asthmatic 
CD45.2+ B6 recipients. (C) One week after the DC10 treatment, the animal’s CD4+ T 
cells were magnetically sorted and stained with specific or isotype control antibodies for 
CD45.1 (upper two panels), as well as the markers indicated in panel A, with gating on 
GFP and CD45 to discern the iTreg and nTreg populations. For each panel one 
representative experiment of three is depicted. 
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Figure 5-3. DC10-induced Treg cells express substantially higher levels of PD-1, 
LAG3 and CTLA-4 than do nTreg cells. 
 133  
 cells expressed substantially higher levels of PD-1, LAG3 and CTLA-4 than the nTreg 
cells, and modestly elevated levels of ICOS and GITR. Nevertheless, the mean 
fluorescence intensity for each of these markers on the nTreg was significantly elevated 
relative to isotype control-stained cells. Similarly, both the nTreg and the iTreg expressed 
higher levels of each marker than did transferred Teff cells from asthmatic mice (Figure 
5-6).  
Having seen differences in expression of regulatory markers by in vitro- and in 
vivo-differentiated Treg, we next compared their activities. We generated cells for these 
assays in vivo, as above, with the exception that the Teff and nTreg were originally 
derived from asthmatic and naïve CD45.1+ OT2 donor mice, respectively. Each Treg 
population was transferred into its own group of DC10-co-treated asthmatic B6 recipient 
mice (5×106 T cells/mouse) and 1 wk later the CD4+CD25+CD45.1+ iTreg and 
CD4+CD25+CD45.1+ nTreg cells were purified from the respective recipients by magnet 
sorting (Figure 5-4 A). We assessed the activities of these Treg by adding them into co-
cultures of Teff cells from OVA-asthmatic B6 mice and OVA-presenting DC-LPS 
(Figure 5-4 B, C). Control cultures were either supplemented with no Treg (Med.) or with 
additional CD4+CD25-Foxp3- Teff cells purified from asthmatic donor B6 mice. We 
found that the in vivo-stimulated nTreg reduced DC-LPS-induced Teff cell proliferation in 
this assay by 45.7+/-7,1%, while the same numbers of iTreg of the same TCR specificity 
reduced proliferation by 73+/-5.5% (p≤0.01). When we measured the levels of IL-4 and 
IL-5 in these cultures we observed a similar outcome, with the nTreg reducing the levels 
of these two Th2 mediators by 40.5+/-6.5 and 52.2+/-13.6%, respectively, while the iTreg 
reduced their expression by 72.7+/-8.5 and 82.7+/-10.3%, respectively (for both 
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 cytokines, p≤0.01). Thus, consistent with the data from our in vitro-induced iTreg, in 
vivo-induced iTreg were substantially more effective than nTreg cells in blocking Th2 
activation in vitro. 
 
5.4.3. DC10-induced Treg more efficiently ameliorate the asthma phenotype than do 
DC10-stimulated nTreg of the same antigen-specificity. 
We had previously reported that passive transfer of 5×105 total 
CD4+CD25+Foxp3+ cells (i.e., unfractionated Treg) from DC10-tolerized asthmatic mice 
approximately 50% reverses the asthma phenotype of asthmatic recipients; 2.5×105 of 
these Treg are completely ineffective in this model, while 1×106 Treg fully corrects the 
phenotype (Huang, Dawicki et al. 2010). Herein we directly compared the in vivo 
regulatory activities of iTreg versus nTreg from OVA TCR-transgenic OT2 mice. We used 
5×105 purified DC10-induced Treg or equal numbers of DC10-exposed nTreg, both 
generated in vitro as above, to treat asthmatic mice at dy 46 after initiation of 
sensitization, and 4 wk later examined the impact of the treatments on the animals’ 
asthma phenotype.  We first assessed their airway hyperresponsivenss (AHR) to 
methacholine, using head-out whole body plethysmography to determine the airflow rates 
at the 50% point in the expiratory cycle (Gordon, Li et al. 2005; Huang, Dawicki et al. 
2010; Lu, Dawicki et al. 2011). The AHR of the animals given 5×105 DC10-induced 
iTreg cells was fully normalized (p>0.05 versus normal mice) whereas the same number 
of nTreg cells had no discernible effect on the asthmatic AHR (Figure 5-5A).  We then 
administered a recall allergen challenge to the animals and two days later assessed their 
airway eosinophil and Th2 cytokine (IL-4 and IL-5) responses. Across three experiments,  
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Figure 5-4. Treg cells induced in vivo by DC10 treatment of asthmatic mice have 
greater inhibitory activity in vitro than do nTreg cells of equivalent antigen 
specificity. 
(A) CD4+CD25+Foxp3+CD45.1+ iTreg and nTreg cells were induced in vivo and 
purified by CD45-based magnetic sorting as in Figure 5-3. These cells, together with 
control populations of Teff from asthmatic B6 mice, were assessed for their abilities to 
antagonize (B) proliferation and (C) IL-4 and IL-5 secretion by DC-LPS-activated Teff 
(3×104 and 1×105 cells/well, respectively) freshly purified from the lungs of OVA-
asthmatic B6 recipient mice. (**p<0.01, vs. iTreg values). One representative experiment 
of three is shown.  
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Figure 5-4. Treg cells induced in vivo by DC10 treatment of asthmatic mice have 
greater inhibitory activity in vitro than do nTreg cells of equivalent antigen 
specificity.
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Figure 5-5. Passive transfer of DC10-induced OT2 Treg, but not nTreg of identical 
antigen specificity, efficiently ameliorates the asthma phenotype in recipient mice. 
 
We injected 5×105 iTreg or nTreg cells (i.v.) generated in vitro as in Figure 5-2 
into otherwise untreated asthmatic recipient mice (n=5) and four weeks later assessed the 
impact of the treatments on the animals’ asthma status. (A) At 4 wk we assessed AHR to 
methacholine, as determined by the airflow rate at the 50% point in the expiratory cycle 
(Flow@50%TVe1). The following day we challenged them with an aerosol of 1% 
nebulized OVA and 2 d later assessed (B) the airway eosinophilia (C) and BAL IL-4 and 
IL-5 levels, and (D) the serum levels of OVA-specific IgE and IgG1. One representative 
experiment of three is shown. 
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Figure 5-5. Passive transfer of DC10-induced OT2 Treg, but not nTreg of identical 
antigen specificity, efficiently ameliorates the asthma phenotype in recipient mice. 
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Figure 5-6. Comparison of the expression levels of ICOS, PD-1, GITR, LAG3 and 
CTLA-4 by Teff, iTreg and nTreg cells. 
CD4+CD25-Foxp3-Teff and CD4+CD25+Foxp3+Treg cells were purified from 
asthmatic GFP-Foxp3/CD45.1 and naïve GFP-Foxp3/CD45.2 OT2 mice, respectively. 
Both T cell populations (5×106 cells/recipient) were injected i.v. into asthmatic B6 
(CD45.2) mice which were then treated i.p. with 1×106 OVA-presenting B6 DC10. One 
wk later CD4+ T cells were purified from the recipients’ spleens, and the cells stained 
with PE-cy5-CD45.1 and PE-labeled antibodies against the indicated Treg cell markers. 
CD45.1+GFP+ (iTreg), CD45.1-GFP+ (nTreg) and control CD45.1+GFP- (Teff) cells were 
gated and their marker expression was analyzed by flow cytometry. One representative 
experiment of two is shown. 
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Figure 5-6. Comparison of the expression levels of ICOS, PD-1, GITR, LAG3 and 
CTLA-4 by Teff, iTreg and nTreg cells. 
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 passive transfer of nTreg cells reduced IL-4 levels by ≈8.8 +/- 1.8 % (p≤0.03 versus 
saline-treated asthmatic mice), IL-5 levels by 22.9 +/- 6 % (p≤0.001 versus saline-treated 
asthmatic mice), and BAL eosinophil numbers by 16.2+/-5.1% (p=0.07 versus saline-
treated asthmatic mice)(Figure 5-5B and C).  Transfer of iTreg cells reduced the numbers 
of airway eosinophils and IL-4 and IL-5 levels to near background (p≤0.001 versus 
nTreg-treated asthmatic mice). In addition, the iTreg treatment markedly reduced the 
levels of OVA-specific IgE and IgG1 Ab (p≤0.001 and 0.01, respectively, versus nTreg-
treated asthmatic mice), while the nTreg had no discernible impact (p>0.05) on the IgE or 
IgG1 Ab responses (Figure 5-5D). 
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 5.5 DISCUSSION 
We demonstrated in this report that allergen-presenting IL-10-differentiated DCs 
(DC10) engage nTreg in a cognate fashion, as determined using FRET assays. These 
DC10-stimulated nTreg 41-56% suppressed proliferation and Th2 cytokine expression by 
immunostimulatory DC-activated Th2 Teff cells in vitro, although DC10-induced iTreg 
were substantially more tolerogenic in this in vitro system. The regulatory activities of 
these iTreg, but not nTreg, were completely blocked by anti-IL10 antibodies, and they also 
expressed higher levels of immunoregulatory molecules (e.g., PD-1, CTLA-4). We 
further found that transferring 5×105 purified DC10-exposed nTreg only modestly 
reduced the asthma phenotype in recipient mice, while equal numbers of purified DC10-
induced iTreg were highly effective in reducing asthmatic responses. As we have 
observed previously, asthmatic B cell (i.e., OVA-specific IgE and IgG1) responses take 
substantially longer to wane than do Th2 responses following tolerogenic treatments 
(Nayyar, Dawicki et al. 2012). 
It has been proposed that nTreg and iTreg subserve distinct functions, such that 
nTreg primarily target autoimmune responses (Takahashi, Tagami et al. 2000) while 
iTreg modulate responses to exogenous antigens (Bilate and Lafaille 2011). One piece of 
evidence that supports this is that depletion of nTreg in naïve mice leads to an 
autoimmune syndrome (Sakaguchi 2005), but it has since been reported that similar 
depletion of CD4+CD25+Foxp3+ T cells in naive mice also leads to augmented asthma 
severity following subsequent allergen sensitization (Lewkowich, Herman et al. 2005; 
Joetham, Takeda et al. 2007). As noted above, it has also been shown that passive 
transfer of nTreg cells from naïve mice into asthmatic recipient animals relatively early 
after asthma induction reduces their asthma phenotype (Kearley, Robinson et al. 2008). 
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 This suggests that while there may well be some divergence of function between iTreg 
and nTreg, the story may well be more complex than a simple dichotomy between 
endogenous versus exogenous antigen dedication for the two cell types. For example, 
recent evidence indicates also that both iTreg and nTreg play requisite roles in 
establishment of full disease tolerance in a mouse model of colitis (Haribhai, Williams et 
al. 2011), although it is evident that there are situations wherein one Treg population 
alone can mediate tolerance. Thus, also as noted above, iTreg are sufficient to induce 
tolerance in a mouse model of pulmonary inflammation (Curotto de Lafaille, 
Kutchukhidze et al. 2008). It was reported that the TCR repertoires of the iTreg and nTreg 
that are effective in the above-noted colitis model overlap by only 3-15% (Haribhai, 
Williams et al. 2011), and that is taken as further evidence that these two cells target 
distinct sets of immunologic processes. However, many antigens feature multiple 
epitopes, some of which may be immunodominant and others less so, while many 
environmental challenges (e.g., microorganisms, allergens) are complex and present the 
immune system with numerous, likely multi-epitope, antigens, and each would require a 
unique TCR. Thus, the reported somewhat restricted overlap in TCR  chain specificities 
of iTreg and nTreg (Haribhai, Williams et al. 2011) notwithstanding, there could be ample 
room for iTreg and nTreg with disparate TCR specificities to target the same disease 
complex. The evidence we present herein confirms that iTreg and nTreg of identical TCR 
specificity were each able to target anti-OVA responses of Th2 cells from OVA-
asthmatic wild-type mice both in vitro and in vivo, although they do so with substantially 
different efficacy. In our model system the iTreg were much more effective in suppressing 
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 asthmatic Th2 responses than were nTreg of identical TCR specificity (i.e., OVA323-339) 
(Robertson, Jensen et al. 2000). 
Natural Treg require TCR signaling via APCs in order to be activated (Thornton 
and Shevach 2000), and our FRET data indicates that cognate, but not irrelevant, 
allergen-presenting tolerogenic DC10 did intimately engage the nTreg cells. An 
unanswered question however is whether these naturally tolerogenic DC10 would have 
activated the nTreg with which they were cultured in the same way as immunostimulatory 
DCs might have. Irrespective of whether the DC10 did so, in our in vitro study the nTreg 
were added into co-cultures of LPS-activated OVA-presenting DCs, and these would be 
expected to also activate the nTreg via TCR signaling (Thornton and Shevach 2000). In 
principle, that could explain our data that suggests that nTreg were apparently 
qualitatively better at inducing tolerance in our in vitro assays than they were in vivo. An 
alternate explanation could be that the nTreg we transferred do not as efficiently enter the 
lung tissues or lung-draining lymph node compartment as do iTreg, so did not have the 
same opportunity to suppress the pulmonary Th2 Teff cell responses in the time-frames of 
our experiments. In our model these iTreg would have recently differentiated from Teff 
cells under the influence of treatment DC10 and would have been highly activated at the 
time of passive transfer (Huang, Dawicki et al. 2010).  
Our data indicated that DC10-induced iTreg cells employed IL-10 as their primary 
tolerogenic mediator, as has been reported previously for peripherally-induced 
CD4+CD25+Foxp3+ Treg (Akbari, Freeman et al. 2002; Cobbold, Nolan et al. 2003), and 
this is consistent with our previous report that bulk CD25+Foxp3+ Treg from the lungs of 
DC10-treated asthmatic mice also employ IL-10 as their primary effector molecule 
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 (Huang, Dawicki et al. 2010). Although iTreg can also include a population of CD25- 
cells that employ IL-10 to suppress T cell responses (Nicolson, O'Neill et al. 2006; 
Roncarolo, Gregori et al. 2006), based on our FACS analysis our magnetically-sorted 
iTreg were predominantly CD25+Foxp3+ cells (data not shown). FACS analysis of our 
Treg cells confirmed that the iTreg also strongly expressed the CD4-related MHCII-
binding iTreg marker LAG3, which is associated with both cell-intrinsic and -extrinsic 
signaling (Okamura, Fujio et al. 2012), but also PD-1 and CTLA4, which provide 
inhibitory signals via the CD28/B7 pathway (Fife and Bluestone 2008). LAG3 on iTreg 
can provide inhibitory signals to immature DCs on engaging their MCHII molecules 
(Okamura, Fujio et al. 2012), and this fits well with other observations in our lab that the 
endogenous lung DCs of DC10-treated mice take on a regulatory phenotype several 
weeks after DC10 treatment of asthmatic mice (C. Li, H. Huang, W. Dawicki, and J.R. 
Gordon, unpublished), in concert with the appearance of highly activated Treg in the 
lungs (Huang, Dawicki et al. 2010). The augmented expression of PD-1 by the in vivo-
induced iTreg is consistent with PD-1 playing an important role in the formation and 
activities of these cells (Francisco, Salinas et al. 2009). PD-1 expression by our iTreg also 
fits well with the fact that these cells were induced by exposure to DC10, which express 
low levels of MHCII, CD40, CD80 and CD86 (Li, Yang et al. 2010; Nayyar, Dawicki et 
al. 2012) leading to reduced TCR stimulation by these cells relative to mature allergen-
presenting DCs (Li, Yang et al. 2010). It has been reported that low-level TCR 
stimulation augments PD-1-dependent negative signaling in T cells (Keir, Butte et al. 
2008). Moreover, we know that our DC10 express high levels of PD-L1 (Y. Ma, C. Li, 
S.A. Gordon, W. Dawicki, and J.R. Gordon, unpublished observation), and PD-L1/PD-1 
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 signaling is important in induction of iTreg (Francisco, Salinas et al. 2009). CTLA-4 can 
play a dual function in T cells, wherein it is inducible and controls Teff cell homeostasis 
(Jain, Nguyen et al. 2010), but also regulatory T cells within which it is constitutively 
expressed (Takahashi, Tagami et al. 2000). Others have reported upregulation of CTLA-4 
and GITR expression on Treg, presumably iTreg, in the context of hookworm infections 
(Ricci, Fiuza et al. 2011), while vasoactive intestinal peptide (VIP)-induced Treg similarly 
express augmented levels of CTLA-4 (Pozo, Anderson et al. 2009). 
It had been reported previously that passive transfer of 5×105 wild-type nTreg is 
sufficient to offset otherwise inevitable lethality in Foxp3-deficient mice (Haribhai, 
Williams et al. 2011). This number of nTreg was also sufficient to ameliorate the asthma 
phenotype in an OVA/alum model not unlike our own, but only if the cells were 
transferred early on in the induction protocol; nTreg transfer after entrenchment of the 
phenotype (i.e., dy 46) had no discernible impact on the disease (Kearley, Robinson et al. 
2008). Interestingly, our lab routinely treats fully asthmatic mice with DC10 (Lu, 
Dawicki et al. 2011; Nayyar, Dawicki et al. 2012) or Treg (Huang, Dawicki et al. 2010) 
at precisely this time (i.e., dy 46), and we see substantial to full reversal of the phenotype 
within 3-4 weeks. The nTreg employed by Kearley et al were unmanipulated nTreg 
(Kearley, Robinson et al. 2008) whereas ours had been exposed to tolerogenic DC10, 
which might explain the differences in our dy 46 treatment outcomes. We did show 
herein that our OVA-presenting DC10 engaged OT2 mouse nTreg in a cognate fashion, 
and thus could have stimulated the regulatory activities of these cells. We had previously 
titrated the numbers of unfractionated CD4+CD25+Foxp3+ Treg from the lungs of DC10-
treated asthmatic mice that are required to passively transfer tolerance to asthmatic 
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 recipients and found that 1×106 cells ablate the asthma phenotype in the recipients, while 
5×105 or 2.5×105 Treg approximately 50% reduced or had little if any impact, 
respectively, on the phenotype (Huang, Dawicki et al. 2010). Thus it seems feasible that 
our transference of limiting numbers of (i.e., 5×105) Treg was important to distinguishing 
so clearly the disparate activities of iTreg versus nTreg in our asthma model. We have no 
evidence relating to whether the nTreg we transferred were able to successfully engage 
Teff cells within the lungs of the asthmatic recipient mice, but functional nTreg are 
recruited into and reside within the lungs of both healthy and asthmatic mice (McGee and 
Agrawal 2009). Nevertheless, we cannot rule out that the nTreg we transferred were 
simply less efficient in engaging allergen-specific Teff cells in the lungs than their 
comparator iTreg. These caveats notwithstanding, our data indicated that DC10-induced 
Treg were distinctly superior to nTreg of identical antigen specificity in their abilities to 
antagonize the asthma phenotype in a mouse model of fully entrenched disease. 
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CHAPTER 6: GENERAL DISCUSSION 
As APCs, DCs process allergens that enter the airway and present their peptide 
products to naïve Th cells. In individuals destined to develop allergic disease, allergen-
specific activation of naïve Th cells induces their differentiation into Th2, but not Th1 
cells. Subsequent allergen challenge induces Th2 cell proliferation and cytokine 
production, and thereby also eosinophilic inflammation and IgE production. With 
repeated allergen exposure these effects culminate in the AHR and eosinophilic airway 
inflammation and airway remodeling that typifies allergic asthma (Cohn and Ray 2000; 
Busse and Lemanske 2001; Lambrecht and Hammad 2003; Hawrylowicz and O'Garra 
2005). 
The initial interactions between APCs and the naïve T cell determines whether the 
T cell differentiates into an activated effector cell, an anergized cell or a regulatory cell. 
One factor that critically regulates this process is the maturation status of the DC, as 
judged by the levels at which they express MHCII and costimulatory molecules and the 
cytokines they secrete, such that allergen-presenting quiescent (CD8α+) splenic DCs are 
tolerogenic when delivered to asthmatic mice (Gordon, Li et al. 2005). Culture of 
immature DCs with IL-10 induces their differentiation into cells (DC10) that display a 
relatively immature phenotype, but secrete elevated levels of IL-10 after activation. IL-10 
moderately dampens MHC class II and costimulatory molecule expression on DCs, and 
this was thought to account for their abilities to induce tolerance.  
Multiple laboratories have reported on the tolerogenic activities of DC10 in 
mouse models and with human T cells (Steinbrink, Wolfl et al. 1997; Bellinghausen, 
Brand et al. 2001; Muller, Muller et al. 2002; Wakkach, Fournier et al. 2003; Koya, 
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 Matsuda et al. 2007; Perona-Wright, Anderton et al. 2007; Lau, Biester et al. 2008; Li, 
Yang et al. 2010). For example, OVA-presenting DC10 can protect against the 
development of OVA-induced asthma (Bellinghausen, Brand et al. 2001; Koya, Matsuda 
et al. 2007; Henry, Desmet et al. 2008) or reverse the asthmatic phenotype (Lu, Dawicki 
et al. 2011; Nayyar, Dawicki et al. 2012) in allergen-sensitized mice, reducing AHR to 
methacholine, eosinophilia and Th2 responses to allergen challenge, although the 
mechanisms by which DC10 induce Th2 cell allergen tolerance have not been fully 
unexplored. 
Numerous laboratories have noted the importance of CD4+CD25+Foxp3+ Treg in 
protecting against the development of asthma (Stock, DeKruyff et al. 2006) and there is 
substantial evidence that tolerogenic DCs have effects on Treg (Zhang-Hoover, Finn et al. 
2005; Adler and Steinbrink 2007; Koya, Matsuda et al. 2007; Henry, Desmet et al. 2008). 
For example, DC10 generated from atopic asthmatics are tolerogenic for autologous Th2 
effector cells, fostering the outgrowth of CD4+CD25+Foxp3+LAG3+CTLA-4+ regulatory 
T cells (Li, Yang et al. 2010). DC10 up-regulated expression of the activated 
CD4+CD25+Foxp3+ Treg cell markers CTLA-4 and LAG3 in the lungs of the DC10-
treated mice (Lu, Dawicki et al. 2011). While we have some insights into how DC10 
affect Treg cell differentiation (Adler and Steinbrink 2007), there is much we do not 
know, particularly in the context of tolerance induction in allergic asthma.  
In general, activation of T cells by APC requires at least three signalling events, 
one elicited by TCR recognition of the MHC/peptide complex on the APC and the second 
incorporates the interactions of costimulatory molecules on the APC with the T cells’ 
counter-ligands (e.g., CD28 and LFA on the T cells with CD80 and CD54, respectively, 
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 on the APC). The third is a polarizing cytokine signal (e.g. IL-4, IL-10 or IL-12). The 
initial interactions between antigen-presenting DCs and the immunologically naïve T cell 
determines the outcome of the T cells’ differentiation into an activated effector cell, an 
anergized cell or a regulatory cell. One factor that critically regulates this process is the 
maturation status of the DC, as judged by the levels at which they express MHCII and 
costimulatory molecules and the cytokines they secrete. Roughly speaking, stable 
interactions between DCs and T cells during antigen presentation effectively prime 
productive immune responses, while brief DC-T cell interactions are associated with 
immune tolerance (Hugues, Boissonnas et al. 2006). 
Both immunosuppressive and immunostimulatory effects of DC on T cells have 
been reported (Hawiger, Inaba et al. 2001; Steinman, Hawiger et al. 2003; Steinman, 
Hawiger et al. 2003). As noted large number of reports have shown that stimulatory DC 
cells activate naïve T cells by providing at least three signals (MHC-peptide-TCR 
complex and costimulatory molecules as well as cytokine) (Chen, Linsley et al. 1993; 
Golovina, Mikheeva et al. 2008; Weaver, Charafeddine et al. 2008). Costimulatory 
molecules can increase APC functions to activate both Th1 and Th2 cells, but there is 
increasing evidence that other "costimulatory" molecules can promote tolerance induction 
by DC. Sergio et al. reported that CD154 (CD40L) blockade can, in some instances, 
engender long-lived, antigen-specific tolerance (Quezada, Jarvinen et al. 2004). 
Scalapino reported that the cell surface CTLA-4 is a critical attenuator of T-cell 
activation and an essential component of the regulatory systems that serve to maintain 
peripheral tolerance (Scalapino and Daikh 2008). Interesting, DCs have been reported to 
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 possess distinct immunoregulatory effects on anergy induction and activation of T cells 
(Hochweller and Anderton 2005; Hadeiba, Sato et al. 2008). 
Small interfering RNA (siRNA) is part of a biological process that can be used 
experimentally to silence gene expression. The introduction of double-stranded RNA 
(dsRNA) into a cell results in targeted posttranscriptional gene silencing. Double-
stranded RNA oligos of 23 nucleotide (nt) in length can be used to mediate gene 
silencing in mammalian cells, because they foster the degradation of mRNA having the 
siRNA target sequence. The application of siRNA technology to mammalian cells is 
advancing the field of functional genomics. It has been used to regulate immune function 
in DC by silencing specific genes (Hill, Ichim et al. 2003; Liu, Ng et al. 2004; Li, Zhang 
et al. 2007; Xiang, Gu et al. 2007). In 2006 the importance of siRNA was recognized 
when its discoverers (Andrew Z. Fire and Craig C. Mello) were awarded the Nobel Prize. 
In the present study, we illustrated that IL-10, CD80/86 and MHCII play 
important roles in tolerance induction by DC10. Our data on IL-10-silenced DC10 is 
consistent with a previous study which results demonstrated that siRNA modulation of 
IL-10 in DC10 decreased tolerogenic capacity in delayed-type hypersensitivity (DTH) 
(Ruffner, Kim et al. 2009). Although the APC signals required for T effector cell 
activation have been studied extensively, herein we documented the importance of these 
three signals in the context of tolerogenic DC for the first time (Figure 6-1). Tolerogenic 
DCs take up and digest allergen into peptides which bind to groove of the MHC class II 
molecule. This MHC-peptide complex is transported to the surface of tolerogenic DC cell 
to provide allergen-specific signals to Th2 cells with an immunological synapse 
(Steinman, Hawiger et al. 2003). Some DC-T cell costimulatory molecule pairings (APC 
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 CD40/T cell CD154, APC CD54/T cell LFA-1) increase the avidity of the synapse, 
thereby further engage tolerogenic DCs and Th2 cells, while others (APC CD80, 86/T 
cell CTLA-4, et al) can provide inhibitory signals. Some tolerogenic DCs secrete 
inhibitory cytokines such as IL-10 and TGF-β to inhibit T effector cell activation and 
promote Treg activity (Maldonado, von Andrian et al. 2010). 
Increasingly, it has been reported that the differentiation of Treg cells is related to 
the strength of TCR and costimulatory signals. High doses of antigen have been shown in 
vitro and in vivo to prevent Foxp3+ Treg differentiation (Molinero, Miller et al. 2011) 
while low doses of antigen promotes induction of Treg cells (Long, Rieck et al. 2011). 
Gabryšová et al reported that reducing the strength of TCR or costimulatory CD28 
signals enhanced the differentiation of Treg cell (Gabryšová, Christensen et al. 2011). 
These observations are consistent with the findings in our study. DC10 generated in our 
lab express low level of MHCII molecules and costimulatory molecules. When pulsed 
with OVA peptide, DC10 were found using on OT2 transgenic mouse system to induce 
Treg differentiation from Foxp3- precursor. Low expression of MHC II and 
costimulatory molecules on DC10 provides appropriate signals to induce Treg 
differentiation by DC10 (Morelli and Thomson 2007). Recently we generated bone 
marrow-derived DCs in the presence of retinoic acid (DCRA), and found that although 
these DCRA highly expressed costimulatory molecules (i.e. CD40, CD54, CD80), they 
still efficiently inhibited both food allergy (Dawicki, Zhang and Gordon; Therapeutic 
treatment for food allergy with suppressive DCs, manuscript in preparation) and 
asthmatic responses (Li, Ma, Dawicki, Gordon, Zhang and Gordon; Therapeutic 
treatment for asthma with retinoic acid treated DCs, manuscript in preparation). This is 
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 probably due to the presence of strong alternate regulatory signals expressed by DCRA 
(i.e. RA and TGF-β). 
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Figure 6-1. Three APC signals required for induction of asthma tolerance by DC10 
DC10 provides three signals to Treg cells and induces asthma tolerance. Signal 1 
is elicited by TCR recognition of the major histocompatibility complex/peptide complex 
presented by DC10. Signal 2 is the stimulation of MHCII and costimulatory molecules 
(e.g., CD80, CD54) expressed on DC10. Signal 3 is immunosuppressive cytokine IL-10 
produced by DC10 itself. These three signals facilitate the expression of Treg-associated 
markers  on Foxp3+Treg cells and thereby augment Treg cell responses. Consequently, 
DC10 activated Treg cells tolerize asthma via inhibiting Th2 responses in term of 
cytokine (e.g., IL-4,5,9,13) secretion, eosinophilia and AHR.  
 
 156  
  
 
Figure 6-1. Three APC signals necessary for induction of tolerance by DC10 
 157  
 CD4+CD25+ Treg cell can be broadly divided into two subsets, natural 
CD4+CD25+ Treg (nTreg) cells and induced Treg (iTreg) cell based on where and how 
they develop. The nTreg cells, which constitute around 5% of peripheral blood CD4+ T 
cells in healthy adult mice and humans, originate in the thymus, while iTreg cells develop 
in the periphery (Bilate and Lafaille 2012; Josefowicz, Lu et al. 2012). The forkhead 
(winged helix) transcription factor forkhead box P3 (Foxp3) is expressed by Treg cells, 
and is essential to their function (Curotto de Lafaille and Lafaille 2009). It is reported that 
the adoptive transfer of nTreg cells could prevent asthmatic response in term of AHR, 
eosinophilia and Th2 cytokines (IL-5, 13) in OVA-alum sensitized asthma mice (Kearley, 
Barker et al. 2005; Kearley, Robinson et al. 2008; Presser, Schwinge et al. 2008). In mice 
and humans, ectopic expression of Foxp3 within non-regulatory CD4+ T cells has been 
shown to convert these cells into functional Treg cells. There is increasing evidence that 
iTreg cells can be differentiated in the periphery from Foxp3- non-regulatory CD4+ T 
cells by APCs with IL-10 or TGF-β (Yamazaki, Dudziak et al. 2008; Huang, Dawicki et 
al. 2010). Treg cells play an important role in the homeostasis of T effector cell (Teff 
cell). Natural Treg cell inhibit Teff cell activity in a contact-dependent manner. Induced 
Treg cells, which secrete inhibitory cytokines ( e.g. IL-10 [Tr1] or TGF- [Th3]) share 
similarities with nTreg cell, but perform their inhibitory functions in a cytokine-
dependent manner (Bluestone and Abbas 2003). In general nTreg cells are specific to self 
antigens for control of excessive autoimmune response, while iTregs cells are specific to 
environmental antigens, and inhibit immune response induced by commensal bacterium 
or allergens (Josefowicz, Niec et al. 2012). Recently it has been suggested that, in vivo, 
nTreg and iTreg cells are functionally similar and that the main function of iTreg cell is 
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 to increase the diversity of the Treg cell pool (Haribhai, Williams et al. 2011). We have 
shown that DC10 secrete IL-10 and up-regulate the inhibitory function of Tregs and 
convert CD4+CD25-Foxp3- T precursor cells to CD4+CD25+Foxp3+ Tregs in the lung of 
asthmatic mice. These Tregs inhibit Th2 responses in mice model of asthma (Figure 6-2). 
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Figure 6-2. A simplistic view of induction of tolerance cascade by DC10 therapy. 
OVADC10 are progressively recruited to the lungs and draining LNs in asthmatic 
mice after i.p. injection, where they are thought to secrete high levels of IL-10 and 
interact with lung-resident Tregs and Teffs. Furthermore, OVADC10 up-regulate the 
inhibitory function of Tregs and convert CD4+CD25-Foxp3- T precursor cells to 
CD4+CD25+Foxp3+ Tregs. Finally, nTregs and iTreg cells reverse Th2 response in 
airway. 
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 Tregs can be isolated from mice and humans on the basis of their expression of 
high levels of CD25 (the α-chain of the IL-2 receptor), but it is critical to remember that 
CD25 is expressed by all activated T cells (ie, effector and regulatory cells alike). Other 
cell-surface markers that were originally thought to be specific for naturally-occurring 
Tregs and, in some cases, involved in their function, include CTLA-4 and GITR but, like 
CD25, these are also expressed by activated T cells. Therefore, to date, we have not yet 
identified any cell-surface markers that are specific for Tregs. Foxp3 was shown to be 
specifically expressed in the cytoplasmic compartment of naturally-occurring Tregs and 
related to the function of these Tregs cells (Fontenot, Rasmussen et al. 2005; 
Hawrylowicz and O'Garra 2005; Randolph and Fathman 2006; Stock, DeKruyff et al. 
2006; Toda and Piccirillo 2006) although human Teff cells transiently express Foxp3. 
Foxp3 is also expressed by immunologically-induced Tregs (Toda and Piccirillo 2006). 
Since Foxp3 is an intracellular marker of Tregs, it can not be used to isolate these cells. 
For example, the CD4+CD25+ draining LN cells isolated by Strickland et al for adoptive 
transfer showed 73% Foxp3+ cells as reported (Strickland, Stumbles et al. 2006), which 
means the transferred cells contained 27% CD4+CD25+Foxp3- activated T cells, which 
could have been activated Teff cells. Therefore the need for a good cell-surface marker to 
distinguish activated effector T cells from Tregs should be highlighted. 
In this study, maximal pulmonary Treg activity was observed at 3 wk (versus 1, 2 
or 4 wk) after DC10 treatment of asthmatic mice in both in vitro (inhibitory assay) and in 
vivo (adoptive therapy) experiments. While we successfully induced CD4+CD25+Foxp3+ 
Treg differentiation from CD4+CD25-Foxp3- Teff both in vitro and in vivo, the Treg 
induce in vivo expressed high levels of the Treg-associated markers LAG3, CTLA-4, 
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 ICOS, PD-1 and GITR. These results suggest that specific allergen-presenting DC10 
initiated an infectious tolerance process, which includes the induction of Tregs from 
CD4+CD25-Foxp3- Teff cells and up-regulation of the inhibitory functions of lung-
resident DC and Tregs, both of which are likely involved in the down-regulation of 
allergen- specific Th2 responses. 
We isolated endogenous DCs from lung in the DC10-treated asthmatic mice and 
observed the increased abilities of these cells to inhibit Th2 response. (Li, Zhang, 
Dawicki and Gordon; The characterization and function of endogenous pulmonary DCs 
in regulatory DC-treated asthmatic mice; unpublished data). This indicated that DC10 
transferred tolerance to endogenous DCs and induced an infectious tolerance. 
Numerous groups have reported that iTreg cells can be differentiated from naive 
CD4+ T cells (Coombes, Siddiqui et al. 2007; Yamazaki, Bonito et al. 2007; Yamazaki, 
Dudziak et al. 2008), but we and others have reported that CD4+CD25+Foxp3+ iTreg cells 
can also be differentiated from CD62LintCD69+ antigen-experienced T cells (i.e. Teff 
cells) (Huang, Dawicki et al. 2010; Schallenberg, Tsai et al. 2010). We found that DC10 
induced CD4+CD25+Foxp3+ Treg cell differentiation in our mouse model of asthma 
(Huang, Dawicki et al. 2010), but we did not know to what extent nTreg versus iTreg 
contribute to the induction of tolerance. This was an important question in our 
exploration of the mechanisms of this tolerance induction.  
Although two subsets of Treg cells, nTreg and iTreg cells, are relatively well 
defined by where and how they develop, so far no markers have been found to distinguish 
iTreg from nTreg cells (Murai, Krause et al. 2010). Thus, in this study we generated 
GFP-Foxp3/CD45.1/OT2 and GFP-Foxp3/CD45.2/OT2 mice and used CD45.1 and GFP-
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 Foxp3 as markers to trace the fate of allergen-specific iTreg and nTreg cell. Since both 
Treg cell types have the same specificity of TCR (OVA), we were able to directly 
compare their suppressive activity. Since the iTreg and nTreg cells were compared in the 
same asthmatic mouse, the experimental conditions in this study closely approximated 
natural physiological processes. We compared the suppressive properties of iTreg and 
nTreg that were induced in vitro and in vivo under the influence of DC10. All our results 
indicated that DC10-induced Treg cells are more effective than DC10-exposed nTreg 
cells in blocking Th2 effector cell responses in vitro and in asthmatic mice (Figure 6-3).  
In a mouse colitis model, transfer of naïve CD45RBhighCD4+ T cells into 
immunodeficient mice induces inflammatory bowel disease (IBD), while transfer of 
CD4+CD25+T cells cured intestinal inflammation and fostered the reappearance of 
normal intestinal tissue structure (Mottet, Uhlig et al. 2003). Further study conducted by 
Haribhai et al (Haribhai, Lin et al. 2009) showed that if naïve CD45RBhighCD4+ T cells 
were derived from mice that were able to generate Foxp3+ iTreg in vivo, treatment with 
nTreg cells could completely resolve the colitis because besides nTreg, iTreg generated 
in vivo from transferred naïve cells were also present. However, if the naïve cells were 
isolated from Foxp3 KO mice, thus, iTreg cells were not able to be converted in vivo, 
then complete protection could only be obtained when nTreg cells were co administered 
with in vitro-generated iTreg cells. These results indicated that both nTreg and iTreg 
were required for protection from the disease, supporting synergistic actions between 
nTreg and iTreg cells. 
In a lymphoproliferative disease model (Haribhai, Williams et al. 2011), mice 
with Foxp3 deficiency developed autoimmune lymphoproliferative disease and did not 
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 survive beyond day 32 of life. Adoptive transfer of only nTreg cells prevented disease 
lethality, but did not suppress chronic inflammation and autoimmunity. However, a 
combined transfer of nTreg cells with conventional T cells (Tconv) reconstituted the 
iTreg pool and established tolerance. Selective iTreg cell depletion in successfully treated 
mice resulted in weight loss and inflammation, but not lethality. This data demonstrated 
that both nTreg and iTreg cells played roles in rescuing mice from lymphproliferative 
disease caused by Foxp3 deficiency. 
Although nTreg and iTreg cells have a distinct roles in immune tolerance to self 
and environmental antigens respectively, they seemingly have overlapping effects or act 
in concert to achieve immune tolerance as shown above. TCR repertoire studies may 
provide molecular mechanisms for these observations. It was found that the TCR 
repertoires of Tconv and Treg cells overlap by 4-40% (Hsieh, Liang et al. 2004; 
Pacholczyk, Ignatowicz et al. 2006; Wong, Obst et al. 2007; Lathrop, Santacruz et al. 
2008) and nTreg and iTreg cells by 3-15% (Haribhai, Williams et al. 2011) depending 
what approach was used for the study. Therefore, it seems possible that, at least in part, 
iTreg and nTreg share TCR specificity and recognize overlapping sets of self or non-self 
antigens. In addition, the gene expression profiles of iTreg and nTreg cells from rescued 
mice with lymphoproliferative disease are remarkably similar to one another (Haribhai, 
Williams et al. 2011). This suggests that iTreg and nTreg cells may share inhibitory 
functions through overlapping effector mechanisms. 
Previous studies reported that iTreg and nTreg cells performed synergic inhibitory 
functions, and in vitro and in vivo differentiated iTreg cells were functionally equivalent 
(Curotto de Lafaille and Lafaille 2009; Haribhai, Williams et al. 2011). Herein our data 
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 suggest that allergen-specific iTreg cells play a more important role in DC10-induced 
asthma tolerance than do allergen-specific nTreg cells. While exploring this difference, 
we found that iTreg cells expressed higher levels of markers (i.e. ICOS, PD-1, GITR, 
LAG3 and CTLA-4) than nTreg cells and that iTreg cells employed IL-10 to inhibit Th2 
responses, unlike nTreg cells. The broader mechanisms by which iTreg and nTreg cells 
mediate asthma tolerance are still largely unknown. To further elucidate these 
mechanisms, we would need determine the full array of inhibitory molecules and 
cytokines expressed by iTreg and nTreg cells. We recently reported that amelioration of 
Th2 response last at least 8 months (Nayyar, Dawicki et al. 2012). Thus another 
important issue for further research is to address the relative contributions of iTreg cells 
and nTreg cells in the late stage of the induction of tolerance. In addition, it has been 
reported that Breg cells suppress experimental autoimmune encephalomyelitis (EAE) 
through their impact on Foxp3+ Treg cells (Ray, Basu et al. 2012; Sun, Czerkinsky et al. 
2012). Exploring the roles of Breg in the induction of tolerance by tolerogenic DCs is 
another pertinently and potentially important question. Tracking the fate of iTreg cells 
and studying their memory in asthma tolerance are other promising avenues for future 
work. 
Over the past 17 years Treg cells have become a increasingly promising avenues 
for clinical immunotherapy in transplant rejection, autoimmune and allergic diseases 
(Leslie 2011). Several clinical trials have been completed, and others are underway, in 
which the therapeutic cells came from freshly isolated CD4+CD25+ Treg cells that were 
ex vivo expanded by anti-CD3 and anti-CD28 antibodies or APC (Wang, Lu et al. 2011). 
Our study suggests that Treg cells differentiated from Teff cells may be more effective 
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 than those from nTreg cells at suppressing ongoing Th2 responses. This is clinically 
important because it is the suppression of ongoing responses (i.e. wherein Teff cells are 
present and activated) that is the major challenge.  
Herein we developed a unique protocol to address the relative roles of nTreg and 
iTreg in immune tolerance in our mouse model of asthma. This protocol has several 
advantages, and it overcomes some limitations posed in earlier studies (Huter, Stummvoll 
et al. 2008; Haribhai, Lin et al. 2009). First, the lack of phenotypical markers that 
distinguishes iTreg from nTreg cells has been a major obstacle to us gaining a complete 
understanding of the relative roles of these two subsets in overall Treg cell biology. Thus, 
we reported herein that we generated two strains of congenic mice, namely GFP-
Foxp3/CD45.1/OT2 and GFP-Foxp3/CD45.2/OT2, and this allowed us to use GFP-
Foxp3/CD45.1 to distinguish iTreg from nTreg cells. Second, while it is not difficult to 
obtain nTreg or iTreg using in vitro culture protocols, nTreg or iTreg cells generated in 
this way may not be representative of cells generated in vivo; in our protocols we 
generated both allergen-specific iTreg and nTreg in vivo. Third, since the nTreg and 
iTreg cells used in our experiments had the same OVA-specific TCR, we are able to 
evaluate their relative contributions to immune tolerance in the same subject. Finally, the 
congenic (CD45) and knock-in (GFP) markers between nTreg and iTreg allowed us to 
track the fate and assess their individual functions in the different organs (e.g. spleen, 
lung, gut) in vivo.  This strategy would also be valuable as a tool to explore the relative 
roles of iTreg and nTreg cells in other disease models (e.g., autoimmune diseases and 
cancers). For example, because we know of no specific surface markers for nTreg and 
iTreg cells, their roles in tumour immunity and tolerance are controversial. Indeed, the 
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 OT2 transgenic cross-bred mice we generated for our study would also lend themselves 
to exploration in tumour models.  A case in point is the EG7 mouse lymphoma cell line, 
generated from EL4 cells that have been transfected to express OVA, or the MO4 mouse 
melanoma  cell line generated by OVA-transgene tranfection of B10F10 cells.  
Clarification of the relative contributions of nTreg and iTreg cells to health and disease in 
asthma and other models is important from a fundamental immunology perspective, but it 
will also be potentially important for clinical applications. 
Tolerogenic DCs (tDCs) can be experimentally generated in vitro from bone 
marrow-derived DCs (BMDC) in mice or peripheral blood monocyte-derived DCs in 
humans. To date there are three major ways to obtain experimentally-induced tDCs for 
potential immunotherapy. (1)  Such DCs can be generated through exposure of immature 
DC to various inhibitory cytokines (e.g. IL-10 and/or TGFβ). The immunosuppressive 
efficacy of these cells has been tested in various disease models. For example, murine 
splenic or BMDCs, or human monocyte-derived DCs that have been generated through 
exposure to IL-10 are able to induce CD4+CD25+ Treg cells in asthma (Huang, Dawicki 
et al. 2010; Nayyar, Dawicki et al. 2012), EAE (Benkhoucha, Santiago-Raber et al. 2010), 
T1D (Tai, Yasuda et al. 2011), and GVHD (Sato, Eizumi et al. 2009). The IL-10 
signalling pathway reportedly maintains immature APCs in an immature state even when 
they are exposed to maturation signals (Lang, Patel et al. 2002).  (2) Tolerogenic DCs can 
also be generated by exposure to immunosuppressive or anti-inflammatory drugs (e.g. 
GC, rapamycin and cyclosporine), which block DC maturation or impair their ability to 
produce IL-12. (3) They can also be generated through genetically modification such that 
they express inhibitory molecules such as IL-10, TGF, IDO, or CTLA4-Ig which, 
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 among other things, can block the expression of co-stimulation molecules. DCs 
transduced to express IDO can prevent the proliferation of allogenetic T cells (Morelli 
and Thomson 2007; Maldonado, von Andrian et al. 2010).  
Therapeutic application of tDCs in the clinic is an attractive option that brings 
with it multiple advantages: (1) tolerance induced by tDCs would be antigen-specific 
(Huang, Dawicki et al. 2010; Lu, Dawicki et al. 2011) such that is would not impact 
unrelated required immune responses (e.g., against pathogens or tumours) and (2) tDCs 
can induce prolonged infectious tolerance (Huang, Dawicki et al. 2010; Nayyar, Dawicki 
et al. 2012). However therapeutic application of tDCs also brings its own challenges: (1) 
The numbers of DCs that can be obtained from each individual may be limiting (Morelli 
and Thomson 2007); (2) the delivery route, timing, dose and frequency of administration 
of the tDCs will need to be optimized for use in the clinic; and (3) some populations tDCs 
generated in vitro could potentially develop into stimulatory phenotype DCs under some 
(e.g., inflammatory) conditions in vivo. Taken together though, the prospect for clinical 
translation of tDC use is promising, despite such challenges. It appears imminent that 
tDC therapeutics will enter the clinic, just as immunostimulatory DCs have entered 
clinical trials in the context of cancer (Bauer, Dauer et al. 2011). Indeed, multiple 
laboratories have begun exploring the potential use of DC10 and similar tDC in the 
context of human disease. 
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Figure 6-3. Tolerogenic dendritic cell-induced iTreg cells are more effective than 
nTreg cells in blocking Th2 effector cell responses in asthmatic mice.  
After i.p. DC10 treatment, DC10 quickly and continually are recruited to the 
airway (i.e. lung parenchyma and lung draining LN) from the peritoneal cavity. In the 
airway, DC10 are thought to secrete high levels of IL-10 and interact with lung-resident 
Tregs and Teffs. Furthermore, DC10 up-regulate the inhibitory function of Tregs and 
convert CD4+CD25-Foxp3- Teffs to CD4+CD25+Foxp3+ Tregs. DC10-induced regulatory 
T cells (iTreg) are more effective than natural regulatory T cells (nTreg) in blocking Th2 
T effector cell responses in asthmatic mice. 
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nTreg cells in blocking Th2 effector cell responses in asthmatic mice.  
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 Overall Summary: 
IL-10 differentiated dendritic cells (DC10) are widely reported to abrogate 
asthmatic responses in both mice and humans. To explore the mechanisms of DC10-
induced asthma tolerization we used DC10 that were deficient in MHCII, or CD80 and 
CD86, or DC10 that were unable to express IL-10 to assess the roles of these three 
distinct components of the antigen-presenting machinery of DC10. We found that in each 
case the deficiency significantly reduced the tolerogenicity of these cells as determined 
by assessment of AHR and Th2 immunoinflammatory responses to recall allergen 
challenge. The data demonstrate that the activities of DC10 are differentially affected by 
IL-10, MHC II and costimulatory molecules expression. 
Next we monitored effects of DC10 on the Treg cells in well established OVA-
asthmatic mice. We observed that adoptive transfer of DC10 activated lung Tregs in 
OVA-asthmatic mice via upregulating Treg-associated markers and enhancing inhibitory 
functions. More importantly, we showed that DC10 treatment induce tolerance at least in 
part by inducing Teff to differentiate into CD4+CD25hiFoxp3+ Treg.  
Natural Treg (nTreg) and induced Treg (iTreg) are the two main types of 
CD4+CD25hiFoxp3+ Treg. We further assessed the relative contribution of nTreg and 
iTreg to the tolerization of asthma. We found that Treg cells induced by DC10 were 
better than nTreg in inhibiting Th2 cell responses in vitro. Induced Treg efficiently 
ameliorated the asthma phenotype in vivo, while equal numbers of nTreg of the same 
antigen-specificity displayed no remarkable activity. These data suggest that induced 
Treg are distinctly superior to nTreg in their abilities to induce asthma tolerance (Figure 
6-3). 
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 Appendix-1. Selection of GFP-Foxp3/CD45.1/OT2 mice. 
 
 
The periphery blood samples were harvested from tail vein of offspring mice. Then red 
blood cells were removed by cell lysis. The remaining leucocytes were stained with anti-
mouse CD45.1 and Vβ5.1,5.2 TCR antibodies and analyzed by cytometry. 
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Appendix-2. IL-10-differentiated dendritic cells intimately engage naturally-
occurring regulatory T cells in an allergen-specific fashion*.  
 
Irrelevant allergen (house dust mite; HDM)- and OVA-pulsed IL-10-
differentiated dendritic cells (DC10) or LPS-activated OVA-presenting dendritic cells 
(OVADC-LPS) were stained with the FRET donor dye DiO, while lung 
CD4+CD25+Foxp3+ T cells purified from healthy OVA TCR-transgenic OT2 mice (nTreg) 
were stained with the lipophylic FRET partner dye DiI. The OVA- or HDM-presenting 
DC10 or DC-LPS were cocultured with the OT2 nTreg, while negative controls included 
DiO-stained T cells or DiI-stained DC10 alone. The cells were exposed to fluorescent 
light (488 nm; the DiO excitation wavelength) and assessed for FRET energy release at 
565 nm wavelength (the DiI emission wavelength) over ≈5 h. The data are expressed as 
relative fluorescence units. OVA-presenting DC10 induced strong FRET responses 
among the OT2 nTreg, albeit with somewhat delayed kinetics relative to OVA-presenting 
DC-LPS, while HDM–presenting DC10 induced no significant FRET signals. 
*Contributed by Xiaobei Zhang 
